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A concerted effort to tackle the global health problem posed by traumatic brain injury (TBI) is long 
overdue. TBI is a public health challenge of vast, but insufficiently recognised, proportions. Globally, 
TBI is the leading cause of mortality in young adults and a major cause of death and disability across 
all ages, with the substantial burden of disability and death occurring in low-income and middle-
income countries (LMICs). This Commission for The Lancet Neurology aims to provide information 
and expert recommendations on TBI care and research to a broad audience of policy makers, 
funders, and patient representatives, as well as health-care professionals and researchers. The 
Commission addresses current and past deficiencies in TBI prevention, clinical care, and research, 
outlines key requirements to advance knowledge and care in TBI, and suggests new paths for 
progress in the field. 
Worldwide, about 50 million people have a TBI each year, and it is estimated that about half the 
world ?Ɛ population will have one or more TBIs over their lifetime. In the European Union (28 Member 
States), approximately 1·5 million people are admitted to hospital and 57 000 die each year because 
of TBI. In LMICs, TBI is an even greater problem. In India, for example, nearly one death from TBI is 
estimated to occur every 3 minutes. The epidemiology of TBI is changing: in high-income countries 
(HICs), the number of elderly people with TBI is increasing, mainly due to falls, while in LMICs, the 
burden of TBI from road traffic incidents is increasing. TBI costs the global economy approximately 
$US400 billion annually.  
Reported incidence and mortality rates for TBI, as well as information regarding the economic impact 
of TBI, are often incomplete and vary between countries and continents. Variations in data collection 
and reporting might contribute to these reported differences. Accurate epidemiological monitoring 
and robust health-economic data collection are important for informing health-care policy and 
prevention programmes, and require improvement. Highly developed and coordinated systems of 
care are crucial for management of patients with TBI. However, in practice, implementation of such 
frameworks varies greatly and disconnects exist in the chain of care. Optimisation of systems of care 
should be high on the policy agenda and could yield substantial gains both in terms of outcome to 
patients and costs to society. 
TBI is a complex condition, and strong evidence to support treatment guidelines and 
recommendations is scarce. Most multicentre clinical trials of medical and surgical interventions 
 6 
 
have failed to show efficacy, despite promising preclinical results. At the bedside, treatment 
strategies are generally based on guidelines that promote a one-size-fits-all approach and are 
insufficiently targeted to the needs of individual patients. Attempts to individualise treatment are 
hampered by the diversity of TBI, and by the use of simplistic methods for characterising its initial 
type and severity. Advances in genomics, blood biomarkers, advanced magnetic resonance imaging 
(MRI), and pathophysiological monitoring, combined with informatics to integrate data from 
multiple sources, offer new research avenues to improve disease characterisation and monitoring of 
disease evolution. These tools can also aid understanding of disease mechanisms and facilitate 
targeted treatment strategies for individual patients.  
Evaluating the effectiveness of treatment and care processes depends on accurate quantification of 
outcomes. In practice, however, the use of simplistic methods hinders efforts to quantify outcomes 
after TBI of all severities. Development and validation of multidimensional approaches are essential 
to improve measurement of clinical outcomes of TBI, both for research and patient care. In particular, 
we need need to find better ways to characterise the currently underdiagnosed risk of long-term 
disabling sequelae in patients with relatively mild injuries.   
Prognostic models are important to help clinicians provide reliable information to patients and 
relatives, and to facilitate comparative audit of care between centres and countries. There is an 
urgent need for further development, validation, and implementation of prognostic models in TBI, 
particularly for less severe TBI.  
This multitude of challenges in TBI ? encompassing systems of care, clinical management, and 
research strategy ? demands novel approaches to the generation of new evidence and its 
implementation in clinical practice. Comparative effectiveness research (CER) offers opportunities to 
capitalise on the diversity of TBI and systems of care and enables assessment of therapies in real-
world conditions; high-quality CER studies can provide strong evidence to support guideline 
recommendations. The global challenges posed by TBI necessitate global collaborations and a change 
in research culture to endorse broad data sharing.  
This Commission covers a range of topics that need to be addressed to confront the global burden 
of TBI and reduce its effects on individuals and society: epidemiology (section 1); health economics 
(section 2); prevention (section 3); systems of care (section 4); clinical management (section 5); initial 
characterisation of TBI (section 6); outcome assessment (section 7); prognosis (section 8); and new 
directions for acquiring and implementing evidence (section 9). Table 1 summarises key messages 
from the Commission and provides recommendations to advance clinical care and research in TBI.  
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We must increase awareness of the scale of the challenge posed by TBI. If we are to tackle the 
individual and societal burden of TBI, these efforts need to go beyond a clinical and research 
audience and address the public, politicians, and other stakeholders. We need to develop and 
implement policies for better prevention and systems of care in order to improve outcomes for 
individuals with TBI. We also need a commitment to substantial long-term investment in TBI research 
across a range of disciplines so that we can determine best practice and facilitate individualised 
management strategies. To achieve these aims, we need a combination of innovative research 
methods and global collaboration, and ways to effectively translate progress in basic and clinical 
research into clinical practice and public health policy. 
 
Table 1: Key messages and recommendations 
Key messages Recommendations 
Read 
more 
Worldwide, traumatic brain injury (TBI) 
is a leading cause of injury-related 
death and disability, and a huge 
burden to patients and their families. 
Concerted efforts to address this vast 
global health problem should focus 
on policies aimed at reducing the 
burden and impact of TBI, through 
better prevention, improved access 
to care, and promotion of clinical 
research to improve treatment 
standards. 
Sections 
1, 3, 4, 9 
In low-income and middle-income 
countries, the incidence of TBI due to 
traffic incidents is increasing, while in 
high-income countries, TBI increasingly 
affects elderly people, mostly due to 
falls. Methodological variations, 
however, confound comparisons of 
epidemiological patterns of TBI 
between regions, countries, and 
continents. 
An international consensus is needed 
on definitions and standardised 
epidemiological monitoring of TBI, to 
allow accurate measurement of 
incidence, prevalence, and mortality, 
and comparison of rates of access to 
community, hospital, and 
institutional care.  
Sections 
1, 4 
TBI might represent an important 
modifiable risk factor for epilepsy, 
stroke, and late-life neurodegenerative 
disease. 
Studies are needed, in children and 
adults, to better understand links 
between TBI of all severities and an 
increased risk of these diseases. 
Section 
1 
TBI results in substantial health-care 
and societal costs. 
More effective strategies for TBI 
prevention are vital, and could 
Section 
2 
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deliver cost savings that help to fund 
research and improved access to 
health care for TBI.  
Repetitive concussions that occur 
before recovery from an initial 
concussion can be associated with 
more severe symptoms and more 
prolonged recovery than a single injury 
of similar severity; therefore, any risk 
of an early second injury after even a 
mild TBI should be avoided.  
Professional sporting organisations 
should set an example for children 
and amateur athletes by immediately 
removing from play anyone with a 
suspected concussion. 
 
Section 
3 
Access to health care is often 
inconsistent between centres, regions, 
and countries, especially for acute and 
postacute care.   
Health-care policies should aim to 
improve access to acute and 
postacute care to reduce the effects 
of TBI on patients, families, and 
society. 
Section 
4 
Evidence underpinning guidelines for 
medical and surgical interventions and 
rehabilitation for TBI is weak. 
Increased funding is needed to 
develop robust evidence to inform 
medical, surgical, and rehabilitation 
interventions, and hence improve 
outcomes for patients with TBI.  
Section 
5 
Methods of diagnosis and classification 
of patients with TBI are inadequate to 
permit targeting of current and new 
therapies to the needs of individual 
patients.  
Funding bodies should implement 
targeted funding calls for research 
that improves the precision of 
diagnosis, classification, and 
characterisation of TBI using 
multidomain approaches. 
Section 
6  
Trauma disturbs the brain in complex 
ways, affecting multiple outcome 
domains. Refined outcome 
assessments could guide improved 
clinical management and support high-
quality research.   
Targeted funding calls are needed to 
facilitate the development and 
validation of multidimensional 
outcome constructs that quantify the 
overall burden of disability from TBI. 
Section 
7  
A validated set of quality indicators is 
essential for the benchmarking of 
quality of care, but none exists for TBI. 
Funding bodies should stimulate the 
development of a set of quality 
indicators for TBI that includes 
structure, process, and outcome 
metrics. 
Section 
8  
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Substantial between-centre variability 
in treatment and outcome in TBI offers 
unique opportunities for comparative 
effectiveness research to improve the 
strength of evidence. 
Comparative effectiveness research 
should be funded to identify best 
practices and to improve the level of 
evidence for systems of care and 
diagnostic and therapeutic 
interventions. 
Section 
9  
Coordinated research efforts on a 
global basis are needed to address the 
growing public health problem of TBI. 
A commitment of governmental and 
non-governmental funding bodies, as 
well as industrial partners, is needed 
to facilitate global collaborations and 
legacy research. 
Section 
9  
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Traumatic brain injury (TBI) is defined as an alteration in brain function, or other evidence of brain 
pathology, caused by an external force.1 It varies in severity from mild TBI (which includes 
concussion) to moderate and severe TBI. Severe TBI has a high mortality rate, estimated at 30 W40% 
in observational studies on unselected populations.2 Survivors experience a substantial burden of 
physical, psychiatric, emotional, and cognitive disabilities, which disrupt the lives of individuals and 
their families, and pose huge costs to society. Such disabilities are not restricted to severe cases, but 
also occur frequently after moderate or mild TBI.  
TBI is a growing public health problem of substantial proportions. More than 50 million TBIs occur 
internationally each year.3 The incidence of TBI in high-income countries (HICs) has increased in the 
elderly to a greater extent than might be expected from demographic ageing,94 W96 whereas increased 
use of motorised vehicles in low- and middle-income countries (LMICs) has led to a rise in TBI from 
road traffic incidents.160 Across all ages, TBI represents 30 W40% of all injury-related deaths, and 
neurological injury is projected to remain the most important cause of disability from neurological 
disease until 2030 (2 W3 times higher than the contribution from Alzheimer ?Ɛ disease or 
cerebrovascular disorders).4 TBI costs the international economy approximately US$400 billion 
annually, which, given an estimated standardised gross world product of $73·7 trillion,5 represents 
approximately 0·5% of the entire annual global output. 
Wide variations in the clinical manifestations of TBI are attributable to the complexity of the brain, 
and to the pattern and extent of damage, which depends on type, intensity, direction, and duration 
of the external forces that cause TBI. In traffic-related injuries, acceleration Wdeceleration forces can 
result in immediate shearing of connecting nerve fibres or trigger progressive loss of connectivity 
over time. Forces generated by a fall or blow to the head more often cause bruises (contusions). 
Individuals can react very differently to similar injury forces. Conceptually, it is important to 
distinguish between the primary damage, inflicted at the time of injury, and secondary damage, 
which evolves over hours, days, weeks, months, or even over a lifetime in some cases. Secondary 
damage is driven substantially by host responses to the primary injury. As a bruised ankle might swell 
following injury, so can the brain. The difference is that the brain is contained within the rigid skull 
and any swelling results in increased pressure within the skull (intracranial pressure). This increased 
pressure, in turn, can lead to life-threatening shifts of brain structures or impair blood flow through 
the brain, resulting in ischaemia and deprivation of oxygen to the brain. TBI is best viewed as a 
collection of different disease processes (figure 1), with different clinical patterns and outcomes, 
each requiring different approaches to diagnosis and management. 
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Figure 1: The multiple faces of traumatic brain injury  
(A) Sheared brain: the typical picture of diffuse axonal injury on CT (top panel) and MRI using susceptibility-
weighted imaging (lower panel) in an adult patient with TBI. Note the greater sensitivity of MRI for dection of 
microbleeds, which are commonly associated with diffuse axonal injury. (B) Bruised brain: contusional brain 
injury on CT in two elderly patients with TBI, typically located in the frontal and temporal regions. (C) Brain 
under pressure: a typical epidural haematoma (bleeding between the skull and outer coverings of the brain) 
on CT in two adult patients with TBI. The haematoma in the top panel is an example of injury that compresses 
the brainstem; the haematoma in the lower panel causes midline shift and indirect compression of the 
brainstem due to raised intracranial pressure. Both are life-threatening, and constitute a neurosurgical 
emergency. Patients can recover completely if operated on quickly. (D) Disconnected brain: white matter tracts 
visualised on MR tractography in an adult patient with TBI 12 days after the injury (top panel) and at 6-month 
follow-up (lower panel). Note the extensive progressive late white matter loss over time. CT=computed 
tomography. MRI=magnetic resonance imaging. TBI=traumatic brain injury.  
 
TBI might also confer a long-term risk for neurodegenerative disorders,6,7 stroke,8,9 parkinsonism,10 W
12 and epilepsy,13 and is associated with an increased long-term mortality rate14,15 compared with of 
the general population. These risks also occur in milder forms of TBI, especially after repetitive 
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injuries. This accumulating knowledge makes it clear that TBI is not a single event, but can be a 
chronic and often progressive disease with long-term consequences. Even after an ostensibly good 
recovery, patients might have to live with a continuing process of coping and adaptation (panel 1).  
 
Panel 1: Living with traumatic brain injuryͶa patient testimony 
In 2011, James Piercy sustained a traumatic brain injury (TBI) in a car accident in the UK. Like many 
people with TBI, he lives with the long-term effects of brain injury. He is now an ambassador for the 
UK Acquired Brain Injury Forum. In the following patient testimony (abridged), Piercy describes the 
aftermath of his injury and highlights what can be achieved with high-quality management and 
support. However, for many patients with TBI, systems of care are still suboptimal, poor, or even 
absent in some regions. For the full testimony, see appendix.  
The injury 
Like many others, I acquired my TBI in a car accident. I was unconscious at the scene (Glasgow Coma 
Scale score of 3 to 5). By good fortune, I was attended very soon after the accident by a police officer 
with good first-aid training. He kept my airway open until a doctor and paramedic from the air 
ambulance could take over my care. I was sedated and intubated at the scene before transfer to the 
local trauma centre. A scan revealed a bleed in my frontal lobe and smaller haemorrhages through 
the brain. Prognostic indicators gave a poor chance of good outcome after 6 months, but I have done 
better than expected. Better prognostic models for individual patients and families would be very 
valuable. I was monitored closely, emerging from post-traumatic amnesia after 25 days and 
transferring to a hospital closer to home. I was discharged after 7 weeks and began slow 
rehabilitation. 
The aftermath 
After 5 years, I am doing well. I have made a very good recovery and am back to work part-time. I 
need to plan my time carefully and avoid stressful and unpredictable situations, which leave me very 
fatigued. This fatigue can be very debilitating, leaving me with speech problems and making decision-
making and concentration very difficult. Learning to live with the chronic conditions which follow TBI 
remains a huge challenge for the individuals and the services which aim to support them. I consider 
myself very lucky to have done so well and put the recovery down to good, prompt intervention, 
strong support from family and friends, and my own determination to improve.  
 
Clinical progress has not kept pace with the rising global burden of TBI and recognition of the 
prolonged effects of injury. The most recent major breakthrough in clinical management was the 
introduction of computed tomography (CT) scanning into routine care ? now more than 40 years ago. 
Since then, there have been no major improvements in outcome after TBI in HICs with developed 
trauma systems. This lack of progress can be attributed to many factors, both in thepolicy and clinical 
domains. Public and political awareness of the magnitude of the problems caused by TBI ? including 
the clinical impact on patients, families, and society, and public health burden and costs to society ?
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is low. Additionally, there has been insufficient clinical recognition of the complex heterogeneity of 
TBI, in terms of disease type, outcome, and prognosis. Treatment approaches provide insufficient 
recognition of specific needs of individual patients, and disconnects exist along the chain of trauma 
care, especially between acute and postacute care. Clinical research has, until recently, focused 
mainly on more severe TBI, but the vast majority (70 W90%) of patients suffer from mild TBI. Although 
the individual impact of mild TBI is less, the category as a whole makes the largest contribution to 
the global burden of disability, and timely intervention and structured follow-up in this group could 
deliver substantial gains in public health and societal costs.16  
We believe that strategic global collaboration is required at several levels. First, policy makers and 
funders need to support an integrated effort by the entire neurotrauma community to identify 
improved approaches to TBI prevention and best practices for systems of care and management. 
Second, research strategies are needed to enable better characterision of TBI through the disease 
course, and emerging research paradigms and tools need to be incorporated into clinical studies. In 
addition to the undeniable need for increased research funding, organisational improvements across 
the chain of trauma care are essential to maximise the benefits of developing global research 
collaborations and to achieve the best possible returns on research funding. Finally, we need an 
intensive knowledge transfer exercise to implement the outputs of these efforts in clinical practice. 
Such implementation requires that we inform and involve health policy makers, health-care 
professionals, and the general public, about the magnitude of the problem, the extent of (and gaps 
in) our current knowledge, and emerging advances.  
The overall aims of this Commission are to set out directions for improvements in clinical care and 
to establish research priorities. We aim to provide a foundation for implementation of policy 
measures that minimise the risk of TBI and maximise chances of recovery when it does happen. This 
manuscript represents the efforts of a consortium of leading health-care professionals with expertise 
in epidemiology, health economics, diagnosis, treatment, outcome assessment, biology, and ethics, 
all of whom are involved in the International Initiative for Traumatic Brain Injury Research (InTBIR) 
studies, with input provided by other collaborating specialists and, crucially, by patients. In 
conjunction with this Commission, four Series papers on clinical advances in TBI, aimed at health-
care professionals, have been published in recent issues of The Lancet Neurology.  
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 
Globally, traumatic brain injury (TBI) is a leading cause of injury-related death and disability,4,33,39 
imposing a huge burden on patients, their families, and society. In low-income and middle-income 
countries (LMICs), the rising burden of TBI from increases in road traffic incidents predominantly 
affects young individuals.160 The changing epidemiology of TBI in high-income countries (HICs) is 
attributable to a high and increasing incidence of TBI in paediatric and elderly subpopulations.29,41,94 W
96,103 Increases in TBI are also reported in the contexts of sports131 W133 and armed conflict.137 
Reported incidence and mortality rates for TBI vary greatly between countries and regions. This 
partly reflects variations in acquisition and reporting of epidemiological data, and makes 
interpretation of official statistics difficult. There is considerable variability in definitions of TBI (panel 
2), resulting in difficulties in diagnosis and case ascertainment. Relatively few epidemiological studies 
of TBI report age-adjusted data, which are required for valid comparisons between countries with 
differing population demographics. Moreover, for many countries or regions, epidemiological 
studies have not been done or available data capture only a proportion of all TBIs, so the scale of the 
problem is likely to be considerably greater than current figures suggest. 
Panel 2: Definitions of traumatic brain injury  
World Health Organization definition17 
 “ŶĂĐƵƚĞŝŶũƵƌǇƚŽƚŚĞďƌĂŝŶĨƌŽŵŵĞĐŚĂŶŝĐĂůĞŶĞƌŐǇƚŽƚŚĞŚĞĂĚĨƌŽŵĞǆƚĞƌŶĂůĨŽƌĐĞƐ ?ĞǆĐůƵĚŝŶŐ
injuries relating to drugs, alcohol or substance abuse, medication or cause by other injuries or 
ƚƌĞĂƚŵĞŶƚ ? ?   
This broad definition of traumatic brain injury (TBI) is widely used, but some ambiguity exists as to 
ǁŚĂƚĐŽŶƐƚŝƚƵƚĞƐ ?ĂŶĂĐƵƚĞŝŶũƵƌǇƚŽƚŚĞďƌĂŝŶ ? ? 
American Congress of Rehabilitation Medicine definition18 
 “ƉĂƚŝĞŶƚǁŝƚŚŵŝůĚtraumatic brain injury is a person who has had a traumatically induced 
physiological disruption of brain function, as manifested by at least one of the following: (1) any 
period of loss of consciousness; (2) any loss of memory for events immediately before or after the 
accident; (3) any alteration in mental state at the time of the accident (eg, feeling dazed, 
disoriented, or confused); and (4) focal neurological deficit(s) that may or may not be transient; but 
where the severity of the injury does not exceed the following: loss of consciousness of 
approximately 30 minutes or less; after 30 minutes, an initial Glasgow Coma Scale score of 13 W15; 
ĂŶĚƉŽƐƚƚƌĂƵŵĂƚŝĐĂŵŶĞƐŝĂ ?Wd ?ŶŽƚŐƌĞĂƚĞƌƚŚĂŶ ? ?ŚŽƵƌƐ ? ?   
This definition is specific to mild TBI and excludes patients with more severe TBI, which conflicts with 
ƚŚĞĐŽŶĐĞƉƚƚŚĂƚƚŚĞƐĞǀĞƌŝƚǇŽĨd/ůŝĞƐĂůŽŶŐĂĐŽŶƚŝŶƵƵŵ ?EŽƚĞƚŚĂƚƚŚĞƚĞƌŵ ?ĐŽŶĐƵƐƐŝŽŶ ?ŝƐŽĨƚĞŶ
ƵƐĞĚƐǇŶŽŶǇŵŽƵƐůǇǁŝƚŚ ?ŵŝůĚd/ ? ?19 See figure 2 for classification of clinical severity with the 
Glasgow Coma Scale.  
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National Institute of Neurological Disorders and Stroke definition1 
 “d/ŝƐĚĞĨŝŶĞĚĂƐĂŶĂůƚĞƌĂƚŝŽŶŝŶďƌĂŝŶĨƵŶĐƚŝŽŶ ?ŽƌŽƚŚĞƌĞǀŝĚĞŶĐĞŽĨďƌĂŝŶƉĂƚŚŽůŽŐǇ ?ĐĂƵƐĞĚďǇĂŶ
ĞǆƚĞƌŶĂůĨŽƌĐĞ ? ?  
This statement acknowledges potential confounders to TBI diagnosis, and suggests that 
symptomatology, imaging, details of the incident, and wider context should all be taken into 
account to inform diagnosis.1 
 
Figure 2: Classification of clinical severity of traumatic brain injury with the Glasgow Coma Scale 
Responses are assessed in three domains (eye, motor, and verbal), and individual scores are added to give a 
Glasgow Coma Scale (GCS) sum score for mild, moderate, or severe traumatic brain injury (TBI).294 
 
Addressing the vast global health problem posed by TBI requires substantial efforts to correct current 
deficiencies in epidemiological monitoring. Robust epidemiological data are essential to quantify the 
public health burden of TBI, to inform policies for prevention, to understand the health-care needs 
of patients, and to allow appropriate allocation of health-care resources. 
In this section, we provide an overview of the epidemiology of TBI, highlight the increasing burden 
of TBI in LMICs, and review the evidence for changing patterns of epidemiology in HICs. We propose 
ways to enhance epidemiological data collection and to improve the usefulness of such data in 
informing health-care policy and prevention programmes. 
[H3] Incidence of TBI 
Reported incidence rates of TBI across the world vary considerably, with substantial gaps in robust 
data for many parts of the world, particularly in LMICs, where TBI rates are likely to be high (figure 
3).3,20 W34 Substantially higher incidence rates for TBI are seen in population-based studies with broad 
definitions of TBI (811 W979 per 100 000 people per year)3,29,32 than in studies based on hospital 
discharge rates (47·5 W643·5 per 100 000 people per year).32,33 Projections from such studies suggest 
that 50 W60 million new TBI cases occur annually worldwide, over 90% of which are mild TBIs.3 For 
the European Union (EU; 28 member states), we estimate that at least 2·5 million new cases of TBI 
occur each year (table 2), and in the USA, the total number of patients with a new TBI has been 
reported to approach 3·5 million per year.35 Results from a recent study using standardised Eurostat 
data from 24 European countries suggested that 1·5 million TBI-related hospital discharges and 57 
000 TBI-related deaths occurred in 2012 in the 28 Member States of the EU.33 The pooled age-
adjusted incidence rate of TBI (hospital discharges) was 287·2 per 100 ]000 people per year, with 
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enormous differences between countries (figure 4) that are likely to reflect differences in study 
methodology rather than true variation.33  
Figure 3: Worldwide incidence of traumatic brain injury 
Age-adjusted hospital discharge rates after traumatic brain injury were available for the USA (69·7 W106·3 per 
100 000 people per year),20 W29,457 Canada (47·5 W83·1),30 W32 Europe (287·2),33 and South Africa (316·4).34 
Population-based incidence rates were available for the USA (823·7 per 100 000 per year),29 Canada (979·1),32 
and New Zealand (811·0).3 The map highlights the absence of robust data for most regions and the variation 
in available data between countries. Reported estimates of hospital discharge rates also vary between 
individual countries, as highlighted for Europe (81·0 W643·5 per 100 000 per year; expanded view).  
 
  European Union USA 
Population (millions) 510 321 
Total number of new cases annually  
(indexed per 100 million population) 
2·5 million 
(0·49 million) 
3·5 million 
(1·09 million) 
Total number of hospital admissions annually 
(indexed per 100 million population) 
1·5 million 
(0·30 million) 
282 000 
(0·09 million) 
Total number of deaths from TBI annually 
(indexed per 100 million population) 
57 000 
(11 220) 
56 000 
(17 445) 
Percentage of all injury-related mortality 
caused by or associated with TBI  
39% 30·5% 
 
Table 2: Estimated annual traumatic brain injury volume in the European Union and the USA 
Estimates for the EU are based on four studies.33,40 W42 Estimates for the USA are based on five 
studies.29,35,39,43,457 Figures have been rounded for easier comparison where appropriate.  
TBI=traumatic brain injury. 
 
Figure 4: Hospital discharge rates after traumatic brain injury in Europe 
Age-adjusted hospital discharge rates after traumatic brain injury in a single year (2012) are shown for 24 
European countries, with a pooled age-adjusted estimate of overall hospital discharge rate across these 24 
countries. The figure highlights the wide variation in reported rates between countries. Data from Majdan 
and colleagues.33  
 
The US Centers for Disease Control and Prevention (CDC) surveillance studies of TBI have used 
standardised case definitions and methods of data collection for nearly three decades,36,37,457 and 
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focus on emergency department visits, admissions to hospital, and deaths. Recent data indicate that 
each year over 2 million Americans with TBI are treated and released from an emergency 
department, over 282 000 are admitted to hospital and discharged alive, and 56 000 die as a 
consequence of TBI.29,457    
Figures for the EU and the USA are discordant (table 2). Relative to population size (EU 510 million, 
US 321 million), the number of deaths due to TBI is lower in the EU than in the USA. Much of this 
difference might be explained by the high death rate from firearms-related wounds in the USA ?
estimated at 10·5 per 100 000 people per year ? since head wounds are often involved in fatalities.44 
This rate of firearms-related deaths is exceeded only by some Latin American nations and is far higher 
than the average rate in the EU of 1·1 per 100 000 people per year.45  
Relative to population size, the reported number of hospital admissions for TBI is more than three 
times higher in the EU than in the USA.29,33,38,457 By contrast, the reported number of new cases per 
year in the USA, adjusted for population size, is double that of the best estimate of new cases in the 
EU (table 2). These differences are probably mainly due to methodological diversity in 
epidemiological studies, including differences in case ascertainment, although variation in hospital 
admission policies might also be a factor. Discrepancies and differences in epidemiological findings 
and health-economic data (section 2) within the EU and between the EU and the USA motivate 
further study and highlight the need to standardise the global conduct and reporting of incidence 
studies. Furthermore, studies in LMICs are urgently needed (panel 3). 
 
Panel 3: Traumatic brain injuryͶa big problem in big countries 
China 
China has a population of 1·3 billion. No reliable nationwide data are available on the incidence of 
traumatic brain injury (TBI). Several large-scale population-based studies, conducted in the 1980s,79 W
81 report an incidence of head trauma of 55·4 W64·1 per 100 000 people per year. This incidence is 
much lower than the estimates reported for other countries, and probably reflects incomplete case 
ascertainment. The current burden of care for TBI is very high in many Chinese hospitals, with many 
neurosurgical departments nearly exclusively treating TBI.  
Traffic incidents are the most common cause of TBI (54%), followed by falls (32 W33%) and violence 
(9 W11%).82,83 The high rate of traffic-related TBI is unsurprising, as car ownership has increased at a 
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compound rate of about 12% per annum between 1980 and 2009, resulting in a 35-times increase in 
car ownership (from 0·018 to 0·628 per capita).84 
In response to a high rate of traffic-related deaths and injuries associated with alcohol use, the 
Chinese ministry of public safety issued the national alcohol penalty law on May 1, 2011, which stated 
that all drunk drivers should be sent to jail.509 Since then, alcohol-related accidents have declined 
rapidly ? eg, a recent study, ƵƐŝŶŐĚĂƚĂĨƌŽŵŚŝŶĂ ?ƐŝƐĞĂƐĞ^ƵƌǀĞŝůůĂŶĐĞWŽŝŶƚƐƐǇƐƚĞŵ ?ƌĞƉŽƌƚĞĚĂ
decrease in TBI mortality from 17·06 per 100 000 people in 2008 to 12·99 per 100 000 people in 
2013.510 Implementation of the law on drinking and driving is likely to have contributed to this 
decrease in mortality. 
Falls as a cause of TBI seem to be increasing from a rate of 12% in 200485 to 29% in 2008 W2009.82 
Interpersonal violence is among the top three leading causes of TBI in China,86 but gunshot wounds 
as a cause of TBI are rare (<1%). According to Chinese law, a Chinese citizen or foreigner in China is 
sentenced to jail if he or she owns, sells or buys, or transports firearms. 
India 
India has a population of 1·3 billion. Accurate data on TBI epidemiology in India are lacking, and there 
is no national trauma registry. The National Crime Records Bureau in India reported a total of 413 
457 accidental deaths in India in the year 2015,90 and this is likely an under-estimation of the actual 
number.556 This represents an increase in accident-related deaths of 49% over the period 2004 W2015, 
while population growth was 16·4%. Approximately 50% of trauma deaths are likely related to TBI 
(Roy, personal communication), which  would imply that about one TBI-related death occurs every 3 
minutes. Nearly a million people are disabled owing to TBI in India each year,87 and between 60% 
and 70% of TBIs result from road traffic incidents.88,89 
Poor recognition and inadequate early management of brain injuries, delays between injury and 
reaching specialist care (only 24% arrive within 1 hour, 30% arrive within 2 W3 hours, and 24% take 
more than 24 hours), lack of adequate pre-hospital care services, and limited trauma care services 
might account for poor outcomes in individuals who sustain a TBI in India.556,557 High-level care can 
be provided in the few specialised neurotrauma centres, but access to such resources is scarce.91 
Many districts lack computed tomography (CT) scanners and crucial equipment such as mechanical 
ventilators, and a great need exists for rehabilitation services.90 W93  
Towards improved epidemiological monitoring 
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Reliable epidemiological data and improved awareness of TBI in India and China are sorely needed 
to understand fully the scale of the problem, to drive forward prevention programmes (section 3), 
and to guide provision of health-care resources for the management and ongoing care of patients 
(section 4). Accomplishing this will be no simple task. Experience in Europe has shown that despite 
uniform approaches to collection and analysis of administrative data, wide variations in reported 
incidence and mortality rates exist between countries,33 restricting interpretation of such data. Close 
interaction between governmental authorities and health-care professionals is required to derive 
the best model for capturing the extent of the burden of TBI in these large countries. 
 
 
[H3] Prevalence of TBI  
Accurate data on TBI prevalence are even more limited than for incidence, particularly for LMICs. A 
meta-analysis of 15 prevalence studies46 revealed that of a total sample of 25 134 adults, 12% had 
experienced a serious TBI with loss of consciousness, with men being at more than double the risk 
of women. Prevalence is higher in young adults ? eg, one birth-cohort study showed that more than 
30% of participants had experienced at least one TBI requiring medical attention before the age of 
25 years.47 In view of the increasing incidence of TBI in elderly populations, it is reasonable to 
conclude that about half the world ?Ɛ population have had a TBI. This inference is supported by the 
results of a population-based survey with random sampling in Colorado, USA, in which 42% of 
respondents reported at least one TBI in their lifetime (36% mild and 6% moderate-to-severe 
injury).48 TBI has a substantial ongoing health impact: in the USA, an estimated total of 3·17 million 
people live with permanent sequelae of a past TBI.49 TBI is among the top three specific neurological 
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conditions accounting for neurodisability globally, both at present and in projections up to 2030.4 
Concerted efforts are required to reduce this high burden of disability. 
 
[H3] Mortality and years of life lost from TBI 
Death rates after TBI are variably reported as mortality rates or case-fatality rates. Mortality rates 
relate the number of deaths over a specific timeframe to the population size ? eg, the number of 
deaths per 100 000 people per year. Case-fatality rates refer to the proportionof reported cases in a 
specified disease or condition, which are fatal within a specified timeframe (usually the acute 
treatment phase) ? eg, the death rate for patients admitted to hospital with TBI. Case-fatality rates 
are therefore greatly influenced by case-mix, and will be higher for patients with severe TBI than for 
those with mild TBI. These parameters capture the number of deaths relative to different 
populations at risk. However, the public health consequences of TBI deaths are better captured by 
the concept of years of life lost (YLL), which gives an estimate of the number of years a person would 
have lived if he or she had not died prematurely ? eg, from a TBI. 
Reported mortality rates vary widely between countries, with figures ranging from 0·33 (Spain)50 to 
39 (Brazil)51 per 100 000 person-years. According to the US CDC, population-based mortality due to 
TBI was 17·1 per 100 000 people in 2010.29 Using Eurostat data from 25 European countries, Majdan 
and colleagues calculated an age-adjusted mortality rate of 11·7 per 100 000 people (95% CI 9·9 W
13·6) in 2012,33 but noted that methods (eg, diagnostic criteria and case ascertainment) varied 
substantially between countries, and studies did not always differentiate deaths directly due to brain 
injury from those due to other complications. Most studies have focused on severe TBI, usually 
defined according to the Glasgow Coma Scale (GCS; figure 2),294 and little is known about the 
contribution of non-severe TBIs to mortality. Patterns of TBI mortality depend on age and injury 
mechanisms and can change over time. HICs show declining rates of traffic-related TBI deaths and 
increasing death rates from fall-related TBI.52 The highest mortality is in adults over 60 years of age.52 
A recent meta-analysis of 24 studies in patients with moderate and severe TBI, with a pooled sample 
size of 93 115 older adults (A? ? ?ǇĞĂƌƐ ?, revealed an in-hospital case-fatality rate of 57% (95% CI 43 W
71) and a 6-month case-fatality rate of 75% (62 W84).119  
Studies with estimates of YLL attributable to TBI are scarce: the YLL related to TBI has been estimated 
at 118 207 years for the Netherlands (2010 W2012)53 and at 14 386 years for New Zealand (2010).54 A 
recent analysis of data from 16 European countries revealed a total of almost 400 000 YLL related to 
TBI, which translates to a pooled age-adjusted rate of 271·4 (95% CI 214·7 W328·2) YLL per 100 000 
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person-years and to an average of 25·4 (23·0 W27·9) YLL with each TBI death. Nearly 74% of all YLL 
due to TBI affect individuals in age groups with potential to work (15 W64 years).511 
The high acute mortality in severe TBI is well recognised: TBI is a contributing factor in 39% of all 
injury-related deaths in the EU33 and about a third (30·5%) of all injury-related deaths in the USA 
(with an average reported number of 169 000 injury-related deaths per year in the USA between 
2002 and 2006).39 Long-term mortality in TBI is a substantial, but less well recognised, problem: TBI 
survivors continue to experience mortality rates that exceed those in age-matched and sex-matched 
population controls and in similar cohorts with non-TBI trauma for many years.55 In a Scottish study 
of patients aged 15 W54 years, the death rate 13 years after TBI was more than six times higher than 
in community controls.14 The Global Burden of Disease studies showed a pooled standardised 
mortality ratio of 2·18 (95% CI 1·88 W2·52) for TBI survivors.56 This excess mortality is in part 
attributable to expected consequences and associations with TBI, such as epilepsy, but also due to 
an increased risk of illnesses not directly related to injury, such as pneumonia, septicaemia, and 
respiratory and digestive disorders.57 TBI has been shown to shorten life expectancy by 6 years.58 
[H3] TBI as a risk factor for later neurological disease 
TBI might be a major risk factor for late neurodegenerative disorders such as dementia and 
WĂƌŬŝŶƐŽŶ ?ƐĚŝƐease, reinforcing the view that TBI can evolve into a progressive lifelong illness. A 
meta-analysis of 15 case-control studies showed a pooled odds ratio of 1·58 (95% CI 1·21 W2·06) for 
development of later-life dementia after a single TBI with loss of consciousness.6 Autopsy studies 
have shown accelerated development of tau and amyloid pathology in a third of TBI survivors who 
died of non-TBI-related causes decades after the initial injury.455 TBI sustained after 55 years of age 
is associated with a 44% ŝŶĐƌĞĂƐĞĚƌŝƐŬŽĨĚĞǀĞůŽƉŝŶŐWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞǁŝƚŚŝŶƚŚĞƐƵďƐĞƋƵĞŶƚ ? W7 
years.11 A population-based clinical and neuropathology survey confirms this association for the 
incidence and progression of parkinsonism, and for Lewy body disease, but not for dementia or 
dementia-related pathology more generally.12 By contrast, a recent Finnish study showed that in 
working-aged people, a history of moderate-to-severe TBI is associated with an increased risk for 
future dementia, but not for Parkinson ?Ɛ disease or amyotrophic lateral sclerosis.512 
TBI-associated dementia might be clinically and pathologically distinct from ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ, with 
more patients experiencing behavioural symptoms such as depression, agitation, and irritability.59 
Preliminary estimates of population-attributable risk, based on TBI prevalence and relative risk of 
dementia in TBI survivors, indicate that as much as 5 W15% of the population burden of dementia 
could be due to brain trauma.60  
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Repetitive mild TBI can result in a distinct pathology known as chronic traumatic encephalopathy 
(CTE).61 In his landmark clinical account of punch-drunk syndrome in boxers, Martland provided the 
first clinical description of the progressive neuropsychiatric sequelae associated with repetitive mild 
TBI,62 and its neuropathological substrate was detailed by Corsellis and colleagues.63 Recent autopsy 
studies have found similar associations with clinical features in non-boxer athletes from sports with 
high risk of concussion or mild TBI, such as American football, ice hockey, soccer, and rugby, as well 
as in ex-military personnel. In these descriptions, the distinguishing clinical features comprise a triad 
of behavioural, mood, and cognitive deficits,64,513 which have been variably associated with 
pyramidal and extra-pyramidal dysfunction and cerebellar impairment in retired professional 
football players,65 and might represent the clinical correlate of CTE pathology.66,513 The risks of 
developing CTE in individuals who play these sports remains unclear.  Although a  recent autopsy 
series reported a rate of CTE of ~99% in professional American football players, this was a highly 
selected group of individuals, and extrapolation to more generalised estimates of risk is not 
appropriate. 
A related, but distinct, issue is the fact that some TBI survivors experience ongoing cognitive decline 
in the medium term (months to years), rather than showing clinical improvement or remaining 
stable. Long-term disability could change with time, and age-related decline in cognitive reserve 
might unmask the consequences of an earlier TBI.7,514 A 13-year longitudinal study in Glasgow, 
Scotland,14 reported such late deterioration in up to 50% of patients, which can be visualised by 
progressive changes on advanced neuroimaging.67 Furthermore, a decline in outcomes from 1 year 
to 5 years after injury was recently reported in 36 of 50 (72%) US military service members with 
concussive blast TBI.515 
Other evidence suggests that TBI is an independent risk factor for stroke.8 A retrospective case-
control study from Taiwan showed that a past history of TBI doubled the risk of stroke (hazard ratio 
1·98; 95% CI 1·86 W2·11) and increased post-stroke mortality (odds ratio 1·57; 95% CI 1·13 W2·19).9  
Post-traumatic epilepsy is a well recognised complication of TBI,13 occurring in up to 20% of patients 
with severe brain trauma and 3 W5% of those with moderate TBI.68,69 Even mild TBI leads to a 1·3-
times increased risk of epilepsy in those affected compared with the general population.69 TBI 
accounts for approximately 4% of cases of epilepsy in the general population and is the leading cause 
of epilepsy with onset in young adulthood.68  
The association between TBI and an increased risk of late neurological disease62,70 remains poorly 
understood, largely owing to the retrospective nature and limited scope of many past studies and 
 23 
 
small cohort sizes in recent, more comprehensive reports. There is a pressing need for research into 
the incidence, clinical presentations, and risk factors in TBI-associated neurological diseases and their 
overlap with existing, better characterised disorders, such as ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ and WĂƌŬŝŶƐŽŶ ?Ɛ
disease.  
[H3] Changing epidemiological patterns of TBI 
The epidemiology of TBI in HICs is changing. TBI due to traffic-related incidents has decreased, and 
falls are now the leading cause of TBI, particularly in elderly patients.41,94 The average age of patients 
with TBI in HICs has nearly doubled since the 1980s (appendix). Evidence for these changes has often 
come from comparisons between studies, which are confounded by differences in enrolment 
criteria, but a few longitudinal studies are available. The Nordic countries were among the first to 
describe an increase in TBI in elderly patients.95,96 In Europe, a decrease in overall TBI incidence rates 
since the late 1990s, mainly due to a decrease in traffic-related injuries, has been reported in 
Scotland, UK,97 Spain,98 and Portugal.99 Most of these studies reported an increase in incidence of TBI 
in elderly patients. The observed decrease in hospital admissions for TBI in Europe has not been 
reported for other high-income countries such as Canada100 and the USA.35 Since the 1970s, a 
decrease in mortality due to TBI has been reported in many studies,52,101 mainly attributable to fewer 
traffic-related deaths.  
The results of a systematic review of TBI mortality over the past 150 years suggested that 
improvements in the clinical management of severe TBI (according to the GCS, or coma at 
presentation in the pre-GCS era) have reduced case-fatality rates by more than 50%.102 However, 
case-fatality rates appeared to have stagnated over the past 25 years,102 an impression confirmed by 
a comparative overview of observational studies, which showed similar rates of unfavourable 
outcome over the past decades (appendix).2 Further improvements in care are needed to reduce 
mortality and to improve outcomes for survivors of TBI.  
 
[H3] TBI in specific populations 
[H4] TBI in children and adolescents 
Despite the growth and dissemination of injury-prevention programmes and education (section 3), 
TBI remains the leading cause of death in children and adolescents in HICs.29 In fact, the full scope of 
the public health crisis of TBI is only now emerging. According to US CDC data,457 in 2013 there were 
more than 640 000 TBI-related emergency department visits for children aged 14 years or younger. 
 24 
 
However, this staggering number is likely to be an underestimate: data from large health networks 
suggest that about 80% of children and adolescents with mild TBI present to primary care physicians 
and not to hospitals,104 indicating a real incidence that is 4 W5 times higher. CDC data457 show that US 
emergency department visits for TBI increased between 2007 and 2013 for the 0 W4 year and 5 W14 
year age groups, rising by 37·8% in the youngest age group (1591·5 cases per 100 000 people), which 
has the second highest incidence for any age group after adults over 75 years of age.  
TBI affects more boys than girls, with a 1·4-times higher incidence in boys less than 10 years old and 
a 2·2-times higher incidence in boys more than 10 years old compared with girls.105 Additional 
disparities in incidence and outcomes exist in relation to race and ethnicity. For instance, African-
American children were at a 40% increased risk of TBI compared with non-Hispanic white children.106 
African-American, Hispanic, and native American children were more likely to experience TBI from 
violence and have more severe TBI and higher mortality rates than were non-Hispanic white children 
in the USA.107 W109  
Injury causes also vary with age. Falls predominate in the 0 W4 year age group, falls and being struck 
by (or having the head strike) an object are equally common in the 5 W14 year age group, and motor 
vehicle incidents predominate in the 15 W24 year cohort.457 The rates of TBI and its complications in 
children and adolescents seem to be similar in Europe and the USA, but are higher in other regions, 
such as China, India, and South America.110  
A unique aspect of TBI in children is that it includes injuries inflicted by child abuse. In abusive head 
trauma, children are generally too young ? or sometimes too injured ? to be reliable historians, and 
investigations are required to eliminate further risks for the injured child and any other children in 
the environment and discover the circumstances surrounding the injury. A comprehensive analysis 
of data from the past 15 years appeared to show declining rates for fatal abusive head trauma.111 
Nevertheless, recent evidence suggests that abusive trauma is the most common cause of severe TBI 
in children under 2 years of age.112 Although some studies have shown poorer outcome in children 
with abusive head trauma compared with those injured by other mechanisms,516,517 this was not 
confirmed in a recent study.518  
At a societal level, the effect of childhood TBI is enormous, with burdens on the health-care system, 
scarce resources for rehabilitation and school systems, and a substantial socioeconomic impact on 
families (sections 2, 4).  
[H4] TBI in the elderly 
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The definition of elderly in the context of TBI is variable: cutoffs in published papers range from 55 
to 75 years of age. However, regardless of the cutoff used, older patients are clearly at a higher risk 
of TBI and experience more severe consequences than do younger patients, even from seemingly 
mild TBIs.3,29,39,113 Demographic projections suggest that future rates of TBI among older individuals 
in LMICs are likely to approach current levels in HICs,459 and hence the future health economic and 
public health burden of TBI is likely to increase dramatically.  
People over 65 years of age represent 10% of TBI cases, but account for 50% of TBI-related 10-year 
mortality risk114 and have high and increasing rates of TBI-related hospital admissions.28 The rise in 
TBI incidence in older patients is not solely attributable to an ageing population. Many elderly 
patients remain mobile and semi-independent owing to decreasing morbidity from cardiovascular 
disease and cancer. They are then at risk of falls, which are the main cause of TBI in this 
group.37,41,94,115 Loneliness and depression might also lead to alcohol abuse, which is increasingly 
being recognised in older individuals and can potentially increase the risk of falls and compromise 
chances of recovery owing to decreased cognitive reserve.116 Moreover, increased use of computed 
tomography (CT) imaging might have improved case ascertainment for TBI in older people.  
Age is among the strongest outcome predictors in TBI, with mortality and unfavourable outcome 
increasing continuously with age (appendix).117,118 The perception of a universally poor outcome has 
sometimes led to therapeutic nihilism and less aggressive treatment for older patients with TBI, who 
experience delayed CT imaging, a lower likelihood of transfer to specialist neurosurgical facilities, 
and care by more junior medical staff.120 Treatment-limiting decisions might be taken sooner in older 
patients. The poor outcome resulting from such suboptimal treatment might fuel self-fulfilling 
prophecies of poor prognosis and reinforce current prejudices. Such nihilism is unjustified: overall, 
when older patients are treated aggressively and promptly following ICU admission, favourable 
outcomes are seen in 39% of patients aged 60 W69 years.121 Epidemiological studies will be crucial in 
helping to understand the burden of TBI and response to treatment in the elderly population. 
Moreover, improved epidemiological monitoring in the elderly could help to raise awareness of the 
risks of head trauma in this group and inform prevention programmes (section 3).  
[H4] Sports-related TBI 
Sports-related concussion is a frequent cause of TBI, and is currently the focus of public debate and 
controversy, owing to uncommon (but dramatic) clinical presentations such as second-impact 
syndrome122,123 and the association of concussion with later cognitive decline65,124 and CTE. In the 
USA, the CDC estimates that between 1·6 and 3·8 million concussions occur annually.125 However, 
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this might be a considerable underestimate, as many concussions do not reach medical attention. In 
the USA, cycling is responsible for the majority of sports-related concussion, according to the 
American Association of Neurological Surgeons,126 whereas in New Zealand, rugby (both league and 
union combined), cycling, and equestrian sports have been linked to the highest rates of sports-
related concussion.127 A recent systematic review of 13 studies of concussion in 12 sports reported 
an overall pooled incidence of 0·23 (95% CI 0.19 W0.28) per 1000 athlete exposures to sport, with the 
highest incidences in rugby, ice hockey, and American football.128 Variations in participation between 
sports and in definitions of concussion between countries result in inconsistent statistics. Concussion 
rates vary by age group, sport, and gender, and are generally reported to be higher in competition 
than in practice.129 In terms of head injuries per hours of sport, equestrian sports appear to have the 
highest rate of concussions.130 There is a lack of research on the epidemiology of sports-related 
injury, across all sports, in Europe. 
Notwithstanding inconsistencies, the reported incidence of sports-related concussion is steadily 
rising. The CDC reported a 62% increase in sports-related TBI treated in emergency departments 
between 2001 and 2009,131 and annual increases of 7 W15% have been suggested for concussion rates 
in collegiate and high-school sports in North America132,133 over the past two decades. These 
concerns are not confined to the USA. For example, the English Rugby Football Union134 has reported 
year-on-year increases in concussions in professional rugby since 2003.135 These trends are generally 
attributed to increased awareness and reporting of concussion, partly promoted by media attention. 
Concerns have also been expressed about players becoming progressively heavier and stronger, and 
more emphasis being placed on the physical element of sport. Nevertheless, the underlying true rate 
of concussion remains unclear, as the majority of these injuries are not reported, either deliberately 
or due to lack of awareness.136 Further efforts to understand and increase awareness of the 
consequences of sports-related TBI are needed, with improved detection of and response to 
concussion, to prevent or reduce the effects of such injuries (section 3). 
[H4] TBI in military conflict situations 
Current global conflicts, and the increasing burden of terrorism across the world, have resulted in a 
steady increase in the number of patients with military and military-type injuries.137 US data show 
that TBI is the signature injury of the Iraq and Afghanistan conflicts, accounting for approximately 
20 W25% of the combat casualties reported in the Joint Theater Trauma Registry.140 Between January 
2010 and August 2016, 352 619 TBIs were reported in US service members.141 Of these, 82% were 
classified as mild, 9% as moderate, and the remaining 9% as severe or penetrating, or not classifiable 
(including instances of death in action and inadequate or incomplete documentation). As with civilian 
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populations, mild TBI constitutes the largest proportion of TBI in military personnel, and although 
most individuals with mild TBI return to full duty with no lasting complications, approximately 10% 
have symptoms that do not resolve.  
Overall, combat-related TBI is a substantial cause of morbidity and mortality, and unlike civilian TBI, 
often includes blast-related TBI and extracranial polytrauma such as amputation, internal 
haemorrhage, and burns. Blast as an injury mechanism was until recently largely confined to conflict 
settings, but has become more relevant in civilian populations owing to an increase in terrorist 
incidents. Injury mechanisms can be more complex than in non-blast TBI, and experience in the 
military setting suggests that the clinical course can also be different.142 Several active research 
programmes are focused on the differences between blast-related TBI and TBI of other causes. The 
most comprehensive of these, from the US Department of Defense, includes efforts to understand 
the epidemiology, identification, management, and treatment of mild TBI, including protocols for 
mandatory screening and detailed clinical recommendations.143,144  
US data from recent conflicts in Iraq and Afghanistan document the lowest killed-to-wounded ratio 
in the history of warfare,519 with many casualties surviving what would previously have been fatal 
injuries. Although advances in body armour might help to explain increased survivial, developments 
in military medical care have likely made a substantial contribution.146 However, a key consideration 
is development of an integrated and effective chain of trauma care in conflict settings (section 4). 
Although the impact of these improvements on TBI outcomes may be less impressive than for other 
trauma (see section 4), understanding the epidemiological and clinical issues facilitates 
improvements in TBI outcome. The lessons learned ? eg, about the effects of improvements in care 
pathways on the burden of TBI ? apply beyond conflict settings and have relevance to the civilian 
population.139,147  
[H4] TBI in offenders  
There is evidence for an association between TBI and crime: TBI appears to be a risk factor for 
criminal behaviour, and a criminal lifestyle might inrease risk of TBI.520 Importantly, there are shared 
risk factors for TBI and criminal behaviour, including socioeconomic adversity and conditions such as 
attention deficit hyperactivity disorder (ADHD), mental health disorders, and alcohol or drug misuse. 
In support of these links, a Finnish birth-cohort study showed that a TBI during childhood or 
adolescence was associated with a four-times increased risk of having a mental health disorder with 
coexisting criminality in men.71 A 35-year, retrospective, total-population study in Sweden showed a 
substantially increased risk of violent crime in people with TBI: 8·8% of those with TBI had committed 
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violent crime, compared with 3% of the population controls (adjusted odds ratio 3·3, 95% CI 3·1 W
3·5); risk was attenuated when those with TBI were compared with unaffected siblings (adjusted 
odds ratio 2·0, 1·8 W2·3).72 Prevalence of TBI is much greater ? 3 W8 times as high ? in offender 
populations than in non-offender groups.73 In a UK prison study, Williams and colleagues found that 
16% of inmates had experienced a moderate-to-severe TBI and 48% had had a mild TBI.74 About half 
of young offenders have had loss of consciousness, with repeated injury being common.73 TBI in 
offenders is associated with earlier offending, higher levels of re-offending,74 violence,75 and 
suicidality.76 A neuroimaging study of prisoners in Germany showed that offenders had a significantly 
higher rate of structural brain abnormalities,77and that violent offenders had significantly higher 
rates compared with non-violent offenders and controls.  
There are intricate links between TBI and ADHD: ADHD can be a consequence of TBI, but it is also a 
risk factor for TBI, and can be complicated by the injury.466 Since ADHD is common in offender groups, 
studies of TBI in these populations should consider the contribution of this condition. In a non-TBI 
study, intervention with medication for ADHD in offenders led to a 30% reduction in criminality, 
possibly owing to improved impulse control.78,456 Screening for and management of TBI in offenders 
is possible,76 and specialist services tailored to offenders with TBI, and comorbid mental health and 
neurodevelopmental disorders, might support changes in behaviour that potentially lead to a 
reduction in crime. 
There is a pressing need for more research to characterise the association between TBI and criminal 
behaviour in offender populations. In particular, longitudinal studies are needed to understand the 
increased risks of crime in those with TBI, the causal relations between TBI and criminal behaviour, 
and the factors that contribute to these risks. Furthermore, studies are needed to characterise 
imaging abnormalities and neuropsychological impairments associated with TBI in offender 
populations to understand how brain injury affects behaviour, including risk of reoffending.520  
[H3] Improving epidemiological studies of TBI 
TBI is a huge but poorly quantified public health problem. The considerable differences in reported 
incidence and mortality rates between countries highlight a need for better standardisation of 
epidemiological data gathering on TBI, for both administrative purposes and research. 
Recommendations for improving epidemiological studies are summarised in the appendix, and 
emphasise the need for standard definitions, standard methods, and standard data presentation. 
Future studies also need to use more standardised methods of data collection, especially for mild 
TBI, to facilitate pooling of data and comparisons between countries and over time.  
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We need population-based studies on the prevalence, incidence, and mortality of TBI across the 
lifespan, particularly in LMICs, to improve the accuracy of estimates of the global impact of TBI. 
Capture Wrecapture methods148,149 could usefully supplement population-based studies, particularly 
when resources are limited. More advanced metrics, including YLLs, years of life with disability (YLD), 
or disability-adjusted life years (DALYs) ? a measure of overall disease burden, expressed as the 
number of years lost due to ill health, disability, or early death ? should be used to better quantify 
the burden of TBI. A simple and cost-efficient approach might be to include a question on TBI in 
routinely conducted health interviews, such as the European Health Interview Survey, which has a 
section on self-reported injury in the past 12 months, and could yield insight on incidence and 
prevalence of TBI in the general population.  
Improvements in completeness and quality of epidemiological data are required for development 
and implementation of policy measures through detection of high-risk populations (such as the very 
young and very old) and identification of key targets for improved prevention and management of 
TBI (sections 3, 4).  
 
[H3] Key messages and recommendations  
(1) Worldwide, TBI is a leading cause of injury-related death and disability, and a huge burden to 
patients and their families. Concerted efforts to address this vast global health problem should 
focus on policies aimed at reducing the burden and impact of TBI, through better prevention, 
improved access to care, and promotion of clinical research to improve treatment standards.  
 
(2) Current epidemiological monitoring is incomplete, especially for mild TBI. Rigorous 
epidemiological studies are needed to capture the changing patterns of epidemiology and 
identify high-risk groups and key targets for improved prevention and management of TBI. 
 
(3) In LMICs, the incidence of TBI due to traffic incidents is increasing, while in HICs, TBI increasingly 
affects elderly people, mostly due to falls. Methodological variations, however, confound 
comparisons of epidemiological patterns of TBI between regions, countries, and continents. An 
international consensus is needed on definitions and standardised epidemiological monitoring 
of TBI to allow accurate measurement of incidence, prevalence, and mortality, and comparison 
of rates of access to community, hospital, and institutional care. 
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(4) TBI might represent an important modifiable risk factor for epilepsy, stroke, and late-life 
neurodegenerative disease. Studies are needed, in children and adults, to better understand 
links between TBI of all severities and an increased risk of these diseases. 
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 ?Ǥ 
Traumatic brain injury (TBI) has a huge economic impact on affected individuals and families, and on 
society as a whole. Understanding the health economics of TBI is an important step in efforts to 
improve efficiency of care and prevention worldwide. However, accurate estimates of TBI costs are 
scarce for many regions, and there is wide variation in reported costs between available studies. This 
partly reflects differences in methods used to calculate costs and variations in definitions of direct, 
indirect, and lifetime costs used in research studies (panel 4).  
 
Panel 4: Definitions of types of costs used in health-economic studies of traumatic brain injury 
Direct costs 
All resources consumed (quantified in costs) within the health-care sector as a result of the traumatic 
brain injury (TBI). Direct costs could also include out-of-pocket expenses and resources outside the 
health-care sector.  
Indirect costs  
All resources foregone as a result of TB. Costs included in this category vary by study but most include 
productivity loss, which arises when people who would otherwise be employed are not able to work 
or work fewer hours because of their TBI. Indirect costs could also include intangible costs due to 
TBI, such as those associated with reduced quality of life or time and effort spent by family members 
on care.  
Lifetime costs  
Costs incurred over a lifetime to provide services to people with TBI that would not be required in 
the absence of the injury, such as ongoing medical care and community services. 
 
Understanding of costs associated with TBI can provide insight into the magnitude and scope of the 
problem and generate the knowledge necessary to anticipate and budget for health-care services 
needed to prevent, detect, and treat TBI. Accurate cost estimates allow assessment of potential 
savings that could be made with interventions aimed at reducing the incidence or improving the 
treatment of TBI. Costs can also be considered to reflect resources used per individual and provide a 
proxy measure of health-care use. Identification of disparities and inequities in access to and delivery 
of health care, crucial for the provision of good treatment, allows researchers and decision makers 
to recognise areas where public health interventions could be beneficial.  
In this section, we review available health-economic data on the costs related to TBI and discuss the 
implications for health-care policy. Furthermore, we suggest directions for future health-economic 
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studies to improve understanding of costs and patterns of health-service use after TBI, which could 
facilitate decisions on prevention strategies and health-service planning.   
[H3] Direct and indirect costs 
The economic consequences of TBI for individuals and for society are enormous. TBI-related costs in 
ƵƌŽƉĞĨŽƌ ? ? ? ?ŚĂǀĞďĞĞŶĞƐƚŝŵĂƚĞĚĂƚ ? ? ?ďŝůůŝŽŶ ?equivalent to about US$48·7 billion in 2016), of 
which direct costs accounted for 41% and indirect costs accounted for 59%.150,151 In the USA, reported 
aggregated direct and indirect cost estimates ranged from US$60·4 billion (about US$84·2 billion in 
2016) in 2000152 to US$221 billion (about US$248·9 billion in 2016) in 2009.153 In the earlier USA 
study,152 15% of the costs were accounted for by lifetime medical costs and 85% by lifetime 
productivity losses. The data from 2009153 showed that 31% of the costs were due to loss in 
productivity and 62% resulted from intangible costs (lost quality of life). The higher total cost 
estimates in the later study might be explained by the inclusion of intangible costs. Costs attributable 
to TBI in Australia in 2008 were estimated to be AUS$8·6 billion (about US$7·7 billion in 2016), of 
which absence from work or productivity loss due to TBI accounted for 55%.154  
Lifetime costs of TBI are high owing to loss of productivity in a substantial number of younger 
patients, but these long-term costs are not considered in all studies. For example, in Europe the 
reported health-service-related and indirect costs for stroke have been estimated to be twice as high 
as those for TBI,150,151 but these comparisons limit reported cost estimates for TBI to the direct and 
indirect costs for the first year after injury. Such calculations grossly underestimate the actual 
societal costs of TBI. 
The average lifetime cost of TBI in the USA was estimated to be US$396 000 per person (equivalent 
to about US$544 000 in 2016).155 In Australia, per-person long-term health-care costs for the first 6 
years after injury ranged from AUS$139 427 for moderate TBI (about US$122 138 in 2016) to 
AUS$226 361 for severe TBI (about US$198 292 in 2016).154 Many studies, especially from the USA, 
use the charges payable by individuals or insurers as a proxy for unit prices (ie, the actual costs of 
provision of care);53 such cost calculations could underestimate total costs, as many patients with 
mild TBI do not seek immediate medical care or are misdiagnosed.  
The omission of mild TBI from many cost studies might result in an overestimate of the average cost 
per individual, but an underestimate of the total cost to society. This is partly because accurate 
population-level data about resource use and the health impact of TBI are scarce. The recently 
completed Brain Injury Outcomes New Zealand in the Community (BIONIC) study was the first to 
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assess the incidence of TBI for all severities across all age groups, in both rural and urban 
populations.3 The BIONIC collaborators found that the cost of treating TBI varies greatly, with first-
year and lifetime costs per person for mild TBI (calculated at US$3395 and US$4636, respectively) 
being significantly lower than those for moderate-to-severe TBI (US$21 379 and US$36 648, 
respectively).16 Other estimates, based on patients admitted to a rehabilitation facility (about $350 
000 for severe TBI,156 for example), underline the high costs of efforts to promote recovery in 
survivors, as rehabilitation interventions are often intensive and prolonged. Costs of care in 
individual patients can be ten times higher, and vary with both injury severity and demographic 
features.156,521 Despite the lower treatment costs of mild TBI for individual cases, the high incidence 
of mild TBI results in a total treatment cost of nearly three times that for moderate-to-severe TBI.16 
Accurate estimates of total global costs of TBI are lacking, but extrapolation from estimates of new 
mild (52 W56 million) and moderate-to-severe (2·2 W3·6 million) TBIs per year worldwide from the 
BIONIC study16 suggests that the global economic burden of TBI could range from US$355 billion 
( ?268 billion) to US$436 billion ( ?329 billion) in 2016, which equates to 0·5% of the annual global 
output, estimated at US$73·7 trillion.5 The actual costs could be even higher as intangible costs, such 
as those related to loss of quality of life or the time and effort spent by family members on care, are 
not taken into account in these estimates.  
Although all studies attest to the high societal costs of TBI, in terms of both medical costs and lost 
productivity, the variation in estimates is striking. Some differences are probably real; however, 
rigorous comparison of these figures is impossible, since the source data are of relatively poor 
quality, calculations involve several assumptions and variable methods, inflation-related changes in 
exchange rates are usually ignored, and the precise cost items included in estimates (and the 
duration of post-injury period to which they refer) vary substantially, or are simply not specified 
(appendix).  
Other indirect consequences, which have rarely (if ever) been taken into account in calculating TBI-
related costs, include caregiver time and eǆƉĞŶƐĞ ?ĐĂƌĞŐŝǀĞƌƐ ?working ability and health, increased 
psychiatric morbidity and injury risk among TBI survivors, increased likelihood of alienation, and 
societal costs, as well as costs related to long-term complications of TBI, including those of dementia 
care.157 Taken together, these limitations underline the need to interpret with caution current 
estimates of health-service use and costs of services. As with other epidemiological data, there is a 
pressing need to ensure uniformity of reporting of health-economic data (section 1). 
[H3] Implications for health-care policy 
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The huge economic burden of TBI worldwide necessitates improved prevention and treatment 
strategies from a health-economic perspective. However, accurate data on costs as a proxy measure 
of health-care use are lacking. Current estimates of the range of total costs are incomplete for both 
mild and severe TBI. For patients with severe TBI, we need better insight into the long-term costs of 
specialised hospital and rehabilitation care. There is a crucial need to couple improved 
epidemiological and economic data collection to rigorous analysis of health-care and lifetime costs 
of TBI, so that we can identify patient groups with high costs of care and deficiencies in access to 
services, and make rational decisions about allocation of health-care resources. Models for 
predicting lifetime costs for individual patients are now emerging, and might also be useful in 
assigning costs to the care needs of survivors of TBI.521 
Data on total costs of TBI, and on indirect costs in particular, are limited. We need improved 
understanding of the negative effects of TBI on work performance, and resulting production losses, 
which dominate the economic burden of TBI. Future research should incorporate the productivity 
costs in cost assessments, as this provides important input for policy decisions and enables priority 
setting on the basis of the total direct and indirect expenses due to injuries. These data are also vital 
to calculate the cost-effectiveness of programmes or treatments to improve the chances of returning 
to work in working-age survivors of TBI. 
Substantial cost savings could be achieved by preventing TBI. At the level of individuals, cost savings 
might be more relevant at the severe end of the spectrum, but the large number of patients with 
mild TBI suggests that effective prevention strategies to reduce incidence of mild injuries could be 
more beneficial at a societal level. Realisation of such cost savings will require investment in 
prevention (section 3). As well as increased governmental investment, additional funds could be 
made available by following the example set by Italy, where a portion of the fees for traffic law 
violations must be spent on traffic incident prevention.522  
[H3] Key messages and recommendations 
(1) TBI results in substantial health-care and societal costs. More effective strategies for TBI 
prevention are vital, and could deliver cost savings that help to fund research and improved 
access to health care for TBI. 
(2) High-quality data on the health-economic effects of TBI are not available for many regions and 
countries, especially for lifetime costs. Increased funding is needed for rigorous and long-term 
health-economic studies on direct and indirect costs, which are necessary to inform rational 
decisions about allocation of resources for clinical care and research in TBI. 
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(3) Methodological variations confound comparisons of the health-economic impact of TBI across 
regions, countries, and continents. International standardisation of methods in health-economic 
research are needed to enable consistent measurement and comparison of costs of TBI care. 
 ?Ǥ 
Traumatic brain injury (TBI) is, to a great extent, preventable, and the benefits for society of 
decreasing its occurence are far-reaching: TBI prevention saves lives, reduces prevalence of 
disabilities, and saves costs inside and outside the health-care system. Although TBI prevention 
strategies (such as those aimed at road traffic safety) in some regions have been remarkably 
successful, these achievements are not universal. Increased use of motor vehicles in low-income and 
middle-income countries (LMICs), coupled with an inadequate infrastructure and insufficient 
adoption of safety measures, have resulted in substantial increases in the burden of TBI.160 Successes 
achieved in prevention of TBI from road traffic incidents in high-income countries (HICs) need to be 
replicated in LMICs. Furthermore, steps need to be taken to address increases in TBI in other 
demographic contexts, including specific measures to reduce the incidence of TBI caused by falls in 
the elderly, and to prevent brain damage in children and in amateur and professional athletes.  
Prevention measures that target injury occurrence, whether primary or secondary measures, should 
be informed by knowledge of epidemiology, TBI cause, and identification of risk groups. Primary 
prevention is directed at prevention of injury occurrence, whereas secondary prevention aims to 
reduce the occurrence of TBI or limit its severity if an injury happens.  
Primary and secondary approaches can be effective in isolation, but use of both prevention strategies 
is needed to maximise benefits. Prevention initiatives can be applied at a population level (eg, with 
legislation, improvements in infrastructure, vehicle safety design, trauma care, and workplace safety 
measures). Alternatively, prevention measures can focus on high-risk subgroups. Examples include 
the targeting of drivers and cyclists to prevent alcohol-impaired driving, speeding, and distracted 
driving; promotion of seat belt, child restraint, and helmet use; a focus on elderly people living alone 
and at risk of falls; and strategies aimed at children at risk of abuse. Finally, it might also be possible 
to specifically target individuals to address their behaviour and risk-taking patterns.159 Irrespective 
of the target population, information campaigns should employ a range of measures to raise 
awareness of key issues in prevention and care of TBI.  
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In this section, we discuss approaches to reduce the occurrence and impact of TBI, focusing on 
prevention of TBI from road traffic incidents, TBI in children and adolescents and the elderly, and 
sports-related TBI.  
[H3] Prevention of TBI from road traffic incidents 
Globally, TBI remains predominately a disease of the young, with road traffic incidents being the 
major cause in LMICs, where vulnerable road users (pedestrians and cyclists) are particularly at 
risk.160 ǀĞŶƚŚŽƵŐŚ>D/ƐŚĂǀĞŽŶůǇŚĂůĨŽĨƚŚĞǁŽƌůĚ ?ƐǀĞŚŝĐůĞƐ ? ? ?A?ŽĨƚŚĞǁŽƌůĚ ?ƐƌŽĂĚĨĂƚĂůŝƚŝĞƐ
occur in these regions,460 a substantial proportion of which are preventable.  
Reduction of traffic-related injuries is the focus of the UN Decade of Action for Road Safety (2011 W
2020), which aims to halve the 1·3 million traffic-related deaths each year by 2020 through improved 
road-safety management, enhanced road and vehicle safety, better-informed road users, and an 
improved post-crash response.161 These improvements are relevant to TBI, since it is a major cause 
of all injury-related deaths (section 1).33,35,162 A recent World Health Organization (WHO) report on 
road safety158 provides specific recommendations for improving road safety, based on interventions 
with proven efficacy. Reductions in speed limits have played a crucial part in decreasing crash 
incidence and injury severity.163 W165 A systematic review of studies from HICs confirmed that 
enforcement of traffic rules decreases road-user deaths.166,167 Non-legislative approaches are equally 
relevant, and include developing safer roadway infrastructure (separating pedestrians and cyclists 
from motorised vehicles), introducing traffic-calming measures, and implementing vehicle and 
safety-equipment standards.168 Other effective population-wide strategies for preventing road 
crashes, injuries, and fatalities include the installation of red-light cameras169 and street lighting.170  
Secondary prevention strategies include use of protective head gear and car safety measures. 
Mandatory helmet use has decreased the number and severity of head injuries in both motorcycle171 
and bicycle users.172 W174 In Taiwan, introduction of the motorcycle helmet law in 1997 reduced 
motorcycle-related head injuries by 33%, and injuries that did occur were less severe and associated 
with shorter hospital stays.175 Despite strong evidence on the efficacy of helmets to reduce the 
severity of injuries from motorcycle crashes and increase the likelihood of survival, helmet laws are 
not universally implemented, even within the USA.523 
In HICs, recent attention has focused on the risks incurred by distracted drivers.177 The likelihood of 
a safety-critical event occurring while driving has been reported to be six times higher for drivers 
dialling a cell phone and 23 times higher for those texting. Although campaigns aimed at influencing 
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ĚƌŝǀĞƌƐ ?ďĞŚĂǀŝŽƵƌƌĞŵĂŝŶƌĞůĞǀant, technological solutions should also be considered. In particular, 
there have been suggestions to develop smart solutions to recognise and block non-hands-free cell 
phone use while driving.177  
[H3] Prevention of TBI in children and adolescents 
The topic of TBI in children and adolescents has substantial emotional, legal, and financial 
ramifications. Children and adolescents are at particularly high risk of accidental TBI, and such 
injuries in this group can have substantial effects on families and communities worldwide. Most 
prevention strategies outlined for road traffic incidents and for sports injuries ? particularly those 
related to concussion detection and prevention from sports injuries, and helmet laws for bicycles, 
motorcycles, and other motorised vehicles ? apply to both children and adults. However, two aspects 
of injury prevention are unique to children: the use of car seats and the concept of multi-agency 
safeguarding for children at risk of abuse, with infants being the most vulnerable.112 
Community-based interventions to promote the use of child car-seat restraints can reduce the risk 
of motor vehicle occupant injuries by 33 W55%.176 In the USA and other areas of the world, local laws 
state that children should be restrained in car seats while the motor vehicle is in motion. For example, 
in Pennsylvania, USA, all children under 8 years of age travelling by car are required to be in a child-
restraint system, with children under the age of 2 years in rear-facing seats. Furthermore, the law 
mandates the use of seat belts for children aged 8 W18 years. These state laws178 are broadly 
replicated in the national best practice recommendations of the US Preventive Services Task Force.461 
Similar laws or guidance exist in many other countries (eg, the European Union [EU], UK, 
Australia);462 W464 however, such regulations are not universal, and even when in place, are 
inconsistently applied.465  
Child abuse or non-accidental trauma has become more widely recognised as an important cause of 
TBI in infants and children. Since awareness of child abuse has increased and family risk factors have 
been elucidated, local programs have been developed in the USA and other countries to educate 
parents about the dangers and long-term effects of brain injury, and to provide caregiver relief and 
advice on coping skills for stress. In the USA, the concept of safe havens for children at risk of abuse 
has been advanced,179 whereby parents who fear they might harm their baby or child can leave the 
child without risk of prosecution. These safe havens are often paediatric hospitals or family refuge 
shelters that provide emergency medical care for the child and assume protective custody until the 
appropriate state authorities can find a more definitive or optimum placement. Whether these legal 
remedies have reduced the incidence of TBI in these children is not clear, and the possibilities of 
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furthering the cycle of abuse in alternative placements has not been studied.466 More research is 
therefore needed to understand the effectiveness of this and other potential interventions, along 
with efforts to educate caregivers and others involved in the lives of children and adolescents to 
prevent TBI in this vulnerable group.   
 [H3] Prevention of TBI in the elderly 
Prevention strategies need to take account of changing epidemiological patterns, which show 
increases in fall-related TBI in older individuals (section 1).41,94,180 W183 Frail elderly people are more 
likely to fall, more likely to suffer a TBI when a fall occurs, and more likely to suffer long-term adverse 
effects even from a seemingly mild TBI.524 There is a clear need, therefore, to address causal risk 
factors and to explore preventive strategies that address the association between frailty and 
vulnerability to TBI through falls.  
Assessment of frailty now involves the use of validated tools, and can be implemented as part of 
health policy.184 Such assessment is clearly important as a primary TBI prevention strategy. Detection 
of frailty can trigger assessment and modification of the home environment (including the provision 
of safety rails for stairs and steps), and prompt critical evaluation of the risk Wbenefit ratio of drugs 
that increase the likelihood of an adverse impact of falls (eg, sedative drugs and medications 
associated with postural hypotension, and anticoagulant and antiplatelet drugs). Frailty assessments 
(and subsequent interventions) were originally the domain of geriatricians rather than primary care 
physicians, and initial trials focused on reducing falls and fall-related injuries in acute hospital 
settings.185 However, emerging data suggest that these interventions can be more usefully applied 
in primary care.186 An example is the Stopping Elderly Accidents, Deaths, and Injuries initiative of the 
US Centers for Disease Control and Prevention (CDC).187 Risk assessment for falls, followed by 
implementation of an individualised management plan, has been shown to reduce falls by 24%,188,189 
highlighting the crucial importance of fall prevention in the elderly as a highly effective TBI-
preventive approach. 
[H3] Prevention of sports-related TBI 
Ongoing research aims to determine the long-term consequences of single concussive injuries. 
However, increasing evidence indicates that multiple concussive and subconcussive impacts can 
have cumulative effects, including more severe symptoms and more prolonged recovery than after 
a single injury of similar severity, as well as increased vulnerability to brain injury and heightened risk 
of any subsequent injury.190,191 In children and adolescents, there are additional concerns about 
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cumulative cognitive and behavioural sequelae of multiple concussions on brain development and 
learning.192 Children and young adults are also at increased risk of second-impact syndrome.122,123  
These emerging concerns underscore the importance of immediately removing anyone from play 
when there is any suspicion of a possible TBI. This recommendation is highlighted in training 
programmes for coaches and parents but, unfortunately, is not always applied in professional sports. 
During the FIFA (Fédération Internationale de Football Association) World Cup in 2014, there were 
several incidents of apparent concussion in players who were allowed to continue play, which led to 
Ă ĐŚĂŶŐĞ ŝŶ ƚŚĞ &/& DĞĚŝĐĂů ŽŵŵŝƚƚĞĞ ?Ɛprotocol, whereby a team doctor now has the 
responsibility and sole authority to make an assessment about suspected concussion and decisions 
about return to play.193 We argue that professional sports organisations should be obliged to remove 
any player with a suspected TBI from play immediately, thus setting an example for amateur athletes 
and, in particular, young players. Such decisions should not be taken by interested parties (eg, 
coaches), but rather by a neutral party such as an independent medic or ? if not available ? the 
referee. Various international efforts have been initiated to develop, refine, and implement rational 
guidance for players, parents, and coaches about the time that needs to be spent away from training 
and contact sport following a concussion.525,526 However, further refinement in diagnosis is needed, 
as is guidance on action required when concussion is reliably diagnosed.194,195  
 
[H3] Key messages and recommendations 
(1) TBI is, to a great extent, preventable, and societies can achieve considerable gains by decreasing 
its occurrence. Policies aimed at reducing the burden of TBI should focus on awareness 
campaigns and prevention of TBI in general, and on strategies to specifically target high-risk 
groups. 
(2) In LMICs, the incidence of TBIs due to traffic incidents is increasing. The recommendations of 
WHO on road safety158 need to be implemented in all countries.  
(3) Children and adolescents are at particularly high risk of accidental TBI. Prevention programmes 
should target contexts in which such injuries typically occur ? eg, promotion of better car safety 
worldwide, promotion of helmet use by bicycle and motorcycle users and in sports such as ice 
hockey, and education for coaches and parents of children who participate in sporting activities 
are needed.  
(4) Non-accidental injury is an increasingly recognised cause of TBI in infants and children, and 
although some policies to reduce this risk are currently in place, their effect is uncertain. Further 
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research is needed to evaluate current initiatives and to explore new options for reducing TBI 
due to child abuse. 
(5) In HICs, epidemiological patterns of TBI are changing, with an increase in elderly patients with 
TBI-related falls. Prevention programmes and health-care delivery need to be tailored to these 
changing epidemiological patterns, and specifically to prevention of falls in the elderly. 
(6) Repetitive concussions that occur before recovery from an initial concussion can be associated 
with more severe symptoms and more prolonged recovery than a single injury of similar 
severity; therefore, any risk of an early second injury after even a mild TBI should be avoided. 
Professional sporting organisations should set an example for children and amateur athletes by 
immediately removing from play anyone with a suspected concussion.  
 ?Ǥ 
In an ideal world, all patients would have access to optimum care for traumatic brain injury (TBI), 
meeting standards of best practice, with continuity of care guaranteed from prehospital to postacute 
care. In reality, systems of care for patients with TBI show substantial variation between and within 
countries,196 W199 with disconnects in the trauma chain, particularly between acute and postacute care. 
Understanding such variation is crucial: practice variations influence TBI outcome and health-care 
costs (section 2), and broad implementation of best practices and guidelines to improve care 
pathways has great potential for improving cost-effectiveness and overall outcome after TBI.  
The spectrum of clinical care for TBI extends from immediate on-site emergency care (lasting minutes 
to hours) to long-term postacute care (extending for years or even a lifetime). This care pathway 
includes several decision points with competing options for care (figure 5). Appropriate choices can 
enable delivery of high-quality, cost-effective care, whereas poor choices incur the risk of disrupting 
continuity and reducing quality of care. Variations in systems of care are largely driven by differences 
in resource availability, local practice, financial frameworks,200 and physician preferences, in addition 
to a general lack of strong evidence to support guideline recommendations. 
 
Figure 5: The chain of trauma care for traumatic brain injury 
The pathway of trauma care ? from on-site emergency care to postacute care ? includes several decision 
points. Continuity of care through the trauma chain enables delivery of high-quality, cost-effective care. Any 
delays or inappropriate interventions at these decision points, or miscommunication between links in the 
trauma chain, can reduce quality of care and lead to increased risk of complications, poorer recovery, or death.   
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In this section, we discuss the current structure and practice of health care for patients with TBI, 
focusing on variations in systems of care in the prehospital, acute, and postacute phases, and we 
consider the cost-effectiveness of interventions. We also address specific challenges in low-income 
and middle-income countries (LMICs) to understand the barriers and opportunities for 
implementation of improved systems of care and best practice.  
 
[H3] Prehospital care  
Prehospital care marks the start of the chain of trauma care and comprises various components: first 
responders, dispatch systems, basic response, mobile medical team, helicopter emergency medical 
services, and hospital choice.201 Together, they form the essential bridge to definitive care. The 
concept of the initial post-injury golden hour is especially pertinent to TBI. Suboptimal care in the 
prehospital phase could result in a progressive cascade of events with detrimental effects throughout 
the subsequent disease course.  
Lack of adequate prehospital care is a particular problem in LMICs (panels 3, 5, 6, 7). The BEST-TRIP 
(Benchmark Evidence from South American Trials: Treatment of Intracranial Pressure) trial,202 
conducted in Bolivia and Ecuador, showed that a third of patients with severe TBI were brought to 
hospital in vehicles other than ambulances, and long transit times were reported. In high-income 
countries (HICs), large variations exist in the structure and processes of prehospital care.203 W207 
Several specific questions remain to be answered ? eg, whether it is beneficial to spend time 
stabilising patients at the scene of injury before transfer rather than transferring them to hospital as 
rapidly as possible (so-called stay and play vs scoop and run). Whether transfer teams should include 
physicians, and when the use of helicopters becomes clinically beneficial and cost-effective also 
remain unclear. A survey conducted in 71 neurotrauma centres in Europe revealed striking 
differences in dispatch systems (23% dynamic vs 73% selective), in basic response (58% advanced life 
support vs 41% basic life support), and with regard to policy at the scene (35% scoop and run vs 51% 
stay and play. Uncertainty exists about best practice and whether this should depend on local 
settings (eg, rural or urban) and distances between the injury location and the hospital (general or 
specialist) offering care. 
 
Panel 5: Challenges for traumatic brain injury care in Latin America  
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Although intensive care unit (ICU) management in Latin America often meets high standards of care 
despite resource and funding limitations, such facilities are not universally available,554 and 
prehospital and postacute care are underdeveloped. Over a third of patients with traumatic brain 
injury (TBI) arrive at hospital in vehicles other than ambulances,202 and ambulances generally provide 
only transportation without major resuscitation interventions. In the post-ICU phase, nurse-to-
patient ratios are very low, much routine care is left to families, and rehabilitation services are largely 
unavailable. In a recent clinical trial, none of the 324 study participants received rehabilitation 
care.202 Although the risk-adjusted ICU death rate is similar to that for high-income countries (HICs) 
at 14 days, mortality after ICU discharge is three times higher.202 Since post-ICU support does not 
match the high level of ICU care, the benefits on long-term outcome are compromised. These 
deficiencies could be addressed not only through increased resource allocation, but also by 
implementing change at the systems and policy levels to improve TBI outcomes in LMICs. Prospective 
trials of specific interventions (eg, physiotherapy, inpatient rehabilitation) are impossible in HICs, 
where their availability is standard, but are feasible and ethical in LMICs. When appropriate decisions 
are taken at each step in the care pathway and the links in the trauma chain remain connected, high-
quality care with positive outcomes can be achieved (panel 6). Access and continuity of care should, 
however, be structurally assured, and not dependent on chance or socioeconomic privilege. 
 
 
Panel 6: When all the pieces fall into placeͶa patient testimony 
In 1988, at the age of 12 years, Laura E Gonzalez-Lara fell down an orchestra pit and suffered a 
traumatic brain injury (TBI) as she took part in a concert in a small town in Mexico. In the following 
patient testimony (abridged), Gonzalez-Lara describes what is possible when high-quality, joined-up 
acute and postacute care are made available, even after a delay in the identification of TBI. At 
present, such care is inconsistently available to patients in low-income and middle-income countries. 
Gonzalez-Lara benefited from the support of her parents, both physicians, and extended family. For 
the full testimony, see appendix.  
Hospital presentation and admission 
During the fall, I fractured my skull, causing a tear in one of the blood vessels overlying the brain. At 
the time, I only complained of a headache. We went through with the concert, though I was feeling 
short of breath by then and felt the stage lights were too bright: I could not actually play and only 
pretended by moving my fingers. Later, as we were getting on the bus, I felt nauseous and vomited. 
It was on the bus where I finally lost consciousness. Back in my hometown of Puebla, my mother 
immediately took me to the local university hospital where she was an attending physician. By the 
time I arrived, my Glasgow Coma Scale score was estimated to be around 7. I benefited from the 
combined experience of two neurosurgeons to evacuate the haemorrhage roughly 5 hours after the 
fall. Next morning, I was transferred to the best intensive care unit in the city by ambulance. 
Postacute care and rehabilitation 
Before the week was over, a physiatrist prescribed exercises for my parents to do with me. By the 
end of the week, I was able to walk and move my right arm. I was released from the hospital a week 
and a day after the fall to the care of my parents at home. My physiatrist followed up regularly during 
the first month and adjusted exercises as needed. I had absence seizures and was on anticonvulsant 
medications until I was around 21 years old. I had regular blood work, electroencephalograms (EEGs), 
and follow-ups with neurologists and neurosurgeons to make sure everything was under control. The 
other sequela that lingered was a short-term memory impairment. I continued to work on fine motor 
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control for some time; after several months, I was playing the recorder and the flute again and even 
rejoined the orchestra. 
 
 
Panel 7: Evolution of traumatic brain injury care in China  
Care for patients with traumatic brain injury (TBI) in China is coordinated primarily by 
neurosurgeons. Progress of Chinese neurosurgery, first founded with Russian cooperation in the 
1950s, was completely halted during the Cultural Revolution from 1966 to 1975. Since then, the 
implementation of modern imaging and monitoring equipment has advanced TBI care. This process 
has been enhanced by periods of training for Chinese neurosurgical trainees in Europe and North 
America. Improved systems for prehospital management and transfer to nearby (level I or level II) 
trauma hospitals have gradually been implemented. The 120 free-call emergency telephone system 
has been set up in most areas of the country to facilitate rapid response and quick transportation. 
In the past decade, the rapid economic growth in China has been accompanied by substantial 
advances in the care of patients with TBI. Specific gains have been achieved through legislation on 
alcohol and driving, improved prehospital management, increased access to CT scanners, wider 
availability of neurosurgical services out of hours and at weekends, and increased access to 
neurointensive care. Teaching programmes and other implementation strategies have increased 
awareness of the importance of guideline-based management of TBI. Chinese TBI guidelines have 
been issued for management, drug treatment, intracranial pressure (ICP) monitoring, and 
decompressive craniectomy.251 W254 Catheters for ICP monitoring, however, still need to be paid for 
ďǇƉĂƚŝĞŶƚƐ ?ĨĂŵŝůŝĞƐ ?resulting in a low rate (24·5%) of ICP monitoring for severe TBI in China.82 
International collaborations are increasingly being established, facilitating integration of Chinese 
research into the international community. Comparative analyses that emerge from such 
collaborations provide cause for optimism: mortality and unfavourable outcome after severe TBI 
(Glasgow Coma Scale scores 3 W8) in specialised centres are 22% and 50%, respectively,82 which 
compare favourably with reported rates in HICs.102  
Nevertheless, despite these advances, long transport times from the scene of accident to hospital 
are common because of large distances or major traffic jams in most Chinese cities (very few 
patients with severe TBI are transported to hospital by helicopter or medical airplanes). Further 
challenges include incomplete cost coverage, as well as shortages of trained neurosurgeons and 
limited access to specialist care, especially in the western regions of China and outside large cities. 
Moreover, the implementation of evidence-based management across China still has a long way to 
go. Despite efforts towards standardisation, use of treatments without proven therapeutic effects, 
such as neuroprotective agents, is common, and many neurosurgeons in China still treat patients 
with TBI according to their personal experience. Increased awareness of these challenges is needed 
to guide health policy and direct investment to close the gaps in TBI care in China.  
 
These uncertainties about the delivery of prehospital care for TBI, and the involvement of multiple 
emergency providers (paramedic, fire, and police services), highlight the need for clear and widely 
accepted practice recommendations for prehospital trauma care. Evidence and experience from 
settings in which risk of TBI is high, such as military settings, might support the development of 
recommendations more broadly.  
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As with civilian TBI, a key consideration in military settings is the need for an integrated and effective 
chain of care throughout the casualty care continuum, including battlefield first-responder care, 
tactical field and evacuation care, and subsequent care across the global military care system.145 
While developments in military medical care in the past decade have clearly made a substantial 
contribution to improved overall survival rates for military personnel injured in conflict areas,146,519 
advances in the treatment of TBI, especially on the battlefield and in the postacute phase, have been 
less impressive.146,527 In more severely injured patients, potential challenges in this context include 
triaging intracranial bleeds and the stabilisation or treatment of concomitant polytrauma 
accompanying TBI at the point of injury and during transportation to specialist trauma centres, which 
can provide the advanced multidisciplinary expertise needed for optimal management of TBI.146 TBI-
related disabilities pose formidable challenges for treatment and rehabilitation, and strategies to 
address these issues include ambitious plans to bring advanced care closer to the injury location to 
ensure rapid intervention within the golden hour.147 These advances are important not only for 
military TBI (and trauma in general), but also for civilian TBI, since the technologies and systems 
developed and refined through these initiatives can inform civilian TBI care.147 
[H3] Hospital care  
Controversy exists about whether patients with more severe TBI should be transported to the 
nearest hospital or taken directly to a specialist trauma centre with specialist care facilities that 
should encompass neurosurgery, neurocritical care, neuroradiology, and neurorehabilitation. This 
controversy is partly due to challenges in reliably diagnosing and categorising the severity of TBI at 
the scene of injury. Retrospective analyses210 W212 of administrative and registry databases suggest 
that transfer from non-specialist hospital settings to specialist trauma centres, and possibly to high-
volume centres, can reduce mortality and improve functional outcome and cost-effectiveness. 
Additionally, many studies suggest that care in centres that practice intensive protocol-driven 
therapy (typically including intracranial pressure [ICP] monitoring) is associated with lower mortality 
and better outcomes in patients with severe TBI.213 W218 Although the benefits of concentration of care 
are generally accepted for patients requiring neurosurgical intervention, identification of such 
patients at the scene of injury is seldom possible ? in one study, only 7% of patients triaged with TBI 
required neurosurgery.209 Consequently, policies regarding primary transfer to trauma centres vary 
widely.  
Transfer to specialist centres might also benefit patients who do not require operative neurosurgical 
intervention at presentation. Supporting evidence comes from registries,210 and from the large 
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prospective RAIN (Risk Adjustment In Neurocritical care) study of patients with TBI who required 
intensive care, which corrected for key known covariates.219 This study showed substantial 
improvements in the risk-adjusted odds ratio for mortality (0·52, 95% CI 0·34 W0·80) in patients 
treated in a specialist trauma centre compared with those who were managed in non-specialist 
centres.219 An equally important consideration is identification of patients who do not benefit from 
acute transfer to a specialist centre, since avoidance of such transfers could have substantial health-
economic and social benefits. Additionally, there are clear risks of transfer, such as deteriorating 
oxygenation or low blood pressure, which could be detrimental even at levels above the commonly 
quoted systolic threshold of 90 mm Hg.220 These risks need to be balanced against the advantages of 
care in a specialist centre, which include specialist expertise and other supportive services, the 
benefits that accrue from increased caseload, and more rapid access to neurosurgical intervention if 
the need for surgery emerges. Furthermore, for the most severely injured patients, experience and 
multidisciplinary approaches are essential to deal professionally with questions concerning diagnosis 
of brain death and possible organ donation. Despite some uncertainty and inconsistent 
implementation, authoritative national and regional guidelines recommend the transfer of patients 
with more severe injuries to specialist centres,221 and although not completely implemented, this 
practice seems to show outcome benefits for adults with severe TBI in some settings.218  
Overall, the evidence for centralisation of care in specialist centres is stronger for paediatric TBI, 
particularly for more severely injured children and adolescents.222,223 At the milder end of the TBI 
spectrum, dissemination of knowledge about best care of patients with TBI to community 
professionals, who manage the vast majority of children and adolescents with minor or mild TBI, 
might be more advantageous. In adults and children, the effects of so-called mild TBI should not be 
underestimated: postconcussion symptoms have been reported in up to 64% of patients with mild 
TBI.224,225 Written discharge instructions and standard follow-up care, either in the hospital 
outpatient setting or by general practitioners, are advocated but inconsistently implemented. A 
survey of 71 European neurotrauma centres528 found that the majority of centres (n=54, 79%) had 
printed discharge information available for patients with mild TBI who had been seen in the 
emergency department, but that only 10% of centres routinely scheduled follow-up visits for these 
patients.226 
[H3] Postacute care 
For the postacute phase, there are great disparities in systems of care and patient management 
between countries, within countries, between institutions, and even from patient to patient within 
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centres of care. A common disconnect between acute and rehabilitation services further compounds 
these problems. Inadequate access to rehabilitation services can slow or complicate recovery, 
increasing the burden of care and compromising functional outcomes. Patients who experience 
discontinuities in care have poorer outcomes than those in whom the chain of rehabilitation is 
continuous.227 
A substantial proportion of people with severe TBI regain functional independence between 1 and 5 
years after injury,228,229 but this depends on provision of specialised neurorehabilitation.230 In 
practice, many patients (up to 55%) are discharged home or referred to a non-specialist facility after 
acute care ? often without any referral to rehabilitation therapy.231,232 This raises questions about 
equity of access to health care, which should be high on the policy agenda. 
[H3] Cost-effectiveness of systems-level management strategies 
Although the clinical benefit of care for patients with severe TBI in specialist trauma centres has 
reasonably wide acceptance, formal assessments of the cost-effectiveness of such strategies are 
scarce. The RAIN study suggested that transfer to specialist trauma centres was cost-effective, even 
when neurosurgical intervention was not indicated.219 An analysis from the UK National Institute for 
Health and Care Excellence (NICE) found that adoption of algorithms for the selection of patients 
with TBI for CT imaging of the head and spine, incorporated into NICE guidelines for TBI management, 
was cost-effective.221 However, a recent systematic review showed that evidence of economic 
benefit was not available for most other interventions for TBI (panel 8), and much of the existing 
evidence was of poor quality.233  
 
Panel 8: Cost-effectiveness of interventions for traumatic brain injury 
x Selective secondary transfer to specialist trauma centres for patients who present with a 
Glasgow Coma Scale score of less than 9 at the injury scene: could save £20 000 per quality-
adjusted life-year* (QALY) gained.209  
x Management of patients with TBI in dedicated specialist trauma centres: could save £14 000 
per QALY gained.239 
x Early transfer of patients with TBI to specialist trauma centres in the absence of need for 
definitive neurosurgery: could save £11 000 per QALY gained.239  
x Liberal use of computed tomography (CT) scanning in children and adults with suspected mild 
TBI on the basis of a high-sensitivity decision rule: could save costs and gain QALYs. 236, 237 
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x Selective CT scanning of adults with mild TBI on the basis of the Scandinavian Neurotrauma 
Committee 'ƵŝĚĞůŝŶĞƐ ?ǁŝƚŚĂĚĚŝƚŝŽŶŽĨƚŚĞďŝŽŵĂƌŬĞƌ^ ? ? ? PĐŽƵůĚƐĂǀĞƵƉƚŽ ? ? ?ƉĞƌƉĂƚŝĞŶƚ
if guidelines are strictly followed.238 
x Management of patients with severe TBI according to the Brain Trauma Foundation Guidelines: 
implemention across the USA could yield societal savings of more than US$3 billion.155  
x Early initiation of continuous chain of rehabilitation care: could save more than US$4000 per 
patient.227  
Cost-effectiveness analyses are not available for many TBI interventions, and for those that are available, the 
evidence is mainly of poor quality. *One quality-adjusted life-year corresponds to a year spent in perfect 
health.  
 
Evidence on the cost-effectiveness of rehabilitation interventions for TBI is also inadequate. A US 
National Institutes of Health (NIH) consensus statement in 1998234 noted a scarcity of quality 
publications on this topic and made recommendations to address evidence gaps. There has been 
little progress since then. Some organisational approaches, such as the appointment of a case 
manager to facilitate rehabilitation access, have face validity and are highly valued in anecdotal 
accounts from patients and families, but there has been little formal evaluation of cost-
effectiveness.235 By contrast, a recent decision-tree analysis of rehabilitation for TBI concluded that, 
compared with a broken chain of care, adopting a more integrated approach yielded a clinically 
relevant decrease in disability, while saving more than US$4000 per patient.227  
Good data on cost-effectiveness of systems of care for TBI are crucial for planning resource allocation 
and for identifying the most cost-effective interventions. Such data need to be viewed in relation to 
local case mix, resource availability, and cultural contexts. Thus, patients with mild and severe TBI 
will have different rehabilitation needs, and survivors who have the support of extended family might 
have different rehabilitation needs compared with those who do not. Different treatment 
recommendations might apply to different subgroups, and cost-effectiveness models should be 
developed separately for each subgroup. Sensitivity analyses are essential when cost-effectiveness 
assessments are undertaken in potentially heterogeneous groups. 
[H3] Specific challenges in low-income and middle-income countries 
About 90% of trauma-related deaths occur in LMICs.460 Disability-adjusted life years (DALYs) due to 
injury progressively rise with decreasing national income levels.240 Moreover, the relative proportion 
of TBI in injury cases is greater241 and the odds of dying as a result of TBI are more than doubled in 
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low-income settings.242 These poorer outcomes are caused largely by insufficient prehospital 
services, lack of postacute care, and inconsistent access to care (panels 5, 7). In particular, the lack 
of postacute care could offset any potential benefit obtained in the acute phase. However, 
notwithstanding the substantial burden of disease, disability, and death in LMICs, the development 
of centres of excellence in TBI treatment has meant that many of these countries are strong 
contributors to international TBI research ? eg, in influential international randomised controlled 
trials (RCTs), such as the CRASH (Corticosteroid Randomisation After Significant Head injury)243 and 
CRASH-2244 studies ? and occasionally they provide the sole context for key studies, such as the BEST-
TRIP trial202 of ICP monitoring in TBI. This involvement in knowledge generation has not yet been 
translated to international clinical guideline development ? a disparity that reflects the narrative of 
the 10/90 gap 245 within the context of a single disease.  
There is a pressing need to involve LMICs in the guideline development process, beginning with 
centres of excellence and taking advantage of local developments that might provide opportunities 
for change. For example, the recent Indian Transportation Research and Injury Prevention 
Programme report246 provided a comprehensive assessment of road safety in India, and triggered 
policy initiatives247 that promise to improve emergency trauma care along key national highways. 
These operational guidelines, published by the Indian Ministry of Health and Family Welfare,248 aim 
to reduce case-fatality rates from road traffic incidents to 10% by developing a pan-Indian trauma 
care network, where designated basic (level III) trauma centres, which have facilities and personnel 
for resuscitation and onward transfer, are available roughly every 100 km. Emergency neurosurgical 
interventions would take place in more specialised (level II) trauma centres, available roughly every 
250 km on key national highways, and could in some cases be done by general surgeons with some 
neurosurgical training, thus increasing access to emergency neurosurgery within the limitations of 
existing resources. Other countries also need to develop their own health-care strategies in the 
context of local priorities and resources (section 3).  
[H3] Current challenges and future goals 
Management of patients with TBI is complex and requires appropriate expertise, coordination, and 
organisation. Timely interventions delivered by well coordinated multidisciplinary teams of experts 
will increase the opportunities for optimising outcome. However, there are wide variations in 
systems of care throughout the trauma chain, and evidence for best practice to inform guidelines is 
lacking, especially for prehospital and postacute care. Therefore, there is a pressing need for new 
evidence to support clinical recommendations, but in the absence of robust evidence, expert 
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consensus-based recommendations are preferarable to no recommendations (section 9). The wide 
variations in systems of care lend themselves to novel approaches such as comparative effectiveness 
research (CER; section 9) to determine best practice. High-quality cost-effectiveness studies of TBI 
interventions are also warranted to establish the optimum systems of care and to improve access to 
acute and postacute care in particular.  
With regard to hospital care, the cumulative evidence strongly suggests that patients with more 
severe TBI benefit from transfer to specialist trauma facilities, irrespective of whether or not they 
need definitive neurosurgical intervention.210 W212,219 Implementation of such a policy is not simple, 
and requires adequate infrastructure and clear communication. Crucially, such initiatives need to be 
supported by high-quality practice recommendations that reach and influence key clinical 
stakeholders. The creation of a network of major trauma services in the UK, for example, along with 
the clear national guidelines for TBI triage, has increased compliance with current best practice249 
and improved outcomes.250 However, the available infrastructure (eg, number of beds in trauma 
centres) could make full compliance with guidelines difficult. Success of any strategies will therefore 
depend not only on effective knowledge transfer to clinical practitioners (section 9), but also on 
allocation of adequate resources to make changes in practice possible. Achieving improvement is an 
incremental process, and the gains that are targeted (and achieved) will need to take account of local 
health-care systems and resources.  
The rigorous assessment of needs and the articulation of effective policies are particularly relevant 
to LMICs. Some LMICs are moving towards models of care delivery, which, although ambitious by 
recent standards, adopt pragmatic approaches to specialist care, such as the policy initiatives246 W248 
to reduce road traffic incidents and improve emergency trauma care in India. The challenge in these 
settings is to allocate new resources in ways that best serve local needs, rather than using 
frameworks developed for the health economies of HICs.  
[H3] Key messages and recommendations 
(1) Access to health care is often inconsistent between centres, regions, and countries, especially 
for acute and postacute care. Health-care policies should aim to improve access to acute and 
postacute care to reduce the effects of TBI on patients, families, and society. 
(2) Substantial variation exists in systems and quality of care for TBI between centres, regions, and 
countries. For systems or interventions for which best practice is reasonably well defined, such 
approaches should be used as a treatment standard to improve quality of care. In cases for 
which best practice is not defined, increased funding to identify best practice is needed. 
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Implementation of best practice could improve patient outcomes and cost-effectiveness of TBI 
care. 
(3) For optimum care, patients should be moved along a chain of trauma care, from prehospital 
though to postacute care, with excellent communication between caregivers. Improving systems 
of care for patients with TBI and ensuring continuity of care ? through urgent and acute care, 
rehabilitation, and community reintegration ? should be high on the policy agenda. 
(4) Centres with higher caseloads and specialised facilities have better outcomes for patients with 
severe TBI than do smaller centres. Incentives need to be implemented to stimulate transfer of 
adult and paediatric patients with severe TBI to specialist centres. 
(5) The epidemiology of TBI and challenges of TBI care in LMICs are different from those seen in 
HICs. Solutions for improving TBI care and outcomes in LMICs should be tailored to local needs 
and resource availability, rather than replicating strategies in HICs. 
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Management of traumatic brain injury (TBI) is currently based on a combination of medical and 
surgical strategies, and, ideally, rehabilitation to promote recovery and social reintegration and 
address the longer-term complications of TBI. However, many randomised controlled trials (RCTs) of 
interventions for TBI have not shown beneficial effects, or have produced results that cannot be 
generalised to the wider population of patients with TBI. Therefore, when guidelines are available, 
they are often based on weak evidence, supplemented by expert consensus or local protocols 
(section 9). 
Clinical management in the intensive care unit (ICU) has evolved over the past two decades towards 
standardised approaches. The international guidelines that underpin these approaches are based on 
evidence from selected patient groups or on targets derived from population averages, which might 
not apply to all patients. Although efforts to develop evidence-based guidelines for routine use in 
the ICU are a step in the right direction, this one-size-fits-all approach ignores the complex clinical 
and mechanistic heterogeneity of TBI. 
International guidelines for the surgical treatment of TBI are not supported by strong evidence, and 
are implemented inconsistently across geographical regions. Furthermore, there is considerable 
uncertainty and debate about which subgroups of patients might benefit most from some types of 
surgery and the optimum timing of surgery. The decision to operate might be influenced by local 
ƉŽůŝĐǇŽƌƚŚĞƐƵƌŐĞŽŶ ?ƐĞǆƉĞƌŝĞŶĐĞ ?ĂŶĚĂůƐŽĚĞƉĞŶĚƐŽŶŽƚŚĞƌĨĂĐƚŽƌƐ ?ƐƵĐŚĂƐĂůƚĞƌŶĂƚŝǀĞŵĞĚŝĐĂů
options, expected outcome, and patient and family preferences.  
Evidence-based guidelines are not available for most rehabilitation interventions. Even when there 
is recognised best practice, implementation is inconsistent between centres, and often does not 
account for the diversity of disability after TBI, which warrants individualised application of robust 
recommendations.  
In this section, we consider the challenges in medical, surgical, and rehabilitation management of 
TBI, and emphasise the need for more robust evidence to underpin guidelines. Such guidelines 
should allow a flexible approach to enable better targeting of treatment based on improved 
understanding of individual pathophysiology and clinical needs.  
[H3] Intensive care management of severe TBI 
Before transfer to the ICU, the priorities for initial hospital care are stabilisation of the patient, and 
rapid detection and emergency surgical treatment of intracranial bleeding (see below). In the ICU, 
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current guidelines for the medical management of TBI emphasise prevention of second insults, such 
as hypoxia and hypotension, and, for patients with severe TBI, optimisation of cardiorespiratory 
physiology, control of intracranial pressure (ICP), and maintenance of cerebral perfusion pressure 
(CPP).255 Initial ICU management comprises a range of medical approaches to attain these targets, 
including sedation, hyperosmotic infusions (to reduce brain oedema), limited hyperventilation (to 
reduce intracranial volume through hypocapnic cerebral vasoconstriction without causing 
ischaemia), drainage of cerebrospinal fluid, and varying degrees of temperature control (ranging 
from meticulous control of normothermia to induced hypothermia). Aggressive cooling (to core 
temperatures of 32 W34oC), deep sedation (to achieve deep metabolic suppression as evidenced by a 
near-isoelectric encephalogram [EEG]), more intensive hyperventilation, and decompressive 
craniectomy (removal of a portion of the skull to accommodate brain swelling) are often classified 
as third-tier therapies and reserved for patients with refractory ICP elevation.256 Such stratification, 
with prioritisation of more conservative medical approaches, is rational since none of these 
treatments is risk-free and they can be associated with a worse outcome.257,258 However, some 
clinical trials of these interventions have not replicated common clinical settings or timing of 
interventions in clinical practice.259,260  
Current treatment approaches aim to maintain single target values (or target ranges) for ICP and 
CPP, derived from analyses in populations of patients with TBI.255 Evidence in support of this single 
goal-directed approach is inconsistent: one meta-analysis suggests benefit from treatment in a 
centre with ICP-driven management,261 but two meta-analyses suggest no overall benefit from 
aggressive, ICP-guided management.262,263 The only available RCT on this approach to management, 
from Latin America, suggests that clinical care based on imaging and serial clinical examination is not 
inferior to care based on ICP-guided management ? at least in that setting.202 The generalisability of 
these results, from low-income and middle-income countries (LMICs), to practice in high-income 
countries (HICs) is debated, since substantial differences in the chain of trauma care exist between 
the two settings (panel 6).  
A number of neuromonitoring modalities (ICP measurement being the best known) can be used to 
detect incipient secondary injury. However, all these techniques, taken in isolation, are at best 
indirect, and at worst crude measures of a complex disease in a very complex organ. Therefore, 
proving efficacy of treatments on the basis of such unidimensional targets is challenging. 
Furthermore, there is a lack of certainty about the thresholds that justify therapies for raised ICP, all 
of which have intrinsic hazards; these hazards should be balanced against the harm caused by 
intracranial hypertension. Therefore, characterisation of a clinically relevant dose (level and 
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duration) of intracranial hypertension remains an important goal264 and is only just beginning to be 
quantified in a systematic way.265 The recently updated international guidelines for management of 
severe TBI recommend an ICP threshold of 22 mmHg for initiating intensive treatment.255 However, 
there have been challenges that the implicit precision of this threshold is unfounded.467,468 Moreover, 
although population-based targets of ICP and CPP management provide a useful initial basis for care, 
required target values or ranges might depend on the specific pathology529,530 and should preferably 
be directed to the needs of individual patients. TBI is pathophysiologically heterogeneous, and the 
dominant pathological processes can vary between patients, within individual patients over time, 
and even between different parts of the brain at any given time. Furthermore, preinjury factors, 
coagulation status, and systemic responses vary between patients. Using a one-size-fits-all 
management strategy is therefore unlikely to be optimum, and more rational decisions about 
therapy choice and intensity must account for individual and temporal variations in pathophysiology.  
[H3] Surgical management of TBI 
Different types of traumatic intracranial haematoma exist (figure 6), all of which can compress the 
brain and could be life-threatening. Timely surgery can be life-saving, but this depends on rapid 
patient transfer to a centre with surgical facilities (section 4). Initial surgical treatment of TBI can be 
either causally directed (eg, to remove space-occupying intracranial haematomas)266 or symptomatic 
(eg, to decrease pressure on the brain to prevent or minimise damage to important structures and 
prevent life-threatening herniation events). Symptomatic approaches include insertion of an 
external ventricular drain for drainage of cerebrospinal fluid267,531 and decompressive craniectomy, 
which can be performed in the same setting as the evacuation of a haematoma, or later to treat 
diffuse brain swelling that is refractory to conservative medical management.  
Figure 6: Different types of post-traumatic intracranial haematoma 
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(A) Epidural haematoma. Epidural haematomas are located between the skull and the outer membrane 
covering the brain (dura mater). They are mostly arterial in origin and can thus rapidly expand, causing 
clinical deterioration and ? if untreated ? death. (B) Subdural haematoma. Acute subdural haematomas are 
located underneath the dura mater, and are generally associated with bruising of the underlying brain tissue 
(contusions). (C) Haemorrhagic contusion or Intracerebral haematoma. These lesions reflect similar 
underlying pathologies that range from local bruising (contusions) to bleeding into the brain tissue 
(haematoma). Figure courtesy of Maartje Kunen, Medical Visuals, Arnhem, Netherlands.  
 
There is substantial variation in surgical practice owing to an inadequate evidence base for 
international guidelines on surgical indications.268 W270 Additionally, at an individual patient level, 
there is debate among clinicians regarding which patients might benefit from some procedures (such 
as surgical treatment for traumatic intracranial lesions and for raised ICP) and uncertainty regarding 
the optimum timing of surgery. Surgery might be life-saving and preserve neurological function in 
some patients,271 but others might survive with an unfavourable functional outcome, ranging from 
severe neurological and cognitive deficits to a persistent vegetative state.272 W274 Conversely, surgery 
might not always be necessary. Indeed, a substantial proportion of patients who are managed 
conservatively have favourable outcomes.275 W279 Therefore, when deciding whether to operate, 
medical therapies that might be effective in achieving the same physiological goals as surgery should 
also be considered. Surgical indications that are too liberal could lead to an increased number of 
survivors with complications of unecessary surgery in less severe injury, or severe disabilities in 
devastating TBI.  Conversely, inappropriate conservative management might result in unnecessary 
death and disability. The decision to operate is based not only on medical but also on ethical 
considerations. Patients ? ĂŶĚƌĞůĂƚŝǀĞƐ ?ǀŝĞǁs of a meaningful quality of life might be different from 
our medical perception of a favourable outcome. These differences could depend on several factors, 
including cultural and religious considerations. If discussion of the expected outcome with relatives 
is possible, past views expressed by patients on an acceptable quality of life should be taken into 
account.532  
Accumulating evidence provides useful support for such decision-making. An illustrative example is 
the use of decompressive craniectomy for intracranial hypertension. Although the procedure can be 
life-saving by lowering ICP, it is associated with surgical complications, and structural distortions 
associated with removal of a portion of the skull might cause additional brain injury in some 
patients.280 Initially used over a century ago, the intervention came back into use over the last two 
decades, but given the need to balance risks and benefits, a clear definition of its role was difficult.281 W
283 Two important RCTs have provided useful guidance in this context. The DECRA trial257 showed 
 55 
 
that very early use of decompressive craniectomy for modest rises in ICP in patients with diffuse 
injuries was associated with worse outcomes. More recently, the RESCUEicp trial284 showed that, 
when used for refractory severe intracranial hypertension, decompressive craniectomy can save 
lives, but resulted in a 9% increase in survival with severe dependance at 6 months. However, by 12 
months there were 13% more survivors who were at least independent at home. As the intervention 
is not uniformly beneficial, individual wishes should be taken into consideration.  
Other studies have addressed similar surgical dilemmas. A recent study suggested that in patients 
with a traumatic acute subdural haematoma, early evacuation was associated with better outcome 
than a more conservative approach.285 Similar trends were noted in the STITCH trial, 286 which 
reported better outcome with early surgical management in patients with traumatic intracerebral 
haematoma. However, the results of the STITCH trial were not statistically significant owing to an 
inadequate sample size caused by premature discontinuation of the trial by the funding agency.286 
Although surgical trials are challenging, funding bodies should recognise that these and ongoing 
studies (eg, the RESCUE-ASDH trial, ISRCTN registry identifier ISRCTN87370545) are crucial for 
creating a rational evidence base for surgical practice. Clinical decision-making could be greatly 
improved by identification of patient subgroups most likely to benefit from the intervention, and, 
importantly, patients who are not likely to benefit. 
[H3] Rehabilitation after TBI 
The sequelae of TBI include long-term physical, cognitive, behavioural, and emotional impairments 
(panels 2, 7), and difficulties with activities of daily life, community integration, work, social life, 
family functioning, and partner relationships (section 7). 484 Rehabilitation for patients with TBI is a 
complex process, and varies with time after injury, the nature of TBI, premorbid functioning, and 
levels of social support.230  
Succesful rehabilitation after TBI is determined by patient potential, and depends on both the timely 
delivery of therapy and the availability of good metrics to characterise the intensity and effects of 
such therapy. Recent summaries of the available data report that strong evidence in support of many 
rehabilitation therapies is limited, However, these summaries largely concentrate on evidence from 
RCTs, which are difficult to design and conduct in this area.  As in other areas of TBI (see Section 9), 
this makes the case for alternative approaches for clinical evidence generation to underpin 
practice.558,559 Medical or health-care insurance payors often justify bypassing specialised 
rehabilitation programmes by highlighting the absence of RCT evidence for rehabilitation strategies 
in TBI, and disparities exist in the level of postacute care provided depending on insurance status and 
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race.287,533 Acquisition of stronger evidence in support of rehabilitation therapies is challenging. First, 
treatment would need to be withheld from the most severely injured patients who are most in need 
of care, which is uncommon in other specialty areas. Second, rehabilitation schemes should be 
targeted to the specific needs of individuals, which would complicate the design and implementation 
of clinical trials. 
Different rehabilitation interventions are appropriate at different phases after injury (panel 9). In the 
subacute phase, the focus is typically on retraining activities of daily life and adjusting environmental 
factors that enable discharge home. In the longer term, rehabilitation goals focus on community 
reintegration, such as social participation, return to work, and other meaningful activities that 
restore quality of life. However, the optimum timing for rehabilitation is debated: some centres 
advocate early in-hospital initiation,227 but most rehabilitation centres accept patients only when 
they are trainable ? ie, after return of consciousness and once they are out of post-traumatic 
amnesia. Therefore, in practice, these goals are often addressed ? if at all ? by different health-care 
providers, and such services tend to develop in isolation. Rigorous studies are needed on best 
practice in the acute setting and optimum timing of specific rehabilitation approaches. 
 
Panel 9: Categories of rehabilitation interventions for traumatic brain injury 
Restitutional rehabilitation 
Strategies that focus on strengthening or re-establishing previously learned patterns of behaviour 
through repetition and rehearsal.  
Example: repeated exercises and drills aimed at restoring specific cognitive domains, such as 
attention.469 
 
Compensatory rehabilitation 
Strategies that exploit intact strengths to substitute for impaired functions. 
Example: use of assistive technology (eg, calendars, paging systems, electronic memory devices, and 
alarms) for mild-to-moderate memory impairment470 and errorless learning strategies for severe 
impairment.471   
 
Adaptive rehabilitation 
Strategies that accommodate residual impairment or disability through reappraisal of self-
perception (eg, cognitive restructuring); this relates to psychosocial adjustment after injury.  
Example: problem-focused coping and management of self-efficacy beliefs (eg, reduced use of 
avoidance, wishful thinking, and emotional restrictions) to promote positive psychosocial 
adjustment.472 
 
 
The diversity and complexity of the consequences of TBI are best addressed with a comprehensive, 
holistic approach to rehabilitation delivered by a specialised multidisciplinary team, in close liaison 
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with the patient and family or caregivers (the patient-centred care approach).473 Evidence from two 
RCTs supports the effectiveness of holistic neuropsychological rehabilitation in both civilian and 
military populations.474,475 This is consistent with the International Classification of Functioning, 
Disability and Health (ICF), which provides a framework for understading disability that is endorsed 
by the World Health Organization (WHO).288 An important feature of the ICF is that it goes beyond 
traditional biomedical approaches to assessment of disability, providing a biopsychosocial, 
integrative, and comprehensive approach that incorporates factors such as health condition, body 
structure and function, activities and participation, and various contextual factors (personal factors 
and environmental factors) relevant to the patient. This is crucial because the level of functioning for 
a patient is determined not only by what is happening at the level of the body, but also by how the 
environment can affect overall disability level. This approach facilitates identification of 
rehabilitation needs and targets for intervention (panel 10). Further research on rehabilitation needs, 
type, quality, and effects of services is needed to guide clinicians in the use of appropriate 
interventions and policy makers in the development of rehabilitation services for individuals with 
TBI. 
 
Panel 10: Domains of rehabilitation and intervention targets after traumatic brain injury  
 
Physical 
Speech, movement, sensation, perception 
 
Behavioural 
Initiation, persistence, flexibility, impulse control 
 
Cognitive 
Concentration, memory, executive function, communication 
 
Emotional 
Management of anger, irritability, anxiety, frustration 
 
Personal 
Family-related functioning, socialisation, schooling, employment 
 
Environmental 
Access to health-care services and technologies, transportation and mobility, community attitudes 
and social support resources 
 
[H3] Future goals for intervention studies and guideline development  
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Clinical care for patients with TBI is often broadly based on international or local clinical guidelines. 
However, weaknesses in available evidence confound strong guideline recommendations, and most 
guidelines fail to capture the complexity and heterogeneity of TBI and its sequelae. The shortcomings 
in guidelines reflect the limitations of clinical trials in this field. Many clinical trials of medical and 
surgical interventions for TBI have involved strict protocols and recruitment criteria, typically 
restricted by age, Glasgow Coma Scale (GCS) score, and comorbidities. Despite these restrictions, 
such trials have largely failed to show benefit, perhaps in part because they have not accounted for 
patient heterogeneity and hence treatments have not been matched to individual patients or groups 
of patients.260,289 W291 In studies that have recorded a clinical effect of an intervention,390 selected 
patient groups and small sample sizes have limited the generalisability of the results to the wider 
population of patients with TBI. 
In view of the substantial knowledge gaps about optimum management and the challenges of 
conducting clinical trials of interventions for TBI, alternative approaches to evidence generation are 
needed for the development of robust guidelines for best practice. For example, conventional 
evidence-generation methods such as RCTs could be supplemented with comparative effectiveness 
research (CER; section 9), in combination with high-quality observational studies, to determine the 
optimum medical, surgical, and rehabilitation interventions and care models.  
Future approaches to management and guidelines for best practice need to account for the clinical 
and mechanistic heterogeneity of TBI and enable therapies to be more carefully matched to patients. 
Clinical studies should be designed to identify (sub)groups of patients of sufficient size in whom the 
target mechanism is dominant. Patient stratification for clinical and research interventions will 
depend on improved characterisation of initial severity and mechanisms (section 6). Advances in 
outcome assessment are needed for rigorous evaluation of therapeutic effects (section 7), while 
improvements in prognostic schemes could inform research design, facilitate comparisons between 
studies, and provide opportunities for comparative audits to improve quality of health-care delivery 
(section 8). 
Besides these general considerations, progress in specific aspects of care could lead to improved 
management. For example, technical advances in invasive and non-invasive monitoring of blood 
flow, brain metabolism, and electrical activity combined with neuroinformatic methods provide 
novel approaches to targeted therapy development and implementation in the ICU setting (section 
6). Studies of surgical interventions for TBI should focus on identification of subgroups of patients 
most likely to benefit from surgery, rather than investigate its use across all possible patients. Future 
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guidelines should allow a flexible approach to take into consideration non-medical aspects such as 
patient and family preferences and beliefs about the value of life and acceptable levels of disability. 
There is a clear need for studies to inform guidelines on rehabilitation approaches and optimum 
timing of rehabilitation in TBI. Such guidelines would need to take into account the growing evidence 
that the diversity of disability after TBI is best addressed through a holistic approach to rehabilitation 
delivered by a multidisciplinary team.  
A change in focus in the clinical management of TBI is required, with interventions based on an 
understanding of the pathophysiology and clinical needs of individual patients. Implementation of 
such an individualised approach to management should occur in the context of robust evidence-
based guidelines. Thus, new studies need to be rapidly integrated into the evidence base and 
translated into guidelines that reflect the latest findings ? aspirations that are being addressed 
through development of living systematic reviews and living guidelines (section 9). Implementation 
of such guidelines will necessitate effective transfer of the latest knowledge into clinical practice. 
[H3] Key messages and recommendations 
(1) Evidence underpinning guidelines for medical and surgical interventions and rehabilitation for 
TBI is weak. Increased funding is needed to develop robust evidence to inform medical, surgical, 
and rehabilitation management to improve outcomes for patients with TBI. Consensus-based 
guidelines might be needed for aspects of management for which evidence is not clinically 
definitive.  
(2) Existing guidelines for clinical management, based on population targets, promote a one-size-
fits-all approach and do not take into account clinical and mechanistic variability, either 
between patients or within patients at different stages of injury evolution. Research funding is 
needed for clinical studies that account for these differences. New evidence-based guidelines 
should emphasise implementation of best practice in the context of an understanding of 
individual pathophysiology and clinical needs, and permit flexibility to achieve an individualised 
approach to management.  
(3) Existing guidelines are not implemented consistently between centres and across geographical 
regions. Information campaigns to improve awareness among clinicians about guidelines and 
recommendations for best practice are needed. 
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Detailed characterisation of injury severity, type and expected outcome is needed to stratify patients 
with traumatic brain injury (TBI) for optimum clinical management. Such characterisation can also 
be used in research to classify goups of patients with similar disease mechanisms to develop and test 
novel therapies in RCTs or identify best practices in comparative effectiveness research (see section 
9). Conventionally, the initial severity of TBI has been classified as mild, moderate, or severe, on the 
basis of assessment of the level of consciousness, measured with the Glasgow Coma Scale (GCS; 
figure 2).294 However, this unidimensional classification ignores the mechanistic heterogeneity of TBI. 
Pathoanatomical insights into the nature of TBI have come from neuropathology studies,300 which 
have highlighted the importance of ischaemic476 and inflammatory304 responses after TBI, and have 
led to the recognition of diffuse axonal injury302,477 and chronic traumatic encephalopathy 
(CTE)61,66,478 as specific entities in the acute and chronic phases of TBI, respectively. 
In TBI, as in other diseases, specific interventions and management strategies need to be tailored to 
the characteristics and needs of individual patients, moving away from the conventional one-size-
fits-all approach (section 5).293 Improved characterisation and better understanding of 
pathophysiology in individual patients will be necessary to permit appropriate targeting of therapy 
and evaluation of outcome. This approach reflects the concept of precision medicine, as advocated 
by the US National Academy of Science,291 which is dĞĨŝŶĞĚĂƐ “an approach to disease treatment 
and prevention that seeks to maximize effectiveness by taking into account individual variability in 
genes, environment, and lifestyle ? ?292  
Opportunities for improvements in this area come from progress in the fields of genomics, blood 
biomarkers, and advanced magnetic resonance imaging (MRI), as well as new approaches to 
pathophysiological monitoring, coupled with informatics to integrate data from multiple sources 
(figure 7). These technologies are at varying stages of maturity in terms of integration into TBI clinical 
care: some, such as genomic stratification for therapy and outcome prognostication, are at a very 
early stage of development, while others, such as use of the blood biomarker S100 astroglial calcium-
binding protein B (S100B) to stratify patients for CT imaging during the acute phase, have already 
been integrated into some clinical guidelines,324 although not widely accepted. 
In this section, we consider current approaches to characterisation of TBI, discuss the continuing 
relevance of neuropathological studies, and explore how incorporation of emerging technologies 
could improve disease characterisation and monitoring to advance the aims of precision medicine in 
TBI. We also consider the challenges and opportunities in integrating multiple sources of data to 
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facilitate translation of these aims. In subsequent sections, we discuss the need for multidimensional 
approaches to outcome assessment in patients with TBI (section 7), and consider how linking initial 
severity and pathoanatomical characteristics of TBI to multiple outcome domains could lead to 
improved prognostic models (section 8), with substantial benefits for patients and their families.  
Figure 7: Application of precision-medicine approaches to traumatic brain injury 
Findings from observational studies based on clinical medicine and from biomedical research can contribute 
to the body of evidence on TBI (the information commons) and knowledge can be combined and shared (the 
knowledge network) to improve characterisation of traumatic brain injury. Improved characterisation and 
understanding of the disease process will lead to more accurate diagnosis, targeted treatment, and improved 
clinical outcomes. ICU=intensive care unit. 
 
[H3] Current approaches to classification and characterisation 
There are wide variations in TBI type and severity. Additionally, the full, integrated picture of TBI 
comprises a range of pathological changes (eg, diffuse axonal injury, contusions, brain swelling, and 
brain(stem) compression by extracerebral haematomas), which contribute in varying degrees to the 
different clinical pictures in individual patients. It is common to separate penetrating TBI from closed 
TBI because the injury biomechanics are very different and the infection risk in penetrating TBI is 
higher. The management principles therefore differ substantially between penetrating and closed 
TBI. However, there has been little attempt to use the full range of pathoanatomical lesions ? within 
both closed and penetrating TBI ? in a systematic way as a basis for rational planning of management. 
Classification of TBI severity is also challenging: presentation can range from a hit to the head with 
symptoms of disorientation or some alteration of consciousness that quickly resolves, to high-energy 
insults leading to loss of consciousness and coma. There are currently no refined criteria for 
classification of TBI severity. The GCS294 is the most commonly used approach to quantify the clinical 
severity of TBI295 (figure 2), but this is relatively crude and does not reflect different pathoanatomical 
subsets of TBI. Moreover, the increasing use of prehospital sedation and tracheal intubation often 
confounds assessment with the GCS and has reduced its usefulness as a metric of injury severity.296 
Existing International Classification of Diseases codes479 also do not adequately capture severity of 
TBI.534 Alternative TBI coding taxonomies ? including the Abbreviated Injury Scale (AIS), which 
categorises severity of intracranial and extracranial injury,297 and the Marshall classification system, 
which is based on head computed tomography (CT) findings298 ? are anatomically oriented and 
summarise the type, location, and severity of injuries. The AIS, which is used globally by trauma 
registries, classifies each patient ?s regional anatomical injuries, from which an aggregated Injury 
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Severity Score can be derived.299 However, scoring with this scale is generally retrospective, and 
severity ratings can be influenced by factors such as admission to hospital or intensive care unit (ICU) 
or by decisions regarding surgical intervention. The Marshall classification system is unidimensional, 
being restricted to CT findings, and is essentially based on only two discriminating features: the need 
for surgery and radiological signs of raised intracranial pressure (ICP). 
There is increasing recognition that appropriate characterisation of the initial type and severity of 
TBI should not be restricted to one dimension (eg, GCS or CT classification), but should include 
multiple domains such as clinical and pathophysiological features, neuroimaging findings, and other 
factors that might influence clinical outcome.  
[H3] Brain banks and lessons from neuropathology 
Efforts to improve clinical characterisation of TBI can be informed by neuropathological research, 
which has provided a foundation for our current understanding of key pathological processes in TBI, 
including diffuse axonal injury,302,477 ischaemia,476 neuroinflammation,304 and amyloid deposition in 
association with neurodegeneration.61,66,303 However, despite the insights afforded by detailed 
neuropathological examination of human brain tissue,300 there are remarkably few research archives 
containing biospecimens suited to studies in TBI. Indeed, only one comprehensive archive of human 
brain tissue exists ? the Glasgow TBI Archive301 ? which is dedicated to studies across the spectrum 
of TBI. This unique archive contains material from the brains of patients with a range of injury 
severities, survival times, and ages. The value of this resource can be traced through the literature, 
with over 150 peer-reviewed publications supported by material from the archive, including many 
of the landmark studies of diffuse axonal injury and neurodegenerative pathology associated with 
TBI.302 W304 More recent high-profile reports of CTE66,305,535 W538 have facilitated accrual of brain tissue 
from retired athletes, which has enabled development of a dedicated brain bank at the Boston 
University CTE Center. Nevertheless, this growing, albeit focused, archive and the Glasgow TBI 
Archive cannot reasonably sustain the international field of TBI research.  
There remains a pressing need to archive brain tissue linked to robust and prospectively accrued 
clinical information from patients with TBI. The richness of knowledge provided by these resources 
could be substantially amplified by post-mortem imaging studies, which would allow correlation 
between the gold standard of neuropathology and the findings of so-called virtual autopsies306 based 
on advanced and tailored MRI techniques.307,308 Finally, these precious archive resources must be 
networked and made widely accessible to be suitable for international collaborative research. 
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[H3] Genetic analysis 
Outcome after TBI is highly variable (sections 7, 8), and some of the differences in disease course are 
likely to be accounted for, at least in part, by genetic variability between patients (figure 8). In 
oncology, precision-medicine approaches are based mainly on knowledge of the molecular genetics 
of the tumour, whereas in TBI, a key focus for precision-medicine strategies is the genomics of the 
host response, which can modulate injury course as well as repair. Compared with oncology, genomic 
characterisation of TBI is in its infancy. If further developed, identification of relevant genetic risk or 
protective factors early after TBI could potentially be used to inform individualised management 
approaches and thus improve outcomes.  
Figure 8: Potential effects of genetic variation on clinical course and outcome of traumatic brain 
injury 
Genetic factors might influence an indŝǀŝĚƵĂů ?ƐƌŝƐŬŽĨĂŶĚƌĞƐƉŽŶƐĞƚŽtraumatic brain injury (TBI), contributing 
to functional outcomes in the short and longer term. Although still speculative, possible applications of such 
knowledge could include use of genetic factors that might modulate TBI outcome (eg, APOE)310 in a 
comprehensive prognostic scheme, or stratification of patients for clinical trials of treatments on the basis of 
genotypes that modulate the host response (eg, proinflammatory response)542 or influence regenerative 
capacity (eg, brain-derived neurotrophic factor concentrations).481  
The most extensively studied gene in the field of TBI is apolipoprotein E (APOE), which encodes a 
protein that has a central role in lipid transport in the central nervous system (CNS), including 
movement of cholesterol into cells to aid repair of damaged neurons.480 Three APOE variants (alleles) 
have been characterised ?ɸ ? ? ɸ ? ? ĂŶĚ ɸ4 ? and ɸ4 has been reported to have pro-inflammatory 
effects in mice309 and to increase the risk of late-onset AlzheimĞƌ ?ƐĚŝƐĞĂƐĞ in humans.60,313 In TBI, 
although the risk of late neurodegenerative disease scales with injury severity, possession of an ɸ4 
allele might modulate this risk.60 Possession of an ɸ ?ĂůůĞůĞŚĂƐďĞĞŶ ĨŽƵŶĚ ƚŽĚŽƵďůĞ ƚŚĞ ƌŝƐŬŽĨ
dementia in the general population, but this risk might be increased by up to ten times in people 
with TBI.313 Moreover, in a group of patients who had sustained a single mild TBI, only those with an 
ɸ ?ĂůůĞůĞ had an increased risk of dementia in the long term compared with the general population.314  
APOE genotype has also been variably shown to modulate TBI outcome.310 One large study311 of 
patients with TBI undergoing rehabilitation showed that ɸ ?ĐĂƌƌŝĞƌƐ had worse outcomes 2 years 
after injury compared with ɸ ? Žƌ ɸ ?carriers. However, initial findings that the ɸ ? ĂůůĞůĞ ŚĂĚ Ă
deleterious effect on TBI outcome315 could not be replicated in a larger cohort by Teasdale and 
colleagues,312 and a recent systematic review310 concluded that this effect might be limited to 
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patients with severe TBI. These contrasting findings might reflect an interaction between age and 
genotype on outcome, as suggested by Teasdale and colleagues.312 They found that, although there 
was no effect of APOE genotype for all age groups combined, children (<15 years) and young adults 
(<30 years) who were ɸ ?ĐĂƌƌŝĞƌƐĞǆƉĞƌŝĞŶĐĞĚƐŝŐŶŝĨŝĐĂŶƚůǇǁŽƌƐĞŽƵƚĐŽŵĞƐƚŚĂŶɸ ?Žƌɸ ?ĐĂƌƌŝĞƌƐ ?
suggesting that younger age does not prŽƚĞĐƚĂŐĂŝŶƐƚƚŚĞĂĚǀĞƌƐĞĞĨĨĞĐƚƐŽĨɸ ?ĐĂƌƌŝĂŐĞŽŶŽƵƚĐŽŵĞ
after TBI. Despite extensive research, the precise relationship between APOE genotype and TBI 
outcome remains uncertain. Other genetic targets of interest include the mitochondrial DNA 
haplotype, mediators of inflammatory responses, and genetic factors involved in regenerative and 
neurotrophic responses such as brain-derived neurotrophic factor (BDNF).481 
The applications of emerging genomic information to TBI care and research are evolving (figure 8). 
Potential roles include better characterisation of injury, identification of patients at increased risk of 
progressive damage, and therapeutic stratification to facilitate an individualised approach to 
management, as well as more accurate prognostication (section 8), and identification of molecular 
targets for future drug development. Current evidence is limited by insufficiently powered studies. 
Exploration of the role of genetic characterisation for precision medicine in TBI requires large, 
prospective studies that can be used to simultaneously analyse the effects of multiple genes in well 
defined populations. APOE is an obvious candidate, but genes with a greater predictive value for 
early catastrophic clinical outcomes, such as death or haemorrhagic events, might be of greater 
clinical use. 
[H3] Blood biomarkers  
There is an unmet medical need for rapid blood-based biomarker tests, as an adjunct to imaging 
studies, to optimise diagnosis, track disease progression, and improve outcome prediction (section 
8) in TBI to facilitate individualised management. Substantial scientific advances in the past decade 
have resulted in identification of a large number of blood-based protein biomarkers that are relevant 
to different phases of TBI (figure 9; appendix).316 W318,541 Ongoing research efforts319 W321,539,540 are 
yielding new classes of biomarkers, including metabolomic and lipid markers, microRNAs, and 
exosomes. All of these hold potential for diagnosis, prognosis, and therapeutic stratification, but are 
not yet in advanced clinical development.  
Acute-phase biomarkers ? eg, glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-
L1 (UCH-L1) ? have substantial potential for use in the prehospital setting and emergency 
departments where large numbers of patients present with head trauma, the vast majority of whom 
will have normal brain CT findings.322,323 Compared with other stages of TBI management, protein 
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biomarkers for the acute phase are probably closest to clinical implementation, and one of these ?
S100B ? is already included in an algorithm to triage patients with mild TBI for CT imaging after head 
trauma in Scandinavian guidelines.317,324 In the subacute phase, neurofilament protein and 
autoantibody biomarkers could be used to track disease progression.325 W327 In the chronic stages, 
markers of neurodegeneration (eg, tau and phosphorylated tau) are being explored for in-vivo 
detection of long-term sequelae, including neurodegenerative disorders linked to TBI such as CTE 
ĂŶĚůǌŚĞŝŵĞƌ ?ƐĚŝƐease.328 W330,541 
Figure 9: Schematic representation of the time course of blood-based protein biomarkers linked 
to pathophysiology in traumatic brain injury 
Individual plots depict current (and still evolving) understanding of the temporal signatures of peripheral 
blood biomarkers that are indicative of pathophysiological changes at different stages after traumatic brain 
injury. AutoAb-[GFAP]=autoantibodies to GFAP. BBB=blood Wbrain barrier. CTE=chronic traumatic 
encephalopathy. GFAP=glial fibrillary acidic protein. MBP=myelin basic protein. P-tau=phosphorylated tau. 
S100B=S100 astroglial calcium-ďŝŶĚŝŶŐƉƌŽƚĞŝŶ ?^W ? ? ?A?ɲ//-spectrin breakdown product 120 kDa. UCH-
L1=ubiquitin C-terminal hydrolase-L1.326 For a more complete biomarker list, see appendix. Modified from 
Zhang et al,482 by permission of Springer.  
Despite the multitude of candidate molecules proposed, translation and widespread adoption into 
clinical diagnostics remain elusive. Progress has been hampered by studies with small numbers of 
patients, variability in sample processing and storage, differences in the assay techniques used, lack 
of reference standards, and incomplete understanding of underlying biomarker biology. Transport 
of biomarkers from damaged tissue to the blood is much more complex in the brain than in the heart 
owing to additional clearance pathways, such as the cerebrospinal fluid and glymphatic systems. It 
is therefore less straightforward to relate brain-specific biomarker concentrations to the presence 
and extent of brain damage in TBI than it is to relate cardiac troponin concentrations, for example, 
to the extent of heart damage following myocardial infarction.483,543 Moreover, small lesions in vital 
brain areas can lead to deep coma, even though numbers of cells lost, and thus changes in biomarker 
concentrations, might be relatively small, whereas more extensive damage in relatively silent areas 
might be associated with high biomarker concentrations in the absence of major clinical 
symptoms.331 Further, the rapid dynamic changes in biomarker levels following TBI make it essential 
that we account for time after injury when using these as diagnostic or prognostic markers.560,561 We 
anticipate a shift from a single-marker approach, which is starting to be implemented in clinical 
practice,324 towards compilation of biomarker panels that can be used to overcome diagnostic 
confounders (eg, extracerebral sources and haemolysis and avoid the overinterpretation or 
misinterpretation of information based on a single-marker analysis.544 Development of a panel of 
multiple biomarkers that reflect many pathogenic mechanisms holds promise for personalised TBI 
care.  
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High-quality, large-scale studies are needed to provide robust evidence of analytical validity and 
clinical utility to lay the foundations for integration of TBI biomarkers into clinical practice.332 
Crucially, regulatory authorities need to oversee standardisation and comparability of assay results 
across different platforms, and ensure a clear distinction between approval for research purposes 
and use as diagnostic standard in clinical practice.333,545  
[H3] Neuroimaging 
CT is the primary imaging modality for TBI, driving key decisions about the need for surgical 
intervention for space-occupying lesions. Scanning times are fast and image processing 
instantaneous. However, CT is relatively insensitive, and in patients suspected of having a mild TBI, 
less than 5% will have CT abnormalities.249,322,323 Standard clinical MRI provides greater sensitivity 
than CT for parenchymal lesions, especially in the posterior fossa, brainstem, and superficial cortical 
areas (figure 10). Advanced MRI can be used to characterise pathophysiology from ictus to outcome 
and across the spectrum of outcome  W from predicting recovery from postconcussional state in mild 
TBI to predicting emergence from coma in the most severely injured subjects.334,562 Diffusion tensor 
imaging and susceptibility-weighted imaging are particularly sensitive for mapping diffuse axonal 
injury and the microhaemorrhages that accompany it (figure 10), and functional MRI can be used to 
map functional disconnections that underlie clinical deficits. Although MRI protocols are speeding 
up,335 when compared with CT, MRI scanning generally takes longer (30 W45 min), limiting its use in 
emergency settings. 
  
Figure 10: Detection of structural brain damage after traumatic brain injury with magnetic 
resonance imaging and computed tomography 
 
A 
 
 
 67 
 
B 
(A) Computed tomography (CT) scan on admission to hospital (left panel) and magnetic resonance imaging 
(MRI) scan (fluid-attenuated inversion-recovery sequence [FLAIR]) within 48 hours of admission from a 
patient with traumatic brain injury. MRI shows a dorsolateral brainstem haemorrhage and surrounding 
oedema that was not detected with CT, highlighting the greater sensitivity of MRI to structural damage 
compared with CT. (B) MRI scans with a FLAIR sequence (left) and susceptibility-weighted imaging (SWI; 
right) from the same patient. Microhaemorrhages associated with diffuse axonal injury are visible only on the 
SWI sequence, showing that advanced MRI is superior to CT for detection of diffuse axonal injury.  
 
 
Although the potential importance of advanced MRI methods for refining characterisation of TBI is 
undeniable, generalisability to everyday clinical practice remains an enormous challenge. Readily 
available and inexpensive MRI-compatible clinical monitoring equipment is needed to allow use in 
the most injured patients. More open (often low-field) MRI systems might ease some logistical 
difficulties in this context. However, use of low-field systems would be contrary to prevailing trends: 
3 Tesla systems are increasingly the standard field strength for clinical use, and 7 Tesla systems are 
on the cusp of approval for clinical imaging. 
Regardless of the field strength of MRI, regulatory authorities and vendors must address cross-centre 
(and inter-device) comparability of images, particularly with regard to quantitative assessments. 
Complete standardisation might not be possible. CT images can be calibrated in Hounsfield units, but 
such a calibration unit does not exist for MRI. Experience of international collaborations in TBI 
research, however, does suggest that harmonisation of protocols can and should be achieved.336,337 
Such harmonisation is essential for large, multicentre clinical studies. Translation of research 
protocols to routine clinical imaging will be a challenging task that requires extensive interaction 
between vendors, MRI experts, and regulatory authorities.  
[H3] Physiological monitoring  
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Current technology now offers opportunities to dissect pathophysiological mechanisms to define 
individualised treatment targets and personalise ICU management of TBI. Such technology includes 
the use of advanced signal processing of ICP waveforms to derive measures of autoregulation, and 
the addition of more novel sensors to monitor oxygenation, metabolism, and the inflammatory 
response, as well as cortical electrical activity and spreading depolarisations.338 W342,546,547 
The combination of these different sources of information provides a more complete understanding 
of brain physiology than is possible with measurement of a single variable, and preliminary evidence 
from a recent RCT shows that such improved understanding ? and appropriate targeting of 
treatment ? can improve treatment results.548 However, these approaches have the inherent 
disadvantage of requiring the insertion of multiple intracranial sensors, each with its own operative 
risk. Although these risks can be partly mitigated by use of a single access device (figure 11), a better 
solution would be the development of multiparametric sensors, which incorporate all the monitoring 
modalities in a single device.343 An alternative approach, which completely removes these risks, is to 
develop and validate noninvasive monitors.343 Unfortunately, the medical field is lagging behind 
technological developments, and such advances will require substantial input from industry, 
academia, and funding bodies.  
Figure 11: Multimodal monitoring of brain physiology after traumatic brain injury 
Several physiological variables in the brain can be measured simultaneously with the use of a single 
intracranial access device with three lumens for separate sensors. Typically, an intracranial pressure (ICP) 
sensor and a probe for measuring the partial pressure of brain tissue oxygen (Pbt02) and brain temperature 
are inserted through two of the lumens. The third probe can be used for a microdialysis catheter, cerebral 
blood flow sensor, or depth electrode for electroencephalography (EEG) monitoring or other monitoring 
probe. In this example, a contusion is shown in the temporobasal region. Whether the sensor should best be 
postioned in the proximity of a lesion or in a relatively undamaged part of the brain, and thus be more 
representative of the global situation, is debated. Figure courtesy of Maartje Kunen, Medical Visuals, 
Arnhem, Netherlands.  
 
[H3] Data integration: challenges and opportunities 
The integration of data from multiple pathophysiological monitoring modalities ? whether from 
invasive or noninvasive sensors or from multiple sensors or single multiparametric sensors ? into an 
understandable format to ensure that it is clinically useful is a major challenge. Merging of diverse 
information streams requires substantial information technology input. In the ICU setting, 
multimodal monitoring is emerging as a clinical tool, and guidelines for monitoring of the partial 
pressure of brain tissue oxygen (PbtO2)338 and for microdialysis340 have been developed. However, 
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the accompanying developments in neuroinformatics that are needed to ensure optimum synthesis 
and interpretation of these data are in their infancy.344 The idea of identifying clinically important 
and treatable parameters, not immediately obvious from raw bedside data, using computational and 
informatics techniques, is compelling and potentially rewarding, but challenging. In recent years, the 
field of machine learning has developed new and sophisticated statistical and computational 
techniques to process high-dimensional data, which have diverse applications in science and 
engineering. Such approaches (so-called big data solutions) might also prove valuable for the analysis 
of time-dependent neuromonitoring data, both for real-time prediction of events and for 
characterisation of physiological states that respond to specific therapies, thus facilitating clinical 
decisions about critically ill patients.  
Improved characterisation and classification of TBI will, ultimately, require integration of information 
not only from multimodal monitoring methods, but also from a range of sources including clinical, 
neuroimaging, genetic, and biomarker techniques. Such integration of information will be a 
considerable endeavour, but has the potential to enable classification of patients into groups with 
more homogeneous pathophysiological mechanisms for targeted trials of novel neuroprotective 
interventions.549 This approach depends on access to large data sources and substantial input from 
the field of neuroinformatics and computational sciences, both of which require interdisciplinary and 
intercentre collaboration (section 9). 
[H3] Key messages and recommendations 
 
(1) Methods of diagnosis and classification of patients with TBI are inadequate to permit targeting 
of current and new therapies to the needs of individual patients. Funding bodies should 
implement targeted funding calls for research that improves the precision of diagnosis, 
classification, and characterisation of TBI using multidomain approaches.  
(2) Few tissue archives containing specimens suited to TBI research exist, and their future 
sustainability is insufficiently guaranteed. Funding agencies need to secure existing research 
archives and develop new archives of well characterised human tissue to support collaborative 
research in TBI. 
(3) Advances in genetics, biomarker research, advanced neuroimaging, and pathophysiological 
monitoring promise improved characterisation of clinical and mechanistic types of TBI as well 
as outcome and prognosis, but progress is limited owing to small study sizes. Increased funding 
is needed for studies using emerging technologies to allow improved targeting of treatment 
strategies to individual patients on the basis of clinical and pathophysiological characteristics. 
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(4) Progress in biomarker and neuroimaging studies is hampered by lack of standardisation. 
Regulatory agencies should mandate standardisation (or at least harmonisation) of biomarker 
technology and advanced neuroimaging to facilitate data sharing in large studies and accelerate 
improved management and outcomes of patients with TBI. 
(5) Developments in digital analysis of large datasets have the power to improve clinical decision 
making, especially for critically ill patients with TBI, in which the volume of physiological 
monitoring data is challenging. Targeted funding of so-called big data solutions is needed to 
develop decision-support systems, especially for critically ill patients with TBI.  
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While improved characterisation of initial injury severity is a prerequisite for the development of 
precision-medicine approaches to traumatic brain injury (TBI; section 6), more refined assessment 
of clinical outcome is equally essential to guide individualised management in the postacute phase. 
Accurate characterisation of outcome is also necessary to evaluate patterns of recovery and 
deterioration in the long term, to predict long-term care needs for patients and their families, to 
understand the impact of clinical care, to compare outcomes between centres, and to assess the 
efficacy of conventional and novel therapeutic interventions. 
Functional outcome is equally, or perhaps more, relevant than is mortality in TBI owing to the high 
rate of disability in survivors, and is generally assessed with the Glasgow Outcome Scale (GOS)345 or 
its extended version (GOSE).346 Despite their clinical appeal, the GOS and GOSE are based on broad 
categories and therefore insufficiently account for the multidimensional nature of outcomes after 
TBI, which can include long-term changes in functional, physical, emotional, cognitive, and social 
domains. 
In this section, we discuss the limitations of current approaches to outcome assessment and 
classification in TBI, and emphasise the need for multidimensional outcome scales for clinical practice 
and research, underlining challenges in the development of such approaches. 
[H3] Current approaches to outcome assessment  
At present, characterisation of outcome in patients admitted to hospital with TBI is based mainly on 
the GOS345 or the GOSE.346,347 These are valuable but relatively simplistic scales for assessment of 
global outcome. The GOS was introduced by Jennett and Bond in 1975345 as a five-category scale to 
capture functional outcome: alterations in major roles such as work and independent living, as 
assessed by the investigator, are used to summarise the effects of diverse changes caused by injury. 
Although attractively simple, the limited sensitivity of the GOS led to the development of the GOSE, 
in which the categories of severe disability, moderate disability, and good recovery are subdivided 
into lower and upper subcategories (figure 12). A structured assessment was proposed to facilitate 
standardised administration.346 However, despite more refined outcome characterisation, the eight-
category GOSE scale still lacks sensitivity to changes within specific domains of function (eg, 
cognition, emotional well-being, and life satisfaction). Even patients with mild TBI ? who would be 
considered to have (lower) good recovery on the GOSE ? often have long-term health problems 
across a number of outcome domains, including pain, sleep disorders, and mental health.70,484,550,551  
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Figure 12: Classification of outcome of traumatic brain injury with the Extended Glasgow Outcome 
Scale 
Decisions involved in assigning an outcome using the Extended Glasgow Outcome Scale (GOSE). The eight-
point GOSE was formed by subdividing three of the categories on the five-point GOS into upper and lower 
bands.345 W347 
The GOS and GOSE are not commonly used for formal categorisation of outcome in everyday clinical 
practice, as summary outcome measures do not allow clinicians to target management of specific 
problems in individual patients. Furthermore, they are unlikely to facilitate future precision-medicine 
approaches by enabling identification of subgroups of patients in whom mechanistically specific 
therapies can be used. Furthermore, the GOS and GOSE do not provide sufficient discrimination to 
reliably detect small, but clinically relevant recovery or deterioration of function and effects of 
treatment over time.485 These considerations suggest the need for detailed assessments that are 
sensitive to smaller transitions in outcome and that take account of a range of aspects of 
outcome.354 W356,486 Nevertheless, summary or integrated measures of outcome could still provide a 
useful basis for allocating patients to broad care pathways, and such applications are worth 
developing.  
Insensitivity of outcome metrics also decreases the chances of detecting treatment effects in clinical 
trials, and this problem is exacerbated by the common practice in TBI of dichotomising the GOS or 
GOSE (jointly referred to subsequently as GOS(E)) into two categories: unfavourable (dead, 
vegetative, severe disability) versus favourable (moderate disability, good recovery). This approach 
is statistically inefficient and should be discouraged.349,350 Currently recommended approaches for 
analysing GOS(E) data in clinical trials involve the use of a proportional odds analysis (evaluation of 
a shift across the categories of outcome) or a sliding dichotomy approach (in which the GOS(E) is still 
dichotomised, but the point of dichotomy varies according to individual baseline prognostic risk).351 
However, even this more refined application of the GOS(E) would be unsatisfactory for assessment 
of patients with mild TBI, who might achieve the best possible outcome (GOSE score 8) but still have 
clinically important cognitive or psychological problems such as post-traumatic stress disorder or 
other depressive or anxiety disorders.352,353  
In addition to the GOS and GOSE, a multitude of instruments for assessing outcome is available: 
recent overviews have identified nearly 1000 (mostly non-overlapping) outcome assessment 
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instruments for TBI (appendix).357 W360 Diversity in outcome assessment is an asset in clinical practice, 
and has been embraced for many years, particularly in the management of TBI after the acute stage. 
However, this diversity is a major obstacle to research progress in TBI owing to difficulties in selecting 
single endpoints for use in clinical trials and in pooling of data and conduct of meta-analyses. 
Moreover, although different assessments might be needed for different purposes, their relevance 
is debated and there is no consensus on a key set of assessments. 
[H3] Multidimensional assessment of outcome 
Heterogeneity in the consequences of TBI and the wide variety of short-term and long-term recovery 
patterns place high demands on outcome assessment. It is increasingly evident that a single outcome 
parameter is insufficient to demonstrate treatment effects in the clinical setting or to be an endpoint 
in clinical trials, and that multidimensional outcome scales that cover a broad range of domains 
(figure 13)361 are essential to describe the consequences of TBI. Crucially, these scales should include 
outcome domains such as cognitive deficits, psychological health, and quality of life (including the 
effects of common symptoms such as sleep disturbance and pain).354 W356 Development of refined, 
multidimensional outcome assessments is a challenging aspiration and various approaches need to 
be considered: (1) identification and standardisation of a core set of outcome instruments; (2) 
recognition that patients who have different grades of outcome will need different assessment tools, 
both generally and to address specific problems that are more relevant to a specific outcome 
category or severity of impairment; and (3) development of more refined global assessementsor 
composite endpoints.   
Importantly, acceptance of the need for multidimensional outcome measures by regulatory 
authorities is essential. Although it is commonly perceived that regulators require the use of the GOS 
or GOSE as an efficacy parameter for clinical trials, experience suggests that they are open to 
considering other early or late outcome measures,362 if there is evidence to support their use and 
clinical validity. In the USA, the Food and Drug Administration (FDA) has recently implemented a 
formal qualification process for clinical outcome assessments that should facilitate adoption of a 
range of instruments in TBI clinical trials. Collaboration between the FDA and clinical investigators 
has been established in the context of the TBI Endpoints Development project.363  
Figure 13: Multidimensional outcome assessment of traumatic brain injury 
Domains of outcome assessment included in both adult and paediatric Common Data Elements for traumatic 
brain injury (TBI; specific instruments are included in brackets). Outcome is defined by selecting multiple 
subdomains and choosing measures that reflect each subdomain. CRS-R=Coma Recovery Scale WRevised. 
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GOS=Glasgow Outcome Scale. GOSE=Extended GOS. QOLIBRI=Quality of Life after Brain Injury Scale. 
QOLIBRI-OS=QOLIBRI Overall Scale. RPQ=Rivermead Post-concussion Symptom Questionnaire. SF-36=Short-
Form 36. Adapted from Kean and Malec,364 by permission of Elsevier.  
Identification of a subset of assessments that cover key dimensions of outcome beyond those 
assessed with the GOSE, and that could be used across studies and over time, would be a major step 
forward. Assessment methods have different strengths and weaknesses, and few can be applied 
across the complete TBI severity spectrum. Approaches considered include health-related quality-
of-life measures, neuropsychological assessments, and composite endpoints. Health-related quality-
of-life assessment can effectively combine different domains, but a quality-of-life measure in 
isolation would still only rarely be considered adequate as an endpoint in TBI clinical trials, and 
people with severe injuries might be too cognitively impaired to complete these assessments. The 
reliability of exclusively self-reported measures can be hampered by limited self-awareness of 
deficits, necessitating access to ĐĂƌĞŐŝǀĞƌƐ ? ǀŝĞǁs, which might be different and possibly more 
accurate than those of patients.365 Neuropsychological tests cover a range of domains, and provide 
a sensitive index of impairments, but can be challenging to complete for TBI survivors: in a trial of 
hypothermia only just over half of patients with severe TBI completed cognitive assessment at 6 
months.366 Moreover, interactions might exist between cognitive performance and the presence of 
post-traumatic stress disorder or depressive symptoms.552  
The use of different approaches and combinations of instruments would depend on the level of 
disability ? eg, patients who have persistent postconcussional symptoms after mild TBI would have 
different assessment needs to those with disorders of consciousness after severe TBI. This need to 
accommodate different outcomes or levels of severity of impairment is concordant with the concept 
of the sliding dichotomy for outcome analysis of the GOS(E), in which the point of dichotomy of the 
GOS(E) is differentiated by initial baseline risk.351 Different outcome instruments might map to 
different levels of disability (figure 13), and accurate characterisation of specific problems (eg, 
paroxysmal sympathetic hyperactivity, which is common after more severe injuries) can provide a 
robust base for targeted treatment of these problems. 
Composite endpoints have been pioneered in a few clinical trials,361,367,368 including the recent BEST-
TRIP (Benchmark Evidence from South American Trials: Treatment of Intracranial Pressure) trial.202 
However, use of composite scores comprising two or more outcome measures can be problematic 
with regard to traditional methodological and statistical approaches, whereby a single measure is 
typically used to calculate the required sample size to reliably detect a treatment effect. In the 
context of composite scores in clinical trials, selection of a parameter that is likely to change over 
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time might lead to sample sizes with insufficient power to detect effects of other outcomes, whereas 
use of the measure that is least likely to change could necessitate impractical sample sizes.361 Other 
issues with the use of global tests or composite measures include the need to weight individual test 
components and how best to achieve this, as well as interpretation of the overall results.  
There have been major initiatives to develop a core set of standardised multidimensional assessment 
methods with global measures or composite endpoints that can be used across different diseases. 
The Cambridge Neuropsychological Test Automated Battery (CANTAB)369 and the National Institutes 
of Health (NIH) Toolbox370 are sets of computerised measures designed to assess cognition, emotion, 
and motor and sensory functions. The Patient Reported Outcomes Measurement Information 
System (PROMIS) project371,553 has developed a set of instruments that can be used across a wide 
range of chronic conditions. These tools could be useful in both research and clinical settings. 
Practical problems might, however, hamper implementation of any comprehensive scheme in an 
international setting (panel 11), and completion of all assessments could be challenging for TBI 
survivors. Further work is therefore needed to establish multidimensional and composite outcomes 
as endpoints for clinical studies of TBI. 
  
Panel 11: Barriers to widespread adoption of recommended outcome assessments in an 
international setting 
Language 
Lack of availability of good-quality versions in languages other than English 
Cultural applicability 
Lack of cross-cultural validation of assessments  
Cost 
Initial costs of some instruments and stipulation of payment per use 
Copyright 
Copyright issues and related difficulties in reproducing materials 
Access 
Restriction of some assessments to particular professional groups 
Scoring 
Charges and restrictions imposed by proprietary scoring systems 
 
Limited availability of many instruments in languages other than English is a major barrier to their 
use in international settings. Additionally, ensuring cultural applicability of assessment methods is 
an important challenge when collecting and analysing data across countries. The CANTAB and the 
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NIH Toolbox have the advantage of being language-independent, and the PROMIS instruments are 
available in many languages; in the context of the CENTER-TBI project (section 9), translations of 
common outcome assessments have been linguistically validated and will be made available without 
restrictions to the neurotrauma community. However, such validation is not simple, since it is very 
time-consuming and resource-intensive, and high priority should be given to the funding of cross-
cultural validation of assessments.372 Charges and restrictions on proprietary measures are a 
substantial hurdle in the internationalisation of many instruments. We strongly believe that outcome 
assessments advocated by the Common Data Elements for TBI should be freely available to the 
clinical and research communities without charge, and that public funding should support ready 
access to high-quality instruments. Developing multidimensional outcome tools and novel ways to 
integrate the various outcome domains will require collaborative efforts in large-scale studies with 
novel approaches to data sharing (section 9).  
[H3] Key messages and recommendations 
(1) Trauma disturbs the brain in complex ways, affecting multiple outcome domains. Refined 
outcome assessments could guide improved clinical management and support high-quality 
research. Targeted funding calls are needed to facilitate the development and validation of 
multidimensional outcome constructs that quantify the overall burden of disability from TBI. 
(2) A substantial number of patients with even mild TBI experience long-term pain, sleep 
disorders, and mental health illnesses, including post-traumatic stress disorder and major 
depression. Understanding the long-term effects of TBI and implementing best practice for 
ongoing care ? in particular, for appropriately targeted health management in the chronic 
phase of TBI with continuing support in the long term ? should be prioritised by politicians and 
health-care professionals.  
(3) Patients with TBI can have late deterioration or recovery of function even 1 year or more after 
injury. Improved multidimensional outcome measures could facilitate long-term 
characterisation of changes in outcome after TBI. Increased funding is needed for long-term 
longitudinal studies to better capture occurrence of late deterioration and the recovery 
process after TBI.  
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Outcome in traumatic brain injury (TBI) depends not only on the quality of care provided, but also 
on patient and injury characteristics such as premorbid state (eg, age or comorbidities), mechanism 
of trauma, injury severity, presence and severity of extracranial injuries, patient response, and social 
environment. Linking patient and injury characteristics at presentation to outcome is the science of 
prognosis and prognostic modelling.487 Prognostic models combine a range of characteristics in a 
mathematical formula and have diverse applications (panel 12) in clinical practice and research in 
TBI. These applications include provision of personalised information on expectations to patients and 
their relatives, adjustment for differences in case-mix between clinical research studies, and 
calculation of standardised outcome rates for benchmarking of quality of care.  
 
Robust prognostic models have been developed for moderate and severe TBI. However, they are not 
used in mainstream clinical practice, and their precision could be improved, primarily with better 
characterisation of injury severity and patient factors at presentation (section 6), and by including 
outcome measures beyond the Glasgow Outcome Scale (GOS) and the Extended GOS (GOSE). 
Prognostic schemes for mild TBI are far less established than are those for moderate-to-severe TBI 
and will require more refined description of outcome (section 7).  
 
In this section, we explore how prognostic models can be used to link patient and injury 
characteristics to outcomes. We consider the applications of prognostic models in clinical practice 
and research, and also discuss the developments and refinements needed to improve prognostic 
models and enhance their use. 
 
Panel 12: Applications for prognostic modelling in traumatic brain injury 
x To provide realistic information to patients and relatives 
x To inform triage decisions 
x To provide insight into possible causes of poor outcomes 
x To enable identification of potentially modifiable causes of poor outcomes 
x To enable risk adjustment for comparisons of patient series 
x To improve design of clinical trials and analyses of trial data 
x To enable benchmarking of quality of care 
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[H3] Applications for prognostic modelling in TBI 
Outcome predictions form an integral part of clinical medicine and serve various purposes ? eg, to 
provide information about expected outcomes to patients and their relatives and to assist with 
treatment and triage decisions (panel 1) ? ůŝŶŝĐŝĂŶƐ ? ĞǆƉĞĐƚĂƚŝŽŶƐ ŽĨ ƉĂƚŝĞŶƚƐ ? ŽƵƚĐŽŵĞƐ ŚĂǀĞan 
inherent degree of uncertainty, and prognostic models could help to refine these expectations by 
providing a probability of a specific outcome.  
 
Prognostic models can further be used to inform our understanding of cause and effect, and provide 
insight into potentially modifiable causes of poor outcomes. However, since an association might not 
be causal, clinical benefit of correction of a modifiable factor would need to be proven with thorough 
evaluation of an intervention, preferably in a randomised controlled trial (RCT). Use of prognostic 
models could also facilitate more efficient design of clinical trials and analysis of trial data,350,487 and 
enable adjustment for differences in case-mix when comparing patient series. As outcome depends 
not only on treatment, but also to a large extent on patient characteristics and injury severity, making 
comparisons between different patient populations is inappropriate, unless these comparisons are 
risk-adjusted for differences in case-mix. Prognostic models could be used to provide estimates of 
expected outcomes for case series adjusted for patient and injury characteristics; any differences 
between observed and expected outcomes might are then with more certainty attributable to 
differences in treatment.  Adjustment for injury and patient characteristics is particularly relevant to 
TBI owing to its complex heterogeneity, including differences in injury type and severity between 
patients.   
Similarly, prognostic models could be used for risk adjustment when comparing outcomes between 
hospitals. Such benchmarking is a specific approach to enable implementation of the best available 
evidence into practice and to optimise quality of care. It allows continuous comparisons between 
hospitals and identification of areas for improvement. Ideally, a set of quality indicators for 
benchmarking would include outcome indicators (eg, mortality rate), process indicators (eg, 
guideline adherence), and structure indicators (presence of facilities to provide good care). However, 
the development of quality indicators for TBI is challenging since mortality is a poor outcome metric 
for benchmarking in TBI: survival with extremely severe disability is generally considered to be an 
undesirable outcome and, for many, survival in a vegetative state might be an outcome worse than 
death. There are currently no broad quality indicators for TBI, and the development of an 
internationally accepted set of indicators should be considered a high priority to ensure 
implementation of evidence-based care and to optimise quality of care for patients with TBI. 
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 [H3] Prognostic models for outcome prediction in moderate and severe TBI 
Many prognostic models have been developed since the 1970s, with varying methodological 
quality.373,374 One aim in developing some of these models was to refine efficacy analyses in clinical 
trials. These models have specifically focused on baseline risk assessment using characteristics 
available at hospital admission, and on mortality and GOS scores at 6 months after injury as 
outcomes of interest. For moderate and severe TBI, two sets of prognostic models have been 
developed on large datasets using state-of-the-art methods: the IMPACT (International Mission for 
Prognosis and Analysis of Clinical Trials in TBI) models, based on eight large datasets,375 and the 
CRASH (Corticosteroid Randomisation After Significant Head injury) models, based on the database 
of a large clinical trial.376 However, the development populations for both models were weighted 
towards severe TBI, and patients with moderate TBI were underrepresented;377 thus, an additional 
focus on moderate TBI is required.  
The IMPACT and CRASH models share some key predictors of outcome: age, Glasgow Coma Scale 
(GCS) scores ? the full score in CRASH, the motor component in IMPACT ? pupillary reactivity, 
presence of second insults (hypoxia and hypotension), computed tomography (CT) characteristics, 
and laboratory parameters. Most predictive information is contained in the core predictors ? age, 
GCS motor score, and pupillary reactivity ? which together explain approximately 35% of the variance 
in outcome487 (appendix). Both the CRASH and IMPACT models have been extensively validated in 
cohorts outside the populations of the original studies, an essential step to test the generalisability 
of a prognostic model beyond the development setting.378 In the absence of external validation, 
prognostic effects are likely to be overestimated. External validation should therefore be a key 
requirement for all new models and when new predictors are added to existing models. Repeated 
validation over time with updating of models should be done to account for the changing 
epidemiology of TBI (section 1) and changes in care processes and treatments.  
[H3] Prognostic models for outcome prediction in mild TBI  
The sequelae of mild TBI can include physical symptoms, behavioural disturbances, and cognitive 
dysfunction, any of which could interfere with return to work or resumption of social activities.484,487 
Prognostic analyses can enable identification of patients at increased risk of such symptoms, who 
could then be followed more closely and receive early interventions to alleviate the psychological 
burden of injury. Mortality is not an appropriate endpoint for prognostic analyses in these patients, 
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and the usefulness of the GOS is doubtful, because although a substantial number of patients with 
so-called mild TBI might have disabling complaints, most will have outcome scores in the upper 
segment of the GOS categories.379 Ceiling effects of the GOS might partly explain why methods for 
predicting outcome in patients with milder forms of TBI are scarce. More sensitive outcome 
measures (section 7) as endpoints for prognostic analyses are required, although these have so far 
been insufficiently or inconsistently investigated. Although prognostic models are now beginning to 
emerge for mild TBI, they have not been fully validated, their generalisability has not been 
determined, and they are less well established than those for moderate-to-severe TBI.380 W382,403,484,489 
Therefore, there is an urgent need for robust validation and further improvement of models in this 
patient group.  
[H3] Advancing the science of prognosis in TBI  
The availability of robust and well validated prognostic models for moderate-to-severe TBI is a major 
step forward. They allow us to deal appropriately with the inherent heterogeneity of TBI populations. 
However, as these models each explain at most only 35% of the variance in outcome,486,490 other key 
patient and injury characteristics are likely to contribute to outcome. Identifying these characteristics 
could improve prognostication and, if modifiable, could provide therapeutic targets. Genetic 
variance, advanced neuroimaging, and other precision-medicine features (section 6) might explain 
part of the residual variance. Inclusion of these features could provide some refinement of 
prognostic models, but treatment differences and centre effects are also likely to contribute to the 
variance in TBI outcome.  
Panel 13: Directions for advancing prognostic modelling in traumatic brain injury 
x Refinement of models for moderate and severe traumatic brain injury (TBI) to adapt to 
changing epidemiology and outcome 
x Exploration of new markers, tests, and imaging (eg, magnetic resonance imaging [MRI] and 
genotype) 
x Development of dynamic predictions beyond baseline assessment (eg, serial clinical or 
imaging assessment) 
x Development and validation of models for mild TBI using sensitive endpoints 
x Development and validation of models to predict quality of life and other outcomes 
 
Various directions for prognostic research in TBI have been identified (panel 13). Prognostic models 
could be improved by including new predictors, by better characterising existing predictors, by 
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adding new information as it becomes available with disease evolution (dynamic predictors), and by 
predicting other relevant outcomes. Various studies have explored the prognostic value of new 
predictive methods, including biomarkers and advanced magnetic resonance imaging (MRI; section 
6), often reporting promising results. However, most have been limited to relatively low numbers of 
patients studied and have compared predictions based on admission characteristics (eg, with the 
IMPACT and CRASH models) with performance of the new predictive method at a later stage (eg, 
advanced MRI at 1 W3 weeks).383,384 A more rigorous approach would be to compare performance of 
the new predictive method (eg, MRI) with the predictive value of clinical information obtained at the 
same time. Prognostic models could also incorporate information that becomes available over time, 
such as repeated CT or additional MRI scans. Such dynamic predictions are complex and require 
specific statistical techniques to capture repeated measures from the same patient.385 Recently 
developed machine-learning techniques might hold promise for use with complex data structures, 
but they have performed inconsistently in predicting outcome after TBI.491,492  
We need to focus on the incremental value of new or extended predictive markers ? ie, their 
prognostic value beyond readily available characteristics. Such evaluation should be phased, starting 
with technical validation of marker measurements, followed by evaluation in small patient series, 
and, ultimately, with rigorous validation in independent cohorts, since development of new models 
without external validation is likely to lead to false-positive identification of features of prognostic 
importance and result in limited generalisability. Several statistical measures have recently been 
proposed to quantify the effect of a marker on classification.386 Decision analyses387 and cost-
effectiveness analyses should also be done to assess the clinical usefulness of any new marker.388 
A related challenge is to make predictions optimally targeted to the specific clinical setting. The 
CRASH model was developed with variants for high-income countries (HICs) and low-income and 
middle-income countries (LMICs).376 Further site-specific customisation could be attempted using 
advanced statistical approaches such as random-effect models, which take into account the 
clustering of patients within sites and incorporate this clustering into the prognostic estimates. Such 
model adaptations aim to improve the calibration of predictions for individual patients in specific 
settings,389 recognising that trauma organisation and treatment policies might differ between sites 
or change over time.378  
International collaborative studies that collect high-quality data on large numbers of patients across 
the full injury severity spectrum, including mild TBI, are required to advance the science of prognosis 
in TBI (section 9). Outcome measures beyond the currently established GOS and GOSE assessments 
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are required. Prognostic models are needed that extend over a long timeframe and include 
multidimensional outcomes, such as cognitive, psychosocial, health-related quality-of-life, and other 
patient-reported outcome measures (section 7). The absence of good prognostic models for mild TBI 
highlights an important gap in our knowledge that requires attention. 
[H3] Key messages and recommendations 
(1) Prognostic models can help clinicians to provide realistic information to patients and families 
and can facilitate treatment and triage decisions. There is an urgent need for further 
development, validation, and implementation of prognostic models in TBI, especially for mild 
TBI. 
(2) TBI affects multiple outcome domains (section 7), and prognostic models are needed to predict 
this range of outcomes, including quality of life. Funding agencies should support the 
development of new prognostic models that focus on predicting outcome beyond mortality and 
GOS scores. 
(3) A validated set of quality indicators is essential for the benchmarking of quality of care, but none 
exists for TBI. Funding bodies should stimulate the development of a set of quality indicators 
for TBI that includes structure, process, and outcome indicators. 
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The heterogeneity of the population at risk of traumatic brain injury (TBI), variations in injury 
patterns, and wide disparities in systems of care pose particular challenges for the generation and 
implementation of clinical evidence in the field of TBI. Evidence underpinning guidelines for trauma 
care pathways and clinical interventions is often weak, and recommendations are inconsistently 
implemented (sections 4, 5). Conventional approaches to reduce heterogeneity in randomised 
controlled trials (RCTs) of medical or surgical interventions have mostly involved use of strict 
enrolment criteria and tight protocols, typically focusing on age, Glasgow Coma Scale (GCS) scores, 
and preinjury morbidity, while neglecting differences in injury mechanisms (section 5). This approach 
has reduced the generalisability of results, while increasing duration and therefore costs of studies. 
Moreover, most multicentre RCTs in TBI have failed to demonstrate efficacy of interventions in the 
populations studied.289,390 A recent systematic overview of RCTs in acute moderate-to-severe TBI 
identified 191 completed RCTs, of which 26 were considered to be robust (high quality, with 
sufficient numbers). Of these, only six showed a statistically significant effect ? three positive and 
three negative. The authors concluded that considerable investment of resources had resulted in 
very little translatable evidence.390  
There is an increasing appreciation that current views that overemphasize the pre-eminence of RCTs 
for clinical evidence generation may be mistaken.555 We must rethink approaches to the generation, 
analysis, and implementation of evidence.291,555 An alternative approach could be to exploit the 
heterogeneity of TBI in terms of disease type, management, and outcome using comparative 
effectiveness research (CER), rather than attempting to reduce the heterogeneity as is common in 
RCTs. Such research would enable assessment of therapies in real-world conditions. CER requires 
large studies, international collaboration, and advanced statistical expertise. It also demands a 
change in research culture to recognise CER outputs as high-quality evidence, and to embrace broad 
data sharing. Large-scale collaborative studies and data sharing are also needed to generate high-
quality research on characterisation of TBI, outcome assessment, and prognosis (sections 6, 7, 8). 
Such research would help to advance precision-medicine approaches to target treatment strategies 
to individual patients on the basis of clinical and pathophysiological characteristics. Such paradigm 
changes are endorsed by the International Initiative for TBI Research (InTBIR), a collaboration of 
funding agencies. Global collaborations modelled on the InTBIR need to be promoted. 
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In this section, we evaluate the application of CER approaches, and explore the advantages and 
challenges of collaborative efforts and data sharing in TBI research. We also discuss a novel approach 
to continually update systematic reviews to optimise existing evidence, and we review the potential 
for knowledge transfer to facilitate implementation of evidence into practice. 
[H3] Comparative effectiveness research 
CER is the generation and synthesis of evidence to compare the benefits and harms of different 
approaches to delivery of care, or of methods to prevent, diagnose, monitor, or treat a clinical 
condition. The purpose of CER is to assist consumers, clinicians, purchasers, and policy makers to 
make informed decisions that will improve health care at both the individual and population levels.391 
The applicability of research results to daily clinical practice is central to CER. Approaches to CER can 
include both experimental and non-experimental designs. Experimental designs include pragmatic 
RCTs, which, in contrast to traditional RCTs, use broad inclusion criteria to increase generalisability 
of results while maintaining the benefits of randomisation.392 Non-experimental designs are 
generally based on observational studies, which exploit existing variability in care and outcome to 
compare systems of care or interventions. Non-experimental designs are methodologically 
challenging and there is a high risk of so-called confounding by indication ? ie, finding an association 
between an intervention and an outcome in the absence of a causal connection because the 
selection of patients who receive the intervention is not random, but influenced by patient 
characteristics, physician preferences, or other uncontrolled factors. Expert methodological input is 
required to deal with the potential problems of confounding by indication. Large-scale studies based 
on collaborative efforts that capture sufficient detail are essential for robust CER study design and 
analysis plans. 
Application of CER to TBI 
CER has particular potential in the field of TBI for several reasons.290 First, there are large between-
centre and between-country differences in both outcome and management. Second, robust risk-
adjustment models are available for TBI, allowing adjustment for patient characteristics that might 
affect outcome. Third, advanced statistical models, including random-effects models, are available 
to analyse differences between centres. Existing variability could relate to structural parameters (eg, 
level 1 vs level 2 trauma centres, or high vs low patient volume centres) or process parameters (eg, 
choice of surgical procedures, use of intracranial pressure [ICP] monitoring, acute management 
protocols, and choice of rehabilitation interventions).  
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In the IMPACT (International Mission for Prognosis and Analysis of Clinical Trials in TBI) studies, data 
were analysed from 9578 patients with moderate or severe TBI from 265 centres, and a 3·3-times 
difference in the odds of unfavourable outcome was found at 6 months between centres at the two 
extremes of the outcome range (2·5th vs 97·5th percentiles). This difference persisted after 
adjustment for chance effects and differences in case-mix.393 Similarly, an analysis of 9987 patients 
across the TBI severity spectrum from 237 centres in 48 countries from the CRASH (Corticosteroid 
Randomisation After Significant Head injury) trial showed a 6·6-times difference in 14-day mortality 
between centres with the lowest (2·5th percentile) and highest (97·5th percentile) mortality rates 
after adjustment for chance and case-mix (appendix).394 Both studies, however, had insufficiently 
detailed data to relate these outcome differences to differences in structure or process of care.  
Many interventions that are part of current clinical practice are not readily assessed using RCTs. In 
many instances, this is because the uncertainties about the interventions involve complex protocols 
of management (such as the order in which aggressive therapies should be used for intracranial 
hypertension) rather than efficacy of individual treatments. In other instances, RCTs might be 
challenging owing to lack of clinical equipoise within individual centres where a given approach is 
strongly established, despite substantial heterogeneity in practice between these centres (as is the 
case with surgery for contusions). CER approaches could provide a more cost-effective means of 
evaluating these interventions (and, potentially, novel therapies) in real-world settings. Early 
evidence in support of non-experimental designs as a promising approach for severe TBI comes from 
studies that relate outcomes to structural parameters210,211,219 (section 4) or that compare surgical or 
medical interventions (ie, process parameters)268 (section 5) using CER.  
In guideline development, however, evidence from non-randomised clinical studies is regarded as 
inferior to that generated by RCTs. The recent update of the guidelines on management of severe 
TBI255 ? which resulted in level 1 recommendations for just one topic ? illustrates the methodological 
rigour with which evidence is currently being evaluated. We suggest that evidence from high-quality 
non-randomised and observational studies could be as valuable as that from RCTs, since the 
increased generalisability of such studies provides specific practical benefits.  
[H3] Collaborative approaches to accelerate TBI research  
Since the 1970s, there has been a rich tradition of academic collaboration for advancement of TBI 
management. In the 1980s, the National Traumatic Coma Data Bank in the USA395 provided 
important data on acute physiology and outcome, which underpins much of current clinical practice. 
This tradition continues in the USA, perhaps best exemplified by the TBI Model Systems program, 
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which provides valuable data based on everyday practice, particularly for post-acute services, in 
collaborating US centres. DŽƌĞƌĞĐĞŶƚůǇ ?h^ĂŶĚ/ŶĚŝĂŶŶĞƵƌŽƐƵƌŐĞŽŶƐĨŽƌŵĞĚĂŶĞǁĐŽĂůŝƚŝŽŶ ? “dŚĞ
Indian Traumatic Brain Injury CŽŶƐŽƌƚŝƵŵ ?ĂŶĚŚĂǀĞ ŝŵƉůĞŵĞŶƚĞĚĂƉŝůŽƚƉƌŽũĞĐƚ ŝŶ ƚŚĞƐŽƵƚŚĞƌŶ
Indian State of Andhra Pradesh to improve outcome after TBI by optimizing systems of care and care 
pathways.556  Important outputs have resulted from international consortia (such as the CHIRAG 
study group563 and the European Brain Injury Consortium,396,397 clinical trials consortia (such as the 
Australia and New Zealand Intensive Care Society Clinical Trials Group,257,398,399 or national audit 
programmes (the UK Intensive Care National Audit and Research Centre.219 More recent initiatives 
address TBI Endpoints Development363 and chronic effects of neurotrauma.400 However, the past few 
years have seen a more strategic approach to encouraging such collaboration, which represents 
synergistic efforts not only of researchers, but also of national and international funding agencies. 
[H4] International Initiative for TBI Research 
A need for a reappraisal of research design and implementation of broad-based, sustainable 
multidisciplinary and international approaches was recognised in 2010 by major funding agencies. 
This led to the establishment of the InTBIR, which represents a concerted effort to tackle the vast 
global health problem posed by TBI. The InTBIR initially arose as a collaboration between the 
European Commission, the US National Institutes of Health (NIH) National Institute of Neurological 
Disorders and Stroke, and the Canadian Institute of Health Research,401 and was more recently joined 
by One Mind (a non-governmental organisation) and by the US Department of Defense. Table 3 
summarises the studies supported within the InTBIR collaboration, which cover the entire spectrum 
of TBI. Each has a different focus but a common goal: to better understand TBI, and to improve its 
prevention, treatment, and outcomes.  
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Project title (trial 
identifier) 
Project acronym 
or short title 
Target 
enrolment 
Current 
enrolment* 
Study design or 
approach 
Focus of study Study duration Funding agency Funding 
Europe 
Collaborative 
European 
NeuroTrauma 
Effectiveness 
Research in TBI 
(NCT02210221)40
2 
CENTER-TBI 
  
5400 adult and 
paediatric 
patients with TBI 
of all severities 
Core data: 4582 
patients; registry: 
20 885 patients 
CER Improved 
characterisation 
and identification 
of best practices 
(biomarkers, 
classification, 
prognosis; systems 
of care, 
management, and 
interventions)  
2013 W2020 European 
Commission 
 ? ? ? ? ? ? ? ? ? 
Collaborative 
REsearch on 
Acute Traumatic 
brain Injury in 
intensiVe care 
medicine in 
Europe 
(NCT02004080) 
CREACTIVE 
 
7000 paediatic 
and adult 
patients with TBI 
in intensive care 
4574 patients CER Improved 
characterisation 
and identification 
of best practices 
(biomarkers, 
imaging, 
prognosis; systems 
of care, 
management, and 
interventions) 
2013 W2018 European 
Commission 
 ? ? 443 350 
USA 
Transforming 
Research and 
Clinical 
TRACK-TBI 2700 adult 
patients with TBI 
2266 patients CER 
 
Improved 
characterisation 
and precision 
2013 W2018 NIH WNINDS US$18 800 000 
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Knowledge in 
Traumatic Brain 
Injury 
(NCT02119182) 
 of all severities; 
300 controls 
medicine 
(biomarkers, 
classification, 
prognosis; systems 
of care, 
management, and 
interventions) 
Approaches and 
Decisions in 
Acute Pediatric 
TBI Trial  
ADAPT 
 
1000 paediatric 
patients with TBI 
in intensive care 
Completed: 1000 
patients 
CER Identification of 
best practices for 
treatment of 
severe TBI in the 
pediatric 
population 
(actute 
interventions) 
2013 W2018 NIH WNINDS US$16 147 544 
Managing 
Severe TBI 
Without ICP 
MonitoringͶ
Guidelines 
Development 
and Testing 
(NCT02059941) 
 
 780 adult 
patients with TBI 
in intensive care 
256/256 patients 
for phase 1; 
250/354 patients 
for phase 2  
CER Creation and 
assessment of 
guidelines for 
treatment of 
severe TBI in the 
absence of ICP 
monitoring 
2012 W2017 NIH WNINDS US$2 586 216 
Canada 
Predicting and 
Preventing 
Postconcussive 
Problems in 
Pediatrics 
5P 
 
Paediatric and 
adolescent 
patients with 
mild TBI: 
derivation cohort 
2000 patients; 
Completed: 3063 
patients  
 
Prospective 
cohort study 
Development of 
prognostic tools 
(clinical 
prediction rule 
2013 W2018 CIHR CAN$1 273 705 
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Study403,493,494  
(NCT01873287)  
validation cohort 
800 patients 
derivation and 
validation) 
Improving the 
Diagnosis and 
Treatment of 
mTBI in Children 
and Youth using 
common data 
elements  
 
PedCDE 
 
500 patients with 
mild TBI aged 6 W
17 years; 50 
 controls 
 
300 patients with 
mild TBI aged 0 W
5 years; 50 
controls  
Completed: 434 
patients aged 6 W
17 years; 50 
controls 
 
55 patients aged 
0 W5 years  
 
Prospective cohort 
study 
Tool 
standardisation 
(CDEs), prognosis  
2013 W2018 CIHR CAN$1 400 000 
Safe to Play: A 5-
year longitudinal 
cohort study of 
mTBI in youth 
ice hockey 
players  
Safe to Play 
 
1000 paediatric 
and adolescent 
ice hockey 
players without 
TBI at baseline 
 2800 pediatric 
and adolescent ice 
hockey players 
(with yearly 
replacements for 
any loss to follow-
up) 
Longitudinal 
cohort study 
Prevention 
(epidemiology, 
risk factors), 
diagnosis, 
prognosis, 
management 
2013 W2018 CIHR CAN$1 500 000 
($300 000 per 
year for 5 years) 
Post-Concussion 
Syndrome 
Affecting Youth: 
GABAergic 
Effects of 
Melatonin 
(NCT01874847)50
2 
PLAYGAME 
 
99 children and 
adolescents with 
postconcussion 
syndrome; 38 
patients who 
have recovered 
from mild TBI as 
biomarker; 30 
healthy controls  
Recruitment 
complete: target 
numbers met  
RCT (three 
parallel group 
design) 
Treatment (3 mg 
melatonin vs 10 
mg melatonin vs 
placebo); 
biomarker 
development  
2013 W2018 CIHR CAN$855 000 
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NeuroCare: A 
Clinical Decision-
Making Tool in 
Youth mTBI  
 
NeuroCare 
 
1400 paediatric 
and adolescent 
athletes; 140 
paediatric and 
adolescent 
patients with 
mild TBI; 140 
controls 
941 athletes; 62 
patients with mild 
TBI; 48 controls 
Longitudinal case-
control study 
Tool development 
(neurophysiologic
al detection of 
readiness for 
return to activity 
after mild TBI) 
2013 W2019 CIHR CAN$1 065 728 
TBI-Prognosis 
Multicentre 
Prospective 
Study 
(NCT02452541)  
TBI-Prognosis 
 
315 critically ill 
adults with 
severe TBI 
Completed: 320 
patients 
Multicentre 
prospective cohort 
study 
Development of 
prognostic models 
(biomarkers, 
imaging, 
electrophysiology, 
classification) 
2013 W2018 CIHR CAN$1 053 131 
Table 3: Current studies supported by the International Initiative for Traumatic Brain Injury Research 
Cofunding partners of the CIHR for the InTBIR team grants are the Fonds de recherche du Québec Santé, the Hotchkiss Brain Institute, the Ontario Brain Institute, and the Ontario 
Neurotrauma Foundation. Cofunding of CENTER-TBI is provided by One Mind and the Hannelore Kohl Stiftung (Germany). CDEs=common data elements. CER=comparative effectiveness 
research. CIHR=Canadian Institutes of Health Research. ICP=intracranial pressure. InTBIR=International Initiative for Traumatic Brain Injury Research. mTBI=mild TBI. NIH=National Institutes 
of Health. NINDS=National Institute of Neurological Disorders and Stroke. RCT=randomised controlled trial. TBI=traumatic brain injury.  
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The InTBIR studies will include over 40 000 patients with TBI of all severities, many of whom will 
provide novel genomics, biomarker, and advanced imaging data. The outputs are expected to 
provide a rational basis for optimising health-care delivery for populations and clinical management 
for individual patients (figure 14). Additionally, these studies will establish well curated 
biorepositories and databases, which will provide a legacy for future research on blood samples from 
well characterised populations of patients with TBI as new methods are developed or longer follow-
up becomes possible. All projects comply with standards based on the Common Data Elements, 
which allow clinical investigators systematically to collect, analyse, and share data across the 
research community.404 European and Canadian studies will address the internationalisation of these 
Common Data Elements, allowing a US-based process to be applied globally, and promote global 
data standards for TBI research. This harmonised data collection will permit meta-analyses of data 
from large numbers of patients ? essential for CER and improvement of TBI characterisation ? and 
deliver outputs that would be impossible with any individual study.  
This collaboration of international funding agencies is unique. The total overall funding for the InTBIR 
studies listed in table 3 will be approximately US$90 million between 2012 and 2020, which 
represents an enormous increase from past levels of funding for TBI research, but this is still 
disproportionally low when compared with that for other neurological diseases. An estimate based 
ŽŶ ĨŝŐƵƌĞƐ ĨƌŽŵ ƚŚĞ /ŶƚĞƌŶĂƚŝŽŶĂů ůǌŚĞŝŵĞƌ ?Ɛ ŝƐĞĂƐĞ ZĞƐĞĂƌĐŚ WŽƌƚĨŽůŝŽ405 suggests that global 
funding for research into dementia, a disease with a comparable impact to TBI, was US$3·4 billion 
between 2008 and 2014.406 Furthermore, between 1998 and 2008, an estimated US$432 million was 
spent globally on research into frontotemporal dementia,407 a condition with a global incidence of 
2·7ʹ4·1 per 100 000 people per year.408 Given the large number of patients with TBI and the huge 
cost burden worldwide, substantial increases are warranted in the funding to support neurotrauma 
research. 
Figure 14: The aims of the International Initiative for Traumatic Brain Injury Research 
The International Initiative for Traumatic Brain Injury Research studies will involve collection of clinical and 
outcome data in observational studies, pragmatic trials, and established biorepositories, creating a highly 
detailed information commons (the body of evidence on TBI). The aims of these studies are to improve 
understanding of the causes and mechanisms of traumatic brain injury to inform prevention strategies 
(prevention) and of disease characterisation to facilitate diagnosis and targeted treatment (precision 
medicine). Data from CER will be analysed with the aims of identifying the most effective and targeted 
therapies (best practice) and translating them into practice recommendations. The increased data on patient 
and injury characteristics should improve prognostic accuracy, which in turn could enable improved 
benchmarking of care (quality of care). CER=comparative effectiveness research.  
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[H4] Towards global collaborations  
The concept of large-scale observational studies combined with CER, as implemented in the InTBIR 
initiative, has attracted global interest and resulted in a number of linked collaborative projects. In 
China, a large-scale observational study was initiated in August 2015 and recruitment was completed 
in June 2017. In total, 13 583 patients with TBI were included from 61 sites (Gao G, unpublished). In 
India, an observational study named CINTER-TBI (Comparative Indian Neurotrauma Effectiveness 
Research) was initiated in June 2016 and recruitment was recently expanded to six centres (Gupta 
D, unpublished). The inclusion of China and India, with their large populations and dramatically 
increasing TBI burden, provides a platform for high-quality research in these countries. Both studies 
are autonomous and conducted nationally, and were investigator-driven with minimal or absent 
local funding. Data collection in both studies is harmonised with CENTER-TBI to enable meta-analyses 
across studies. Therefore, for the first time, data collection in the field of TBI is globally harmonised 
and coordinated. 
In view of the trend for clinical trials initiated by pharmaceutical companies to be moved from Europe 
and the USA to east Asia, the international collaborations described above could deliver key insights 
into the generalisability of results. These initiatives reflect increasing recognition of the potential 
benefits of broad collaborations503 and represent a new approach to research, to which funding 
agencies must adapt to enable truly global collaborations. Major challenges include a lack of funding 
mechanisms for global research and restrictions to crossborder data transfer owing to privacy 
legislation. Despite the collaborative ethos of the InTBIR initiative, the studies conducted under its 
aegis are funded independently by respective funding agencies, and funding is not currently planned 
for meta-analyses across InTBIR studies, or with linked projects such as the initiatives in China and 
India. The greatest synergies will emerge from integrated analyses of the combined data in all 
relevant studies. The initiative established by the InTBIR needs to be expanded globally, and 
consolidated by facilitating meta-analysis across studies, thus ensuring future research continuity. 
[H3] Data sharing 
CER and precision-medicine research in TBI require large sample sizes and data sharing. Funding 
bodies, journal editors, and research regulators promote such data sharing.409 W416,504 Although the 
principle of data sharing receives almost universal support, implementation is not easy. Any solution 
must comply with privacy and ethical regulations, ensure high-quality data standards, promote 
sensible data use, maintain incentives for researchers who collect data, and appropriately account 
for the true costs of data sharing. Balancing these competing demands is challenging.417  
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[H4] Consent issues 
In TBI, particular challenges arise from loss of capacity to consent and from the need to initiate data 
collection as early as possible after injury. In the USA, the Health Insurance Portability and 
Accountability Act regulations418 recognise proxy consent in principle, and permit the use of a waiver 
of consent, particularly if underpinned by community consultation. The regulatory situation in 
European Union (EU) jurisdictions is in a state of flux: the General Data Protection Regulation 
(regulation 2016/679) will apply from May 2018,419 and although it makes provisions for research, it 
remains ambiguous with regard to incapacitated patients in emergency situations. There is a strong 
case for explicitly defining the acceptable use of data for legitimate clinical research in this context, 
and doing so in a way that meets the research needs of TBI and other acute diseases that could be 
characterised by lack of capacity to consent.  
[H4] Intellectual capital and costs of data sharing 
The emergence of open data sharing has created clear tensions with the way in which research 
success is currently measured. Given that the conventional currency of such success is based on 
publications and grant awards, the data that underpin these are viewed as academic capital by many 
researchers. The perceived loss of such capital in the context of unrestricted data sharing is therefore 
seen as an obstacle to its implementation by individual researchers and institutions. Although this 
challenge is recognised, it remains unresolved.504,505 These tensions are a particular issue for TBI, 
since the demands of data collection at the acute stage can be substantial in patients who are 
critically ill and often have multiple injuries. Most of these patients will not have the capacity to 
provide consent, and obtaining proxy consent from distraught family members requires sensitive 
and experienced research staff who need to be available around the clock. Provision of staff and 
support for patient recruitment is demanding on resources and is rarely fully recompensed in publicly 
funded studies. Additional costs accrue from the process of data sharing itself. A recent 
commentary420 identified four major categories of costs for data sharing, including infrastructure and 
administration, data standardisation, human resources, and opportunity costs. It is essential that 
funders recognise these additional data-related costs, estimated to represent up to 15% of study 
costs.420  
[H4] Approaches to data sharing 
The desire to obtain a justifiable return on intellectual capital and local resource subsidies has led 
many researchers to make data available primarily in the context of a collaboration, with an 
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anticipated reward of at least one joint publication, which benefits all collaborating parties. This 
recapitulates arrangements in the open-source community, where source code licences (such as the 
GNU General Public License)421 encourage the return of any improvements or new developments in 
the software product to the owner, thus ensuring a collaborative approach to product development. 
Many of the major InTBIR studies have elected to formalise such collaborative ventures through 
data-use agreements, which provide a clear understanding of data use between the collaborating 
parties.422,423 
The NIH have mandated that all data from US publicly funded TBI studies must be deposited in the 
Federal Interagency Traumatic Brain Injury Research424 informatics system, but transfer of data from 
European InTBIR studies to this repository might contravene the new EU data privacy legislation. 
However, data collected in a standard manner do not necessarily have to be stored together to be 
integrated for combined analyses. The pros and cons of central versus individual repositories for 
specific studies were explored in a recent Wellcome Trust Report417 and an abstracted summary is 
listed in the appendix.  
Irrespective of how data are stored, enabling open access while ensuring personal privacy remains a 
work in progress. An additional privacy concern is that new data-mining tools could allow 
identification of individuals in supposedly anonymised datasets.425 One possible solution could be 
provided by so-called gatekeeper software, which allows access while balancing the seemingly 
irreconcilable demands of openness versus privacy through differential privacy algorithms.426,427 
However, technology can provide solutions only in the context of rational regulation, and any digital 
solutions will need to be underpinned by new paradigms of consent428 and social contracts between 
researchers and patients.429 Emerging trends provide cause for optimism in this context.430,431  
 
[H3] Optimising existing evidence: living systematic reviews 
Health-care decisions should be informed by knowledge about what works and what does not. Such 
understanding is best achieved with systematic reviews that assess and critically appraise integrated 
results from multiple studies using transparent and reproducible methods.432 However, conventional 
systematic review processes are labour-intensive and time-consuming, often undertaken by small 
teams working in isolation, and seldom updated as new research is published. In an analysis of 792 
studies incorporated into 73 systematic reviews across 28 neurotrauma topics, the median time from 
primary study publication to its inclusion in a published systematic review ranged from 2·5 to 6·5 
years.433,434 Therefore, systematic reviews are often outdated by the time they are published.435  
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An innovative knowledge-management approach known as living systematic reviews (LSRs)434,436 is 
currently being pioneered within the CENTER-TBI project. LSRs are timely and high-quality online 
summaries of health research that are updated as new studies become available.434 LSRs transform 
the production of systematic reviews from a process of undertaking sporadic large projects every 
few years to an activity characterised by ongoing surveillance and more frequent smaller packages 
of work as new research findings emerge. Whereas the main questions driving conventional reviews 
relate to the totality of evidence and what it tells us about the effectiveness of an intervention or the 
accuracy of a diagnostic test, the real-time nature of LSRs shifts the emphasis to the question of how 
the new evidence changes what we already know.  
By pairing clinical TBI experts with experts in systematic review methods, the teams leading the 
InTBIR studies are laying the foundations for an ongoing dynamic TBI knowledge base and 
community. To date, two LSRs have been published,94,207 and topics planned for future LSRs cover 
diagnosis, prognosis, and interventions. Completed reviews are published in an open-access format. 
Searches are being automatically run every 3 months, and machine-learning technology is being 
piloted to reduce the workload.437 W439 LSRs are a new challenge for academic publishers, but the 
Journal of Neurotrauma has agreed to include updates in the online versions of reviews at 
approximately 3 W6 month intervals. The LSR author groups will also seek to publish updates as new 
manuscripts ? subject to peer review ? when new evidence leads to a change in conclusions. 
Interest in LSRs is growing rapidly, with multinational research collaborations being formed to 
maintain and curate the evidence base in a range of clinical areas.440,441 Notably, Cochrane, the global 
producer of systematic reviews, is also piloting LSRs. In the field of TBI, these pioneering efforts of 
CENTER-TBI are now being integrated within the InTBIR initiative. However, funding is limited to the 
duration of current InTBIR studies. We need mechanisms to ensure future continuity, in terms of 
both knowledge management and funding. 
One of the most attractive aspects of a living evidence synthesis model is the potential to produce 
living clinical practice guidelines or recommendations, and this is currently being considered by the 
Brain Trauma Foundation, the main producer of guidelines in TBI.442 While we strongly support a 
move towards living guidelines, an alternative approach could be to consider LSRs as the evidence 
base upon which more practical treatment recommendations can be tailored to national and local 
settings. A major criticism of current guidelines is that the emphasis on methodological rigour has 
decreased their practical value. Presenting the evidence base and practice recommendations 
separately might be a way to combine methodological rigour with practical applicability. There is also 
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a growing recognition of the value of practice recommendations based on expert consensus to 
facilitate care delivery for areas of clinical practice for which rigorous guidance is lacking or 
unclear.443 While ongoing efforts continue to strengthen the evidence base, ensuring the practical 
relevance of guidelines is essential to stimulate their implementation into clinical practice. 
[H3] Implementing evidence into practice: knowledge translation 
Translating evidence into practice and policy has become a distinct science, which complements that 
of discovering, developing, and synthesising research results. The emerging field of knowledge 
translation is defined as  ?the science of developing strategies to integrate evidence-based knowledge 
into health policy and practice, based upon understanding of behavioural drivers of practice within 
specific settings ?.432 The science of knowledge translation has developed in response to recognition 
of gaps between research evidence and clinical practice. The evidence-based practice movement of 
the early 1990s444 reshaped clinical practice by promoting consideration of best evidence, clinical 
expertise, and patient preferences in making treatment decisions.445 Nevertheless, a series of 
landmark studies published in the early 2000s revealed that only 55 W67% of patients received 
recommended care, and 20 W25% received care that was unnecessary or potentially harmful.446 W449 In 
the field of TBI, a recent systematic review207 concluded that although guideline adherence was 
associated with improved outcome, general adherence to guidelines was highly variable, and in many 
instances, poor. For example, the mean figure for adherence to the Brain Trauma Foundation 
guidelines for ICP management was 31% (range 18 W83%).207 
There is much to be gained from harnessing knowledge translation to address the evidence Wpractice 
gap in TBI. Economic modelling has shown that more widespread adoption of Brain Trauma 
Foundation guidelines across the USA could save more than 3500 lives, and, by raising the proportion 
of favorable outcomes from 35% to 66%, could yield an estimated annual cost saving of US$4 
billion.155  
Use of a knowledge-translation approach involves three core tasks: defining the target behaviour, 
measuring current behaviour, and understanding current behaviour. Defining the target behaviour 
establishes the desired health-care standard by which the success of a knowledge-translation 
intervention can be measured. For example, the Brain Trauma Foundation guidelines on nutrition 
after d/ƌĞĐŽŵŵĞŶĚ “ĨĞĞĚŝŶŐƉĂƚŝĞŶƚƐƚŽĂƚƚĂŝŶďĂƐĂůĐĂůŽƌŝĐƌĞƉůĂĐĞŵĞŶƚĂƚůĞĂƐƚďǇƚŚĞĨŝĨƚŚĚĂǇ
and, at most, by the seventh day post-ŝŶũƵƌǇ ?ƚŽĚĞĐƌĞĂƐĞŵŽƌƚĂůŝƚǇ ?255 Next, knowledge of current 
practice is required to determine the scope and nature of the evidence±practice gap.447,450,451 Härtl 
and colleagues452 examined adherence to the guideline on nutrition and found that patients not fed 
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within 5 and 7 days after TBI had a two-times and four-times increased risk of death, respectively, 
and that every 10-kcal/kg decrease in caloric intake was associated with a 30 W40% increase in 
mortality rate.452 These data underscore the importance of ensuring that practice reflects evidence.  
Finally, understanding behaviour is necessary for successful implementation of new practices. 
Quantifying the evidence Wpractice gap defines the problem but does not give information on why 
practice is the way it is. The importance of gaining this understanding of behaviour before attempting 
a quality-improvement (knowledge-translation) strategy cannot be overestimated. Without this 
understanding, precious resources can be wasted. For example, a common assumption is that people 
do not follow guidelines because they are not aware of them. This frequently drives educationally 
focused strategies such as lecture presentations and passive guideline dissemination. However, 
there are numerous barriers to best practice other than lack of knowledge, including peer-group 
influence, attitudes and beliefs of health professionals, organisational barriers such as lack of 
equipment, and structural barriers such as financial disincentives (panel 14).432 By addressing only 
the assumed barrier of lack of knowledge, an educational quality-improvement strategy risks being 
ineffective and wasting resources. 
Advances in both the science and the uptake of knowledge translation are required to close the 
evidence Wpractice gap. A key challenge for knowledge-translation scientists is the existence of 
multiple terms (eg,  “ĚŝƐƐĞŵŝŶĂƚŝŽŶ ĂŶĚ ŝŵƉůĞŵĞŶƚĂƚŝŽŶ ƌĞƐĞĂƌĐŚ ? ?  “ƋƵĂůŝƚǇ ŝŵƉƌŽǀĞŵĞŶƚ ? ?
 “ŝŵƉůĞŵĞŶƚĂƚŝŽŶƐĐŝĞŶĐĞ ? ?ĂŶĚ “ƌĞƐĞĂƌĐŚƚƌĂŶƐůĂƚŝŽŶ ? ?and frameworks to understand, describe, and 
influence the behaviour of health-care practitioners. Knowledge-translation scientists are working to 
address this challenge through the development of conceptually simpler and shorter frameworks 
that can be used to standardise knowledge-translation interventions in a similar way to the 
standardisation achieved in the clinical trials arena with the CONSORT (Consolidated Standards of 
Reporting Trials) statement.453 One such example is the AIMD framework, which seeks to 
characterise knowledge-translation interventions in terms of four domains identified as integral to 
all such interventions: Aims (purpose and target of behaviour change, Ingredients (what makes up 
the intervention), Mechanism (how the intervention is proposed to work on the basis of behavioural 
theory), and Delivery (mode of delivery ? eg, online or printed material).506 Uptake of knowledge-
translation science needs to be increased in clinical and other communities that are less familiar with 
applying behavioural theory to close the evidence Wpractice gap. It is hoped that clinician engagement 
in universal and simple frameworks can contribute to this. 
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Health-care quality improvement is complex and there is never likely to be a one-size-fits-all 
approach. What is beyond dispute, however, are the words of the former Director General of the 
WHO, Lee Jong-wŽŽŬ P “Health work teaches us with great rigour that action without knowledge is 
wasted effort, anĚŬŶŽǁůĞĚŐĞǁŝƚŚŽƵƚĂĐƚŝŽŶŝƐĂǁĂƐƚĞĚƌĞƐŽƵƌĐĞ ?.454 
[H3] Key messages and recommendations 
(1) Substantial between-centre variability in treatment and outcome in TBI offers unique 
opportunities for CER to improve the strength of clinical evidence. CER should be funded to 
identify best practices and to improve the level of evidence for systems of care and diagnostic 
and therapeutic interventions. 
(2) Coordinated research efforts on a global basis are needed to address the growing public health 
problem of TBI. Commitment of governmental and non-governmental funding bodies, as well 
as industrial partners, is needed to foster global collaborations and to establish national and 
international biorepositories and databases that could facilitate future TBI research. 
(3) Standardisation of clinical data collection, based on the TBI common data elements, provides 
a common language for global research. The common data elements need to be made 
internationally applicable to ensure global standardisation of clinical data collection. 
(4) CER studies and research on disease characterisation, outcome, and prognosis will require 
many patients, large datasets, and broad data sharing. Investment is needed in systems for 
efficient collection and sharing of data across borders, including funding of costs for rigorous 
data curation, annotation, and long-term database maintenance to maximise the returns on 
research investment from public funding. 
(5) Collaborations formalised in data-use agreements offer the best guarantee for driving research 
and care forward, but existing frameworks for recognising the success of research projects, 
individual researchers, or institutions are a major obstacle to data sharing. The current way in 
which research is valued needs to be critically assessed and revised, and funders should 
provide incentives for data collection and sharing.  
(6) TBI is often characterised by incapacity of patients to provide informed consent themselves. 
Regulatory frameworks for research should take account of acute loss of capacity to give 
consent in conditions such as TBI, and include appropriate provisions, such as recognition of 
waived, deferred, or proxy consent, to allow vital research to continue. 
(7) Overly restrictive interpretation of privacy legislation can inhibit greatly needed research and 
productive data sharing, and might even make research and data sharing impossible in TBI and 
other conditions that result in loss of capacity to consent. Regulation should avoid 
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unnecessarily restrictive interpretation of privacy clauses and complex bureaucratic 
procedures.  
(8) There are substantial delays in integrating research results into recommendations for best 
clinical practice. Funders and publishers should support rapid transfer of new research results 
into the evidence base, facilitated by new digital tools for their subsequent collation and 
integration into LSRs. LSRs should form the basis for practical treatment recommendations, 
with potential for a transition towards living clinical guidelines.  
(9) In TBI, as in many areas of medicine, substantial gaps exist between best current evidence and 
clinical practice. Barriers to transfer of knowledge from research to the clinic include a lack of 
dissemination or awareness, attitudes and beliefs, and organisational and structural barriers. 
Such barriers can result in poorer patient outcomes. Information campaigns, resources, and 
ƐƚƌĂƚĞŐŝĞƐ ƚŽ ĐŚĂŶŐĞ ĐůŝŶŝĐŝĂŶƐ ? ďĞŚĂǀŝŽƵƌ ĂƌĞessential to overcome barriers to knowledge 
translation, and to ensure implementation of guidelines and best practice. Such approaches 
could optimise the benefits of future research advances in clinical practice, improve outcomes, 
and make cost savings in health care. 
 
Panel 14: A thought experiment about the importance of knowledge transfer in traumatic brain 
injury 
Suppose that strategies that maximise outcomes for patients with traumatic brain injury (TBI) have 
been identified through comprehensive studies and their efficacy determined beyond any doubt. 
Suppose that they apply to all severities of injury, all mechanisms of trauma, and all patient groups, 
regardless of age, gender, and ethnic origin. Moreover, suppose that the evidence has been compiled 
into guidelines that are considered to be influential within the field. Given these assumptions, what 
barriers, if any, would exist to a future with optimum patient outcomes? 
Health care is delivered within a system that has multiple levels, each constraining or facilitating 
conscious or unconscious choices about whether and how to use evidence-based practices. Even in 
a future with perfect guidelines, obstacles to guideline implementation will remain at all levels, from 
individual health-care professionals and factors related to individual patients, to teams of clinicians 
working in hospital systems. Strategies to address the full range of barriers will be crucial to realise 
successful outcomes. 
We invite the reader to engage in frank introspection, considering the range of barriers to evidence-
based, guideline-driven care, and challenge decision makers and clinicians to develop a plan of attack 
for implementation that guides efforts to embed evidence into practice. Every hospital that seeks to 
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implement TBI guidelines will need to run its own thought experiment, because the barriers are likely 
to vary by location. Planning holds the promise of avoiding traditional pitfalls if sufficient resources 
can be brought to bear on the question of not just what to implement, but also how to implement 
evidence into practice. It is important that all stakeholders recognise the need for funding and 
resources to support knowledge transfer in TBI ? a vital step in bridging the gap between evidence 
and practice. For more on this thought experiment, see appendix.  
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Traumatic brain injury (TBI) is predicted to remain the largest global contributor to neurological 
disability for the next two decades, with a disease burden that far exceeds that of conditions such as 
cerebrovascular disease and dementia.4 Crucially, TBI-associated disability often affects young 
individuals at their productive peak, and results in huge burdens to individuals, families, and society 
(section 1). Extrapolation from available estimates suggests a global annual cost of TBI as high as 
US$400 billion5 ? a figure that represents approximately 0·5% of global gross domestic product 
(section 2). The precise magnitude of the problem, however, remains largely uncharted. Current 
estimates of 50 W60 million new TBIs per year3 are an approximation because wide variations in 
methodology exist between countries, including differences in data capture and reporting. We 
urgently need consensus on descriptors of TBI and its severity, as well as standardisation of methods 
for epidemiological monitoring across countries. Worldwide, patterns of TBI are changing, with 
increases in road traffic injuries in low-income and middle-income countries (LMICs) and a growing 
problem with falls among elderly individuals in high-income countries (HICs). Other key drivers that 
contribute to the burden of TBI include sports-related concussion and international conflict. 
Regardless of the cause, TBI results in an enduring burden of late morbidity and increased mortality, 
and might represent a risk factor for dementia in later life;  the attributable risk from TBI to overall 
dementia incidence could be as high as 15%.60 Improved knowledge of epidemiology will be key to 
more effective targeting of TBI prevention strategies in different populations (section 3).  
 
When TBI does occur, we need better ways to organise systems of care that provide cost-effective 
approaches to minimise preventable mortality and morbidity, ensuring that patients receive 
appropriate health care as soon as possible (section 4). Substantial variations in outcome exist 
between centres, and tackling these differences has the potential to far outweigh any benefit that 
might be realistically expected from a new treatment. There is growing evidence of a relation 
between management in high-volume centres and improved centre outcomes,210 W212 which suggests 
that care for the most critically ill patients should be centralised. Substantial gains could be made 
from adequate prehospital care, appropriate referral, and continuity along the chain of care, with 
early access to effective rehabilitation. The solutions that relate to care systems for TBI must take 
account of local economic and social factors and, in particular, work is needed to develop cost-
effective systems of care in LMICs.  
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Clinical management of TBI should be based on robust guidelines.  However, evidence in support of 
guideline recommendations is often weak and not applicable to all patients, as most studies are 
population based and do not take into account the heterogeneity of TBI, its severity, and differences 
between individual patients. As a result, current management strategies are based on guidelines that 
favour a one-size-fits-all approach, and the care of patients with TBI is therefore poorly individualised 
(section 5). Moreover, despite investment of many billions of dollars by pharmaceutical companies, 
no effective drugs exist for treatment in the acute setting ? a failing, in part, due to insufficient 
targeting of therapies to patients in whom the relevant mechanism is active. We need better 
methods to characterise TBI to allow identification of patient subgroups, with a common dominant 
disease mechanism, who are more likely to respond to specific treatments ? a concept now being 
popularised as precision medicine (section 6). We also need to enable better characterisation of 
outcome after TBI: mortality is an inappropriate metric for a disease that can result in considerable 
disability in survivors, and current outcome assessment tools are limited by their unidimensional 
approaches. We need improved multidimensional outcome assessment schemes that take better 
account of the substantial physical, cognitive, behavioural, and mental health sequelae of TBI 
(section 7). Improved disease and outcome characterisation will also provide a robust foundation for 
better prognostication of outcome. This could support better counselling of relatives, improve 
comparative audit of care between centres and countries, facilitate research, and help in 
management planning for individual patients (section 8). Huge opportunities exist for improvements 
in characterisation of initial severity, outcome, and prognosis, and for more accurate tracking of 
disease processes, by building on the current scientific advances in modern neuroimaging, genomics, 
disease biomarker development, and pathophysiological monitoring. Developments in these 
technologies could facilitate the goals of precision medicine in TBI. 
 
Comparative effectiveness research (CER) is a novel approach in which disease heterogeneity ? in 
terms of clinical and pathophysiological type and outcome ? and variations in clinical management 
and systems of care can be exploited to identify best practices (section 9).The data gathered from 
such research in real-world situations could enrich the limited evidence base on clinical care for TBI. 
Critical gaps in our knowledge of how best to treat TBI necessitate common methods and descriptors 
for collaborative research efforts. The development of common data elements for TBI research ?
allowing systematic collection and analysis of data across the research community  ? is an important 
step, but these tools need to be internationalised, particularly for use in LMICs. Clinical research in 
TBI is also hampered by vendor-specific differences in platforms used for neuroimaging and 
laboratory investigation. It is crucial that national and international regulators mandate common 
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standards for imaging and laboratory results, so that outputs from different studies can be usefully 
integrated. Industry has been a valuable partner in improving TBI care in the past, and we need to 
continue to facilitate such support through regulatory design and collaborative funding 
arrangements. 
 
Large cohorts of patients are needed to deliver meaningful advances in precision medicine, for robust 
CER, and to improve prognostic schemes. Such studies can be realised only through global 
collaboration (section 9). Current international initiatives, such as the International Initiative for TBI 
Research (InTBIR), and a growing ethos of data sharing represent an unprecedented opportunity to 
achieve these aims. However, such collaborative approaches to research depend on regulatory 
frameworks that enable consent for research and data sharing  ? a growing concern in the context 
of ever more rigorous privacy legislation, particularly in the context of TBI, in which patients often 
lose the capacity to consent at the onset of injury. Given the high public health interest, regulatory 
frameworks need to find ways to legitimise research inTBI and other contexts, where explicit patient 
consent cannot be obtained, and to implement solutions that resolve the conflict between personal 
privacy and wide access to research data.  Research funders also need to recognise the substantial 
costs of data sharing.  
 
The knowledge that is gained from clinical research must be rapidly translated to improvements in 
care. There is typically a gap of up to 6·5 years before the results of a study are integrated into a 
systematic review433,434 and a further delay before such integrated information is translated into 
clinical guidelines. Novel digital tools for literature searching and integration could speed up this 
process with the development of living systematic reviews (LSRs) and living guidelines, which are 
continually updated as new information becomes available. 
 
The problems and potential solutions described in this Commission have been inspired by patients 
and brought together by a wide international group of active clinical researchers who seek to 
improve outcomes for people with TBI. Clinicians and researchers, in consultation with patients and 
their families, need to play their part in taking these recommendations forward. Collaboration 
between funding agencies is required to coordinate the strategy and conduct of research, and 
commitment from policy makers essential to facilitate research and ensure timely implementation 
of research outputs. Integration of all these efforts will result in an end-product that is more than 
the sum of its parts, with rich dividends in terms of better and more cost effective care, and improved 
patients outcomes. 
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